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Summary 
This thesis is based on the evaluation of pharmacy-based screening concepts for 
cardiovascular risk factors (particularly for type 2 diabetes and dyslipidaemia) and of 
related health promoting activities. 
Type 2 diabetes mellitus and the metabolic syndrome including hypertension and 
dyslipidaemia are major public health concerns, and projections of future effects are 
alarming. These metabolic disorders are linked to an increased risk of cardiovascular 
disease. Type 2 diabetes is one of the most costly and burdensome diseases of our 
time and is a condition that is increasing in epidemic proportions throughout the 
world. Early detection and treatment of type 2 diabetes and metabolic syndrome can 
reduce the burden of complications. In addition, there is large evidence that weight 
loss and lifestyle changes in nutrition habits and physical activity have positive effects 
on the prevention of diabetes and cardiovascular disease. 
Community pharmacies are regarded as a suitable setting to promote awareness, 
screen high-risk patients, and to deliver health promoting counselling to persons at 
risk for diabetes and cardiovascular disease. However, triage guidelines for diabetes 
and lipid screening in community pharmacies and appropriate cut-off points for 
measurements in capillary blood are missing. In addition, measurements used in 
pharmacy-based screenings for diabetes or cardiovascular risk (such as blood 
pressure and blood glucose) are not validated. 
It was the goal of this thesis to develop and evaluate screening concepts for type 2 
diabetes and dyslipidaemia including appropriate triage guidelines and cut-off points 
for community pharmacy practice as well as to investigate the influence on lifestyle 
behaviour of different types of counselling. The thesis consists of five projects: 
 
Project A investigated whether a white coat effect in blood pressure measurements 
(as known from physicians’ measurements) can be observed and quantified in 
community pharmacy practice. Up to date no such findings have been published. It 
was the aim of this study to validate blood pressure measurement in community 
pharmacy practice as hypertension is a major risk factor for cardiovascular disease 
and an important part of screening concepts. For this purpose blood pressure was 
measured in four different settings: pharmacy, outpatient clinic (measurement by a 
nurse), self-measurement at home and daytime ambulatory blood pressure 
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monitoring. Pharmacy blood pressure was statistically significantly higher compared 
with daytime ambulatory blood pressure monitoring in both systolic and diastolic 
values. In contrast, only diastolic values of outpatient clinic blood pressure were 
statistically significantly higher compared with daytime ambulatory blood pressure 
monitoring. In addition, a total of 16% of the participants showed a white coat 
hypertension, defined as elevated pharmacy blood pressure (≥140/90 mmHg) and 
normal daytime ambulatory blood pressure (<135/85 mmHg). Thus, the results of this 
study have shown that white coat effect and white coat hypertension exist in 
community pharmacy practice and are at least similar to the effects in an outpatient 
clinic. 
In Project B, a sequential screening concept for type 2 diabetes to be used in 
community pharmacy practice was evaluated. Triage guidelines and appropriate cut-
off points for capillary blood glucose have been elaborated in an interdisciplinary and 
multi-institutional collaboration. A large pharmacy-based national diabetes screening 
campaign called “Stopp Zucker – Jetzt testen!” provided the possibility to evaluate 
the sequential screening concept. Community pharmacies participating in this 
campaign offered a free of charge diabetes risk assessment with consecutive 
capillary blood glucose measurement. Readiness for lifestyle change has been 
assessed based on the transtheoretical model (Prochaska) of behaviour change. 
During five weeks of spring 2002, a total of 94124 persons were screened for 
previously undiagnosed type 2 diabetes in 530 pharmacies of the German speaking 
part of Switzerland. The campaign attracted a large number of Swiss German 
speaking adults (2.4% of the total population) and the sequential screening concept 
could successfully be implemented into pharmacy practice. Of the generally elderly 
population screened, a total of 6.9% were suspected to have type 2 diabetes 
showing abnormal blood glucose values in the screening. A large proportion (71.5%) 
of the screened population had at least two risk factors but showed normoglycaemia. 
This provided an opportunity to provide targeted counselling towards health 
promoting lifestyle change. 
In the context of a pilot study, project C developed triage guidelines and cut-off 
points for dyslipidaemia which were evaluated in a regional screening campaign for 
metabolic syndrome in 30 community pharmacies. The results suggested that 
screening for the coincidence of ≥2 values of lipid profile above normal with ≥2 other 
risk factors for cardiovascular disease is the more promising approach than is 
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exclusive screening for ≥1 or even ≥2 abnormal lipid values without coincidence with 
other cardiovascular risk factors as this would lead to large referral rates to 
physicians. On the other hand, if a single value of the lipid profile is elevated on the 
level requiring drug treatment, even without coincidence with other risk factors, 
referral is required. 
In project D, the changes in lifestyle behaviour and body weight after counselling in 
community pharmacies during the national diabetes screening campaign were 
investigated. Three different counselling intensities were compared: Standard (non-
specific recommendations towards lifestyle change), intensive (additional specific 
advice to reduce body weight), and standard plus referral to physician for persons at 
high risk for type 2 diabetes. Three months after screening a stratified sample of 
3800 randomly chosen overweight individuals at risk for type 2 diabetes were 
addressed with written questionnaires to assess changes in body weight and 
lifestyle. Half a year and one year later the assessment was repeated. All counselling 
groups showed a significant weight loss three months after screening (0.6-1.9 kg; 
p<0.001). One year later a further significant weight reduction was observed. This 
reversed the general trend in the common population. Lifestyle changes in physical 
activity and/or nutrition habits were reported by 72.5% of all persons. Reported 
lifestyle changes as well as weight loss were most pronounced in the population at 
high risk for type 2 diabetes. The findings of this study showed that the immediate 
and targeted counselling after screening for type 2 diabetes in community 
pharmacies can result in significant and sustainable lifestyle changes and weight loss 
in overweight individuals. However the uncontrolled design of this project did not 
allow for stringent conclusions. 
Therefore, project E investigated the effect of a telephone-based counselling on 
body weight and lifestyle of overweight persons in a randomised controlled trial. 
Subjects for this study were recruited out of individuals who participated in the 
national diabetes screening campaign and provided informed consent for further 
investigations. After baseline assessment with a written questionnaire, subjects were 
randomly selected for intervention and control group. Within three months three 
telephone-based counselling sessions of 15 minutes were provided to the 
intervention group. Changes in lifestyle and body weight were assessed three 
months after counselling and another half year later with two evaluation 
questionnaires. Three months after telephone-based counselling the intervention 
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group showed a significantly higher weight loss than the control group (-0.37% vs. 
+0.09%; p<0.05). Half a year later differences in weight loss were not significant 
anymore. However, a greater proportion of subjects in the intervention group 
progressed at least to the next higher stage of change in the transtheoretical model 
regarding physical activity (27.0% vs. 21.3%; p<0.05) and reported lifestyle changes 
in nutrition habits and/or physical activity (80.5% vs. 62.9%; p<0.001). Thus, the 
results of this study have shown that a three times 15 minutes telephone-based 
counselling is able to result in measurable weight loss and significant lifestyle 
changes in overweight individuals. Best modalities and, because of seasonal 
interference, the best point in time of a telephone-based counselling need further 
investigation. 
 
In conclusion this thesis showed that: 
• Screening for cardiovascular risk in community pharmacies benefits from a 
sequential procedure: First an assessment of all risk factors including blood 
pressure, second capillary blood glucose measurements with retest in case 
of borderline results and with measurement of lipid profile if possible and 
finally counselling of persons at risk to initiate lifestyle change. 
• The elaborated and evaluated triage guidelines with the cut-off points for 
diabetes and for lipid screening appear to be appropriate and can be 
recommended for community pharmacy practice. 
• A total of 6.9% of the population screened in the national diabetes screening 
campaign were suspected to have type 2 diabetes showing abnormal blood 
glucose values. This rate is representative for the population screened but 
due to selection effects not for the general Swiss population. 
• Blood pressure measurements in community pharmacies are as reliable as 
those of other health professionals. They are subject to a white coat effect, 
also known from measurements by physicians and nurses. 
• After screening for cardiovascular risk pharmacists should offer targeted 
counselling to persons at risk according to the readiness to change their 
lifestyle. 
• Health promoting activities provided in community pharmacies or by nurses 
through telephone-based counselling can have positive effects on lifestyle 
behaviour and therewith on public health. 
General introduction 
16 
1 General introduction 
1.1 Pathophysiology and diagnosis of type 2 diabetes mellitus and 
its correlation to metabolic syndrome and cardiovascular 
disease 
Diabetes is a metabolic disorder characterized by resistance to the action of insulin, 
insufficient insulin secretion, or both. The major clinical manifestation of the diabetic 
state is hyperglycaemia. However, insulin deficiency and insulin resistance also are 
associated with disturbances in lipid and protein metabolism. The chronic 
hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and 
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels. Several pathogenic processes are involved in the development of diabetes. 
These range from autoimmune destruction of the β-cells of the pancreas with 
consequent insulin deficiency to abnormalities that result in resistance to insulin 
action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in 
diabetes is deficient action of insulin on target tissues. Deficient insulin action results 
from inadequate insulin secretion or diminished tissue responses to insulin at one or 
more points in the complex pathways of hormone action. Impairment of insulin 
secretion and defects in insulin action frequently coexist in the same patient, and it is 
often unclear which abnormality, if either alone, is the primary cause of the 
hyperglycaemia [1-3]. 
Symptoms of marked hyperglycaemia include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, and blurred vision. Impairment of growth (in children) 
and susceptibility to certain infections may also accompany chronic hyperglycaemia. 
Acute, life-threatening consequences of uncontrolled diabetes are hyperglycaemia 
with ketoacidosis or the nonketotic hyperosmolar syndrome. Long-term complications 
of diabetes include retinopathy with potential loss of vision; nephropathy leading to 
renal failure; peripheral neuropathy with risk of foot ulcers, amputations and Charcot 
joints; and autonomic neuropathy causing gastrointestinal, genitourinary and 
cardiovascular symptoms as well as sexual dysfunction. Patients with diabetes have 
an increased incidence of atherosclerotic cardiovascular, peripheral arterial, and 
cerebrovascular disease. Hypertension and abnormalities of lipoprotein metabolism 
are often found in people with diabetes [3]. 
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The vast majority of diabetic patients are classified into one of two broad 
etiopathogenetic categories. In one category, type 1 diabetes, the cause is an 
absolute deficiency of insulin secretion which results from autoimmune destruction of 
the pancreatic b-cells [4, 5]. Individuals at increased risk of developing this type of 
diabetes can often be identified by serological evidence of an autoimmune pathologic 
process occurring in the pancreatic islets and by genetic markers. While this form of 
diabetes usually occurs in children and adolescents, it can occur at any age. Younger 
individuals typically have a rapid rate of β-cell destruction and present with 
ketoacidosis, while adults often maintain sufficient insulin secretion to prevent 
ketoacidosis for many years [6]. The more indolent adult-onset variety has been 
referred to as latent autoimmune diabetes in adults. Eventually, all type 1 diabetic 
patients will require insulin therapy to maintain normoglycaemia. In the other, much 
more prevalent category, type 2 diabetes, the cause is a combination of resistance to 
insulin action and an inadequate compensatory insulin secretory response. In the 
latter category, a degree of hyperglycaemia sufficient to cause pathologic and 
functional changes in various target tissues, but without clinical symptoms, may be 
present for a long period of time before diabetes is detected. During this 
asymptomatic period, it is possible to demonstrate an abnormality in carbohydrate 
metabolism by measurement of plasma glucose in the fasting state or after a 
challenge with an oral glucose load. Besides these two broad categories, women 
who develop diabetes during their pregnancy, are classified as having gestational 
diabetes. Finally, there are a variety of uncommon and diverse types of diabetes 
which are caused by infections, drugs, endocrinopathies, pancreatic destruction, and 
genetic defects [1-3]. 
The degree of hyperglycaemia (if any) may change over time, depending on the 
extent of the underlying disease process (see Figure 1). A disease process may be 
present but may not have progressed far enough to cause hyperglycaemia. The 
same disease process can cause impaired fasting glucose (IFG) and/or impaired 
glucose tolerance (IGT) without fulfilling the criteria for the diagnosis of diabetes. In 
some individuals with diabetes, adequate glycemic control can be achieved with 
weight reduction, exercise, and/or oral glucose-lowering agents. These individuals 
therefore do not require insulin. Other individuals who have some residual insulin 
secretion but require exogenous insulin for adequate glycemic control can survive 
without it. Individuals with extensive β-cell destruction and therefore no residual 
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insulin secretion require insulin for survival. The severity of the metabolic abnormality 
can progress, regress, or stay the same. Thus, the degree of hyperglycaemia reflects 
the severity of the underlying metabolic process and its treatment more than the 
nature of the process itself [3]. 
 
Figure 1: Disorders of glycaemia: etiologic types and stages. 
*Even after presenting in ketoacidosis, these patients can briefly return to normoglycaemia without requiring 
continuous therapy (i.e., “honeymoon” remission); **in rare instances, patients in these categories (e.g., Vacor 
toxicity, type 1 diabetes presenting in pregnancy) may require insulin for survival. 
1.1.1 Pathophysiology of type 2 diabetes 
Type 2 diabetes, previously referred to as non-insulin-dependent diabetes or adult-
onset diabetes, is a term used for individuals who have insulin resistance and usually 
have relative (rather than absolute) insulin deficiency [7-10]. This form of diabetes is 
ranging from predominantly insulin resistance with relative insulin deficiency to 
predominantly an insulin secretory defect with insulin resistance. In absolute terms, 
the plasma insulin concentration (both fasting and meal-stimulated) usually is 
increased, although "relative" to the severity of insulin resistance, the plasma insulin 
concentration is insufficient to maintain normal glucose homeostasis [11, 12]. But at 
least initially, and often throughout their lifetime, these individuals do not need insulin 
treatment to survive. 
There are probably many different causes of this form of diabetes. Although the 
specific etiologies are not known, autoimmune destruction of β-cells does not occur 
[2]. Most patients with this form of diabetes are obese, and obesity itself causes 
some degree of insulin resistance [13, 14]. Patients who are not obese by traditional 
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weight criteria may have an increased percentage of body fat distributed 
predominantly in the abdominal region [15]. Ketoacidosis seldom occurs 
spontaneously in this type of diabetes; when seen, it usually arises in association 
with the stress of another illness such as infection [16-18]. This form of diabetes 
frequently goes undiagnosed for many years because the hyperglycaemia develops 
gradually and at earlier stages is often not severe enough for the patient to notice 
any of the classic symptoms of diabetes [19-21]. Nevertheless, such patients are at 
increased risk of developing macrovascular and microvascular complications [21-25]. 
Whereas patients with this form of diabetes may have insulin levels that appear 
normal or elevated, the higher blood glucose levels in these diabetic patients would 
be expected to result in even higher insulin values had their β-cell function been 
normal [26]. Thus, insulin secretion is defective in these patients and insufficient to 
compensate for the insulin resistance. Insulin resistance may improve with weight 
reduction and/or pharmacological treatment of hyperglycaemia but is seldom 
restored to normal [27-31]. The risk of developing this form of diabetes increases with 
age, obesity, and lack of physical activity [3, 20]. It occurs more frequently in women 
with prior gestational diabetes mellitus (GDM) and in individuals with hypertension or 
dyslipidaemia, and its frequency varies in different racial/ethnic subgroups [3, 20, 21]. 
Type 2 diabetes is often associated with a strong genetic predisposition, more so 
than is the autoimmune form of type 1 diabetes [32, 33]. It is more common in 
minority ethnic groups, i.e. Mexican-Americans, Latinos, American Indians, Pacific 
Islanders, than in individuals of European ancestry. However, the genetics of this 
form of diabetes are complex and not clearly defined [2, 34]. 
1.1.2 Diagnosis of type 2 diabetes 
The diagnostic criteria for diabetes mellitus have been modified in 2003 by the Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus [2] from those 
previously recommended by the National Diabetes Data Group [35] or WHO [36]. 
The revised criteria for the diagnosis of diabetes are shown in Table 1. Three ways to 
diagnose diabetes are possible, and each must be confirmed, on a subsequent day, 
by any one of the three methods given in Table 1. For example, one instance of 
symptoms with casual plasma glucose ≥200 mg/dl (11.1 mmol/l), confirmed on a 
subsequent day by 1) fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l), 2) an 
oral glucose tolerance test (OGTT) with the 2-h postload value ≥200 mg/dl (11.1 
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mmol/l), or 3) symptoms with a casual plasma glucose ≥200 mg/dl (11.1 mmol/l), 
warrants the diagnosis of diabetes [2]. 
For epidemiological studies, estimates of diabetes prevalence and incidence should 
be based on an FPG ≥126 mg/dl (7.0 mmol/l). This recommendation is made in the 
interest of standardization and also to facilitate field work, particularly where the 
OGTT may be difficult to perform and where the cost and demands on participants’ 
time may be excessive. This approach will lead to slightly lower estimates of 
prevalence than would be obtained from the combined use of the FPG and OGTT [2]. 
 
Table 1: Criteria for the diagnosis of diabetes mellitus 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥200 mg/dl (11.1 
mmol/l). Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. 
or 
2. FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. 
or 
3. 2-h postload glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The test should be 
performed as described by WHO, using a glucose load containing the equivalent of 75 g 
anhydrous glucose dissolved in water. 
In the absence of unequivocal hyperglycaemia, these criteria should be confirmed by repeat testing on 
a different day. The third measure (OGTT) is not recommended for routine clinical use. 
 
The Expert Committee [2] recognizes an intermediate group of subjects whose 
glucose levels, although not meeting criteria for diabetes, are nevertheless too high 
to be considered altogether normal. This group is defined as having FPG levels ≥100 
mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 mmol/l) or 2-h values in the OGTT of ≥140 
mg/dl (7.8 mmol/l) but <200 mg/dl (11.1 mmol/l). The lower cut point defining IFG 
was recommended to be reduced from 110 mg/dl (6.1 mmol/l) to 100 mg/dl (5.6 
mmol/l) by the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus in 2003 [37]. Thus, “normol” was now defined as a FPG < 100 mg/dl instead 
of < 110 mg/dl. The criteria to diagnose diabetes were redommended to remain as 
previously defined. Therefore, the categories of FPG values are as follows [3, 37]: 
 
• FPG <100 mg/dl (5.6 mmol/l) = normal fasting glucose 
• FPG 100 – 125 mg/dl (5.6 - 7.0 mmol/l) = impaired fasting glucose (IFG) 
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• FPG ≥126 mg/dl (7.0 mmol/l) = provisional diagnosis of diabetes (the diagnosis 
must be confirmed, as described above). 
 
The corresponding categories when the OGTT is used are the following: 
 
• 2-h postload glucose (2-h PG) <140 mg/dl (7.8 mmol/l) = normal glucose 
tolerance 
• 2-h PG ≥140 (7.8 mmol/l) and <200 mg/dl (11.1 mmol/l) = impaired glucose 
tolerance (IGT) 
• 2-h PG ≥200 mg/dl (11.1 mmol/l) = provisional diagnosis of diabetes (the 
diagnosis must be confirmed, as described above). 
 
The terms impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) refer 
to a metabolic stage intermediate between normal glucose homeostasis and 
diabetes, now referred to as pre-diabetes. This stage of impaired glucose 
homeostasis includes individuals who have IGT and individuals with fasting glucose 
levels ≥110 mg/dl (6.1 mmol/l) but <126 mg/dl (7.0 mmol/l) (IFG). The term IFG was 
coined by Charles et al. [38] to refer to a fasting plasma glucose (FPG) level ≥110 
mg/dl (6.1 mmol/l) but <140 mg/dl (7.8 mmol/l). The Expert Committee [2] is using a 
similar definition, but with the upper end lowered to correspond to the new diagnostic 
criteria for diabetes. A fasting glucose concentration of 109 mg/dl (6.1 mmol/l) has 
been chosen as the upper limit of “normal.” Although it is recognized that this choice 
is somewhat arbitrary, it is near the level above which acute phase insulin secretion 
is lost in response to intravenous administration of glucose [39] and is associated 
with a progressively greater risk of developing micro- and macrovascular 
complications [40-44]. It must be noted that many individuals with IGT are 
euglycemic in their daily lives [45] and may have normal or near normal glycated 
hemoglobin levels [46]. Individuals with IGT often manifest hyperglycaemia only 
when challenged with the oral glucose load used in the standardized OGTT [2]. 
1.1.3 Insulin resistance, the metabolic syndrome and cardiovascular risk 
Obesity, particularly abdominal (visceral) obesity, is associated with resistance to the 
effects of insulin on peripheral glucose and fatty acid utilization, often leading to type 
2 diabetes mellitus. Insulin resistance, the associated hyperinsulinemia and 
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hyperglycaemia, and adipocyte cytokines (adipokines) may also lead to vascular 
endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular 
inflammation, all of which promote the development of atherosclerotic cardiovascular 
disease (CVD) [14, 47-49]. A similar profile can be seen in individuals with abdominal 
obesity who do not have an excess of total body weight [50, 51]. 
The co-occurrence of metabolic risk factors for both type 2 diabetes and CVD - 
abdominal obesity, hyperglycaemia / insulin resistance, dyslipidaemia of the high-
triglyceride and/or low-HDL type and hypertension— suggested the existence of a 
"metabolic syndrome" [47, 48, 52, 53]. Other names applied to this constellation of 
findings have included syndrome X, the insulin resistance syndrome, the deadly 
quartet, or the obesity dyslipidaemia syndrome [54]. Genetic predisposition, lack of 
exercise, and body fat distribution all affect the likelihood that a given obese subject 
will become overtly diabetic or develop CVD. 
 
The metabolic syndrome should not be confused with another disorder called 
syndrome X in which angina pectoris occurs in patients with normal coronary 
arteries. Because metabolic syndrome traits co-occur, patients with just a few traits 
are likely to have many other traits as well as insulin resistance [55]. Whether it is 
valuable to assess insulin resistance in addition to more readily measured traits of 
the syndrome is currently uncertain. Guidelines from the 2001 National Cholesterol 
Education Program (Adult Treatment Panel [ATP] III) suggest that the clinical 
identification of the metabolic syndrome should be based upon the presence of any 
three of the following traits [56]: 
 
• Abdominal obesity, defined as a waist circumference in men >102 cm (40 
in) and in women >88 cm (35 in). ATP III recognized that some men 
develop multiple metabolic risk factors when waist circumference is only 
marginally increased (94 to 102 cm [37 to 39 in]); such patients may have 
a genetic contribution to insulin resistance. 
• Serum triglycerides ≥150 mg/dL (1.7 mmol/L). 
• Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 
mmol/L) in women. 
• Blood pressure ≥130/85 mmHg. 
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• Fasting plasma glucose (FPG) ≥110 mg/dL (6.1 mmol/L). However, a 2004 
report from the National Heart, Lung, and Blood Institute and the American 
Heart Association recommended that the FPG threshold be lowered to 
≥100 mg/dL (5.6 mmol/L) [54]. This is in accordance with a 2003 
recommendation from the American Diabetes Association redefining 
impaired FPG as ≥100 mg/dL (5.6 mmol/L) [37]. 
 
The complications resulting from metabolic syndrome and type 2 diabetes are a 
significant cause of morbidity and mortality. The chronic hyperglycaemia is 
associated with long-term dysfunction, damage, and failure of various organs, 
especially the eyes, kidneys, nerves, heart, and blood vessels. Individuals with type 2 
diabetes are also at a significantly higher risk for coronary heart disease, peripheral 
vascular disease, and stroke, and they have a greater likelihood of having 
dyslipidaemia, hypertension, and obesity [47, 48, 57-61]. Thus, other traits of the 
metabolic syndrome besides hyperglycaemia often are present in patients with type 2 
diabetes. Because of these abnormalities, patients with type 2 diabetes have a 
further increased risk of developing macrovascular complications (myocardial 
infarction and stroke) [49]. 
The treatment of diabetes has become increasingly sophisticated, with over a dozen 
pharmacological agents available to lower blood glucose, a multitude of ancillary 
supplies and equipment available, and a clear recognition by health care 
professionals and patients that diabetes is a serious disease. Nevertheless the 
normalization of blood glucose for any appreciable period of time is seldom achieved 
[62]. In addition, in well-controlled so called “intensively” treated patients, serious 
complications still occur [63-66], and the economic and personal burden of diabetes 
remains. Furthermore, microvascular disease is already present in many individuals 
with undiagnosed or newly diagnosed type 2 diabetes [67-70]. 
 
There is growing evidence that at glucose levels above normal but below the 
diabetes threshold diagnostic now referred to as pre-diabetes (impaired glucose 
homeostasis; IFG / IGT), there is a substantially increased risk of cardiovascular 
disease (CVD) and death [61, 71-74]. In the absence of pregnancy, IFG and IGT are 
therefore not clinical entities in their own right but rather risk factors for future 
diabetes and cardiovascular disease [40]. IFG and IGT are associated with the 
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metabolic syndrome [47] and appear as risk factors for type 2 diabetes at least in part 
because of their correlation with insulin resistance, which is directly involved in the 
pathogenesis of this type of diabetes [2]. In contrast, the explanation for why IFG and 
IGT are also risk factors for cardiovascular disease is less clear. The metabolic 
syndrome includes well-recognized cardiovascular risk factors such as low HDL 
levels and hypertension. In addition, it includes hypertriglyceridaemia, which is highly 
correlated with small dense LDL and increased plasminogen activator inhibitor-1 
(PAI-1) levels. The former is thought to have enhanced atherogenicity, perhaps as a 
result of its greater vulnerability to oxidation than normal LDL. PAI-1 is a 
cardiovascular risk factor probably because it inhibits fibrinoloysis. Thus, the insulin 
resistance syndrome contains many features that increase cardiovascular risk. IFG 
and IGT may not in themselves be directly involved in the pathogenesis of 
cardiovascular disease, but rather may serve as statistical risk factors by association 
because they correlate with those elements of the insulin resistance syndrome that 
are cardiovascular risk factors [2]. But the fact that CVD risk factors are more 
prevalent in individuals with impaired glucose homeostasis [61, 67, 71, 73, 75-78], 
which of course further increases the cardiovascular risk, is possibly not sufficient to 
totally explain the increased risk for cardiovascular disease and death of those 
individuals [79]. 
In contrast to the clear benefit of glucose lowering to prevent or retard the 
progression of microvascular complications associated with diabetes [63-66], it is 
less clear whether the high rate of CVD in people with impaired glucose 
homeostasis, i.e., those with impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT), or diabetes, is caused by elevated blood glucose levels or will 
respond to treatments that lower blood glucose. Epidemiological studies have shown 
a clear relationship [22, 80], whereas intervention trials in people with diabetes 
suggest, but have not demonstrated, a clear benefit of glycemic control [63, 64, 66]. 
Additionally, there are no studies that have investigated a benefit of glucose lowering 
on macrovascular disease in subjects with only pre-diabetes (IFG or IGT) but not 
diabetes. 
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1.2 Screening for type 2 diabetes and cardiovascular risk factors 
1.2.1 Risk factors for type 2 diabetes 
Type 2 diabetes is often asymptomatic in its early stages and can remain 
undiagnosed for many years [81]. Because early detection and prompt treatment 
may reduce the burden of diabetes and its complications, screening for diabetes may 
be appropriate under certain circumstances [81]. 
There are certain risk factors that either directly cause type 2 diabetes or are 
associated with it. The correlation of a risk factor(s) with development of diabetes is 
never 100%. However, the greater the number of risk factors present in an individual, 
the greater is the chance of this individual developing or having diabetes. 
Conversely, the chance of an asymptomatic individual without any risk factors having 
or developing diabetes is relatively low [81, 82]. 
The risk of developing type 2 diabetes increases with age, obesity, and lack of 
physical activity (see Table 2 [82]). Type 2 diabetes is more common in individuals 
with a family history of the disease and in members of certain racial/ethnic groups. It 
occurs more frequently in women with prior GDM or polycystic ovary syndrome and 
in individuals with hypertension, dyslipidaemia, impaired glucose tolerance, or 
impaired fasting glucose [82]. 
 
Table 2: Risk factors for type 2 diabetes 
Age ≥45 years 
Overweight (BMI ≥25 kg/m2*) 
Family history of diabetes (i.e., parents or siblings with diabetes) 
Habitual physical inactivity 
Race/ethnicity (e.g., African-Americans, Hispanic-Americans, Native Americans, Asian- 
 Americans, and Pacific Islanders) 
Previously identified IFG or IGT 
History of GDM or delivery of a baby weighing >9 lbs 
Hypertension (≥140/90 mmHg in adults) 
HDL cholesterol ≤35 mg/dl (0.90 mmol/l) and/or a triglyceride level ≥250 mg/dl (2.82 mmol/l) 
Polycystic ovary syndrome 
History of vascular disease 
*May not be correct for all ethnic groups. 
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1.2.2 Principles to assess the value of screening for type 2 diabetes 
There is a major distinction between diagnostic testing and screening. When an 
individual exhibits symptoms or signs of the disease, diagnostic tests are performed, 
and such tests do not represent screening. The purpose of screening is to identify 
asymptomatic individuals who are likely to have diabetes. Separate diagnostic tests 
using standard criteria are required after positive screening tests to establish a 
definitive diagnosis [81]. 
Generally, screening in asymptomatic populations is appropriate when seven 
conditions are met [81]: 
 
1) The disease represents an important health problem that imposes a 
significant burden on the population. 
2) The natural history of the disease is understood. 
3) There is a recognizable preclinical (asymptomatic) stage during which the 
disease can be diagnosed. 
4) Tests are available that can detect the preclinical stage of the disease, 
and the tests are acceptable and reliable. 
5) Treatment after early detection yields benefits superior to those obtained 
when treatment is delayed. 
6) The costs of case finding and treatment are reasonable and are balanced 
in relation to health expenditures as a whole, and facilities and resources 
are available to treat newly diagnosed cases. 
7) Screening will be a systematic ongoing process and not merely an isolated 
one-time effort. 
 
For type 2 diabetes, conditions 1–4 are met. Conditions 5–7 have not been met 
entirely because there are no randomized clinical trials documenting the 
effectiveness of screening programs in decreasing mortality and morbidity from 
diabetes, and some controversy exists regarding the cost-effectiveness of screening 
and whether screening as currently carried out is a systematic and ongoing process. 
Randomized clinical trials would be the best means to evaluate the benefits and risks 
of diabetes screening and early treatment. However, rigorous studies that apply 
currently available treatments to a screened group but not to a control group have not 
been done and are unlikely to be performed soon because of feasibility, ethical 
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concerns, and costs. Thus, while it is well established that treating diabetes 
diagnosed through standard clinical practice is effective in reducing diabetic 
microvascular complications [63], it is unknown whether the additional years of 
treatment that might be received by individuals diagnosed through screening would 
result in clinically important improvements in diabetes-related outcomes. A large 
clinical trial, the Diabetes Prevention Program (DPP), was performed in the U.S [83]. 
It has been designed to answer the question of whether treatment with lifestyle 
interventions or metformin for patients with IGT or IFG detected through a screening 
program will reduce the incidence of type 2 diabetes. As the DPP has demonstrated 
a reduction in the incidence of type 2 diabetes as a result of the lifestyle 
interventions, more widespread screening for these conditions, which would 
incidentally detect many cases of asymptomatic diabetes, possibly may be justified 
[82]. 
The effectiveness of screening may also depend on the setting in which it is 
performed. In general, community screening outside a health care setting may be 
less effective because of the failure of people with a positive screening test to seek 
and obtain appropriate follow-up testing and care or, conversely, to ensure 
appropriate repeat testing for individuals who screen negative. That is, screening 
outside of clinical settings may yield abnormal tests that are never discussed with a 
primary care provider, low compliance with treatment recommendations, and a very 
uncertain impact on long-term health. Community screening may also be poorly 
targeted, i.e., it may fail to reach the groups most at risk and inappropriately test 
those at low risk (the worried well) or even those already diagnosed [82]. 
1.2.3 General recommendations of the ADA for screening of type 2 diabetes 
Based on the lack of data from prospective studies on the benefits of screening and 
the relatively low cost-effectiveness of screening suggested by existing studies, the 
American Diabetes Association (ADA) recommends in the clinical practice 
recommendations [82] that the decision to test for diabetes should ultimately be 
based on clinical judgment and patient preference. 
On the basis of expert opinion [82], screening should be considered by health care 
providers at 3-year intervals beginning at age 45, particularly in those with BMI 
≥25 kg/m2. The rationale for this interval is that false negatives will be repeated 
before substantial time elapses, and there is little likelihood of an individual 
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developing any of the complications of diabetes to a significant degree within 3 years 
of a negative screening test result. 
Testing should be considered at a younger age or be carried out more frequently in 
individuals who are overweight and have one or more of the other risk factors shown 
in Table 2. Moreover testing may be considered in other high-risk patients who 
display any of the following characteristics: 
• Have a family history of type 2 diabetes in first- and second-degree 
relatives; 
• Belong to a certain race/ethnic group (Native Americans, African-
Americans, Hispanic Americans, Asians/South Pacific Islanders); 
• Have signs of insulin resistance or conditions associated with insulin 
resistance (acanthosis nigricans, hypertension, dyslipidaemia, polycystic 
ovary syndrome). 
 
Although there is ample scientific evidence showing that certain risk factors 
predispose individuals to development of diabetes (Table 1), there is insufficient 
evidence to conclude that community screening is a cost-effective approach to 
reduce the morbidity and mortality associated with diabetes in presumably healthy 
individuals. While community screening programs may provide a means to enhance 
public awareness of the seriousness of diabetes and its complications, other less 
costly approaches may be more appropriate, particularly because the potential risks 
are poorly defined. Thus, based on the lack of scientific evidence, community 
screening for diabetes, even in high-risk populations, is not recommended. The ADA 
concludes that although the burden of diabetes is well known, the natural history is 
well characterized, and there is good evidence for benefit from treating cases 
diagnosed through usual clinical care, there are no randomized trials demonstrating 
the benefits of early diagnosis through screening of asymptomatic individuals. 
Considering the methodological difficulties it is not surprising that such trials are 
missing. Nevertheless, according to the ADA recommendations, there is sufficient 
indirect evidence to justify opportunistic screening in a clinical setting of individuals at 
high risk. Also, clinicians should be vigilant in evaluating clinical presentations 
suggestive of diabetes [82]. 
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1.2.4 Recommended tests in screening for type 2 diabetes 
The best screening test for diabetes recommended by the ADA [82], the fasting 
plasma glucose (FPG), is also a component of diagnostic testing (see Table 1). The 
FPG test and the 75-g oral glucose tolerance test (OGTT) are both suitable tests for 
diabetes; however, the FPG test is preferred in clinical settings because it is easier 
and faster to perform, more convenient and acceptable to patients, and less 
expensive [3]. An FPG ≥126 mg/dl (7.0 mmol/l) is an indication for retesting, which 
should be repeated on a different day to confirm a diagnosis. If the FPG is <126 
mg/dl (7.0 mmol/l) and there is a high suspicion for diabetes, an OGTT should be 
performed. A 2-h postload value in the OGTT ≥200 mg/dl (11.1 mmol/l) is a positive 
test for diabetes and should be confirmed on an alternate day [3, 37, 82]. 
Nondiabetic individuals with an FPG ≥100 mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 
mmol/l) are considered to have IFG, and those with 2-h values in the OGTT ≥140 
mg/dl (7.8 mmol/l) but <200 mg/dl (11.1 mmol/l) are defined as having IGT. Patients 
with IFG and/or IGT are now referred to as having “pre-diabetes,” indicating the 
relatively high risk for development of diabetes in these patients. Normoglycaemia is 
defined as plasma glucose levels <100 mg/dl (5.6 mmol/l) in the FPG test and a 2-h 
postload value <140 mg/dl (7.8 mmol/l) in the OGTT [3, 37]. 
If necessary, plasma glucose testing may be performed on individuals who have 
taken food or drink shortly before testing. Such tests are referred to as casual plasma 
glucose measurements and are given without regard to time of last meal. A casual 
plasma glucose level ≥200 mg/dl (11.1 mmol/l) with symptoms of diabetes is 
considered diagnostic of diabetes. A confirmatory FPG test or OGTT should be 
completed on a different day if the clinical condition of the patient permits [82]. 
Laboratory measurement of plasma glucose concentration is performed on venous 
samples with enzymatic assay techniques, and the above-mentioned values are 
based on the use of such methods. The HbA1c test values remain a valuable tool for 
monitoring glycaemia, but it is not currently recommended for the screening or 
diagnosis of diabetes. Pencil and paper tests, such as the American Diabetes 
Association’s risk test, may be useful for educational purposes but do not perform 
well as stand-alone tests. Capillary blood glucose testing using a reflectance blood 
glucose meter has also been used, but because of the imprecision of this method, it 
is better used for self-monitoring rather than as a screening tool [82]. In a report of 
the WHO and International Diabetes Federation in 2003 [84], fasting capillary blood 
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glucose is regarded as a possible approach in screening for type 2 diabetes but not 
yet well investigated concerning appropriate cut-off points. It is very important that 
screening tests are evaluated regarding sensitivity and speciticity [84]. The sensitivity 
of a screening test is the proportion of people with the disorder who test positive on 
the screening test (a highly sensitive screening test is unlikely to miss a subject with 
diabetes). The specificity of a screening test is the proportion of people who do not 
have the disorder who test negative on the screening test (a highly specific test is 
unlikely to misclassify someone who does not have diabetes as having diabetes.) 
Although it is desirable to have a test that is both highly sensitive and highly specific, 
this is usually not possible. In choosing a cut-off point a trade-off needs to be made 
between sensitivity and specificity, since increasing one reduces the other. The 
receiver operator characteristic (ROC) curve expresses this relationship. The true 
positive rate (sensitivity) is plotted on the y axis against the false positive rate (1-
specificity) over a range of cut-off values. Tests that discriminate well crowd toward 
the upper left corner of the ROC curve. In ideal cases, as sensitivity increases, there 
is little decrease in specificity, until very high levels of sensitivity are reached [84]. 
 
1.3 Health promotion and lifestyle change in the prevention of 
type 2 diabetes and cardiovascular disease 
Diabetes is one of the most costly and burdensome chronic diseases of our time and 
is a condition that is increasing in epidemic proportions in the U.S. and throughout 
the world [85, 86]. It is estimated that in 2025 about 300 millions of persons 
worldwide will be affected by type 2 diabetes (see Figure 2). For Switzerland in 
particular it is estimated that in 2030 about 340’000 persons will be affected by type 2 
diabetes [87]. 
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Figure 2: Regional estimates of people with diabetes mellitus (in millions) for 1995, 2000, and 
2025. 
 
Given these facts, it is not surprising that studies have been initiated in the last 
decade to determine the feasibility and benefit of various strategies to prevent or 
delay the onset of type 2 diabetes. Two early reports [88, 89] suggested that changes 
in lifestyle can prevent diabetes, but weaknesses in study design limited their general 
relevance. Recently, however, four well-designed randomized controlled trials have 
been reported [83, 90-93]. 
In the Finnish study [90], 522 middleaged (mean age 55 years) obese (mean BMI 31 
kg/m2) subjects with IGT were randomized to receive either brief diet and exercise 
counseling (control group) or intensive individualized instruction on weight reduction, 
food intake, and guidance on increasing physical activity (intervention group). After 
an average follow-up of 3.2 years, there was a 58% relative reduction in the 
incidence of diabetes in the intervention group compared with the control subjects. A 
strong correlation was also seen between the ability to stop the progression to 
diabetes and the degree to which subjects were able to achieve one or more of the 
following: lose weight (goal of 5.0% weight reduction), reduce fat intake (goal of 
<30% of calories), reduce saturated fat intake (goal of <10% of calories), increase 
fiber intake (goal of ≥15 g/1,000 kcal), and exercise (goal of >150 min/week). No 
untoward effects of the lifestyle interventions were observed. 
In the Diabetes Prevention Program (DPP) [83, 91, 92], the 3,234 enrolled subjects 
were slightly younger (mean age 51 years) and more obese (mean BMI 34 kg/m2) 
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but had nearly identical glucose intolerance compared with subjects in the Finnish 
study. About 45% of the participants were from minority groups (e.g, African-
American, Hispanic), and 20% were ≥60 years of age. Subjects were randomized to 
one of three intervention groups, which included the intensive nutrition and exercise 
counseling (“lifestyle”) group or either of two masked medication treatment groups: 
the biguanide metformin group or the placebo group. The latter interventions were 
combined with standard diet and exercise recommendations. After an average follow-
up of 2.8 years (range 1.8–4.6 years), a 58% relative reduction in the progression to 
diabetes was observed in the lifestyle group (absolute incidence 4.8%), and a 31% 
relative reduction in the progression of diabetes was observed in the metformin group 
(absolute incidence 7.8%) compared with control subjects (absolute incidence 
11.0%). On average, 50% of the lifestyle group achieved the goal of ≥7%weight 
reduction, and 74% maintained at least 150 min/week of moderately intense activity. 
No serious side effects were seen in any group. 
Two other studies, each using a different class of glucose-lowering agent, have 
shown a reduction in progression to diabetes with pharmacological intervention. In 
the Troglitazone in Prevention of Diabetes (TRIPOD) study [93], 235 Hispanic 
women with previous gestational diabetes were randomized to receive either placebo 
or troglitazone (a drug now withdrawn from commercial sale in the U.S. but belonging 
to the thiazolidinedione class, of which two related drugs are currently available). The 
mechanism of action of the thiazolidinedione drugs is based upon a reduction of 
insulin resistance (“insulin sensitizers”). After a median follow-up of 30 months, the 
annual incidence of type 2 diabetes in the two groups was 12.3 and 5.4%, 
respectively. Thus, troglitazone treatment was associated with a 56% relative 
reduction in progression to diabetes. 
In the STOP-NIDDM trial [94, 95], 1,429 participants with IGT were randomized in a 
double-blind fashion to receive either the α-glucosidase inhibitor acarbose or a 
placebo. The subjects had a mean age of 55 years and a mean BMI of 31 kg/m2. 
After a mean follow-up of 3.3 years, a 25% relative risk reduction in progression to 
diabetes, based on one OGTT, was observed in the acarbose-treated group 
compared with the placebo group. If this diagnosis was confirmed by a second 
OGTT, a 36% relative risk reduction was observed in the acarbose group compared 
with the placebo group. The absolute risk reduction in the acarbose-treated group 
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was 9%. The effect of acarbose was consistent among all age groups, BMI values 
and between both sexes. 
The ADA and the National Institute of Diabetes and Digestive and Kidney Diseases 
concluded from these findings that there is now substantial evidence that type 2 
diabetes can be prevented or delayed. Individuals at high risk of developing diabetes 
(those with pre-diabetes) can be identified easily. It is not yet known whether the 
successful interventions will cost-effectively reduce the morbidity and mortality 
associated with diabetes. Diabetes prevention policies that focus on lifestyle 
modification, specifically modest weight loss and increased physical activity, are also 
very likely to have additional health benefits. Public health messages, health care 
professionals, and health care systems should all encourage behaviour changes to 
achieve a healthy lifestyle. Further research is necessary to understand better how to 
facilitate effective and efficient programs for the primary prevention of type 2 diabetes 
[79]. 
To reduce the risk for coronary heart disease (CHD) the Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) 
[96] recommends a multifactorial lifestyle approach. This approach is referred to as 
therapeutic lifestyle change (TLC) and includes the following components: reduced 
intake of saturated fats and cholesterol, therapeutic dietary options for enhancing 
LDL (low density lipoprotein) lowering, weight reduction and increased regular 
physical activity. According to the ATP III, at all stages of dietary therapy, physicians 
are encouraged to refer patients to registered dieticians or other qualified 
nutritionists. A high proportion of patients with the metabolic syndrome are 
overweight or obese and sedentary; for them, weight reduction therapy and physical 
activity guidance is required to obtain further CHD risk reduction beyond that 
achieved by LDL lowering through dietary alterations. 
1.4 Community pharmacies – a suitable setting for screening and 
health promoting activities 
Community pharmacists are well placed to assist in the provision of preventive care 
because pharmacies are highly accessible and often the first point of entry into the 
health care system [97-99]. Pharmacies are regarded to be a suitable place to 
promote awareness, screen high-risk patients, and to counsel patients on 
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intervention strategies to delay the onset of diabetes and CVD [82, 100, 101]. 
Moreover, community pharmacists are in an excellent position to collaborate with 
other health professionals in screening, monitoring and educating patients with 
diabetes and cardiovascular risk to prevent long-term complications. 
Investigations on implementation of screening programs in community pharmacy 
practice have already been performed. A lipid screening program in a large chain 
pharmacy with 159 participants was evaluated [102]. The investigators concluded 
that the screening program was successfully implemented in community pharmacy 
practice, but nevertheless more efforts need to be devoted to marketing this service 
to create value for the customer and to establish it as a viable component of 
pharmacy business. Another study investigated the implementation of a pharmacist-
delivered screening service for cardiovascular risk factors. The authors concluded 
that community pharmacies are a feasible site for health promotion and screening 
services for cardiovascular risk factors [103]. Another study demonstrated that, 
through ongoing screening programs, community pharmacists are in an ideal position 
to screen patients at risk for cardiovascular and cerebrovascular disease and refer 
patients to their physicians for further evaluation [104]. For early detection of type 2 
diabetes, a combination of risk factor assessment and blood glucose measurement 
performed in community pharmacies is regarded to be a promising approach and an 
opportunity for health promotion [82]. However, triage guidelines for diabetes 
screening in community pharmacies and appropriate cut-off points for capillary blood 
glucose are largely missing. 
Intervention studies in community pharmacies have been performed and they have 
been shown to have positive effects on cardiovascular risk factors, for example by 
improving outcomes in hypertension or cholesterol management [105-107]. There is 
growing evidence that incorporating a pharmacist or some services typically provided 
by traditional pharmacists into physician practices can improve blood pressure 
control [108]. A randomized controlled trial has shown that successful weight 
management can be achieved in a pharmacy setting, where patients have been 
consulted by the pharmacist every 3 weeks for a time period of 5 months [109]. 
Moreover, a community pharmacy diabetes care program has shown a clear 
relationship between pharmaceutical care services and improved HbA1c, improved 
patient satisfaction with pharmacy services, and decreased all-diagnosis costs. The 
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authors concluded that pharmacists can act as appropriate diabetes educators to 
help patients with diabetes improve clinical outcomes [110]. 
There is enough evidence that community pharmacies are a suitable setting to 
promote awareness, screen high-risk patients, and to deliver health promoting 
counselling to persons at risk for diabetes and cardiovascular disease. Unfortunately, 
triage guidelines for diabetes and/or lipid screening in community pharmacies and 
appropriate cut-off points for measurements in capillary blood are missing. In 
addition, measurements used in pharmacy-based screenings for diabetes or 
cardiovascular risk (such as blood pressure and blood glucose) are not validated. 
1.5 Swiss national diabetes screening campaign 
With the background described above, the Swiss federation of pharmacists has 
organised in spring 2002 a national “Self Care” diabetes screening campaign in 
Switzerland called “Stopp Zucker – Jetzt testen!”. The goal of this campaign was to 
detect individuals with previously undiagnosed type 2 diabetes and to provide 
information and advice towards lifestyle change for persons at risk. The campaign 
has been prepared in an interdisciplinary and multi-institutional collaboration with 
physicians, experts in the field of diabetes, health promotion or public health and 
representatives of patient organisations and health insurances. The pharmaceutical 
care research group at the Institute of Clinical Pharmacy, University of Basel, was 
assigned to evaluate the screening activities of the campaign. This presupposed the 
development of a screening concept with triage guidelines and cut-off points for 
capillary blood glucose measurement. The campaign attracted a large number of 
persons and resulted in a huge amount of data. For this reason, the evaluation was 
limited on the data records obtained in the German speaking part of Switzerland. The 
campaign was later enlarged with a 3 step follow-up study aiming to investigate the 
impact of a community pharmacy based screening campaign and to enable 
additional intervention studies. 
As dyslipidaemia is like type 2 diabetes associated with an increased risk for 
cardiovascular disesase, it makes sense to develop a screening concept for 
metabolic syndrome including screening for type 2 diabetes and dyslipidaemia. A 
regional screening campaign in community pharmacies gave the opportunity to 
evaluate in a pilot study the elaborated pharmacy-based triage guidelines for lipid 
screening. 
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1.6 Aim of the thesis 
The aim of this thesis was to develop and evaluate screening guidelines for 
cardiovascular risk factors in community pharmacy practice (in particular for type 2 
diabetes and dyslipidaemia) including appropriate cut-off points for triage decisions 
and to investigate the changes in lifestyle behaviour after a pharmacy-based 
screening campaign and related activities. 
 
As key elements towards these aims, the following projects were elaborated in this 
thesis: 
 
Blood pressure measurement in community pharmacy practice 
Hypertension is a major risk factor for cardiovascular disease. It is therefore 
important to include blood pressure measurement in any screening for cardiovascular 
risk factors. Moreover, blood pressure measurement is offered by most community 
pharmacies with the aim to screen for undetected hypertension or to monitor treated 
patients. 
 
Project A: The objective of this project was the validation of blood pressure 
measurement in community pharmacy practice. Therewith it was the aim 
to investigate whether a white coat effect and white coat hypertension, as 
known from blood pressure measurement by physicians, can also be 
observed in community pharmacy practice. 
 
Screening campaigns in community pharmacies 
Community pharmacies are regarded as a suitable setting to promote awareness and 
screen high-risk persons for diabetes and cardiovascular disease. Unfortunately, 
triage guidelines for diabetes and lipid screening in community pharmacy practice are 
missing. 
 
Project B: It was the aim of this project to develop a sequential screening concept for 
type 2 diabetes in community pharmacy practice. A national diabetes 
screening campaign (Self Care 2002: “Stopp Zucker – Jetzt testen!) 
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provided the possibility to evaluate the elaborated triage guidelines and 
cut-off points for capillary blood glucose measurements. 
  
Project C: The objective of this project was in the context of a pilot study to 
implement screening for dyslipidaemia in a regional pharmacy-based 
campaign and to investigate the developed triage guidelines and cut-off 
points for lipid screening in community pharmacies. 
 
Health promotion and lifestyle change 
There is growing evidence that weight loss and lifestyle changes in nutrition habits 
and physical activity have positive effects on the prevention of diabetes and 
cardiovascular risk. Therefore health promoting counselling in suitable and cost-
effective settings, which is able to induce lifestyle changes and weight loss, would be 
of great value. 
 
Project D: It was the objective of this project to investigate the changes in lifestyle 
and body weight after immediate counselling in community pharmacies 
during a national screening campaign for type 2 diabetes.  
  
Project E: In an additional randomised controlled trial it was the aim to investigate 
the effect of a telephone-based counselling on lifestyle changes and body 
weight of persons at risk for type 2 diabetes. 
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2 Blood pressure measurement in community pharmacies 
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pharmacy practice 
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Abstract 
Objective 
The aim of the present study was to investigate whether a white coat effect (WCE) 
can be observed and quantified in community pharmacy practice. 
Methods 
In five community pharmacies of Basel, Switzerland, clients asking for blood pressure 
(BP) measurement were recruited to participate in a free of charge study. Blood 
pressure was measured in four different settings: pharmacy (using mercury 
sphygmomanometers), outpatient clinic (measurement by a nurse using mercury 
sphygmomanometers), self-measurement at home (using automated wrist devices) 
and daytime ambulatory BP (ABP) monitoring (using SpaceLabs 90207 monitors). 
White coat effect was defined as the difference between pharmacy or outpatient and 
daytime ABP. 
Results 
A total of 50 subjects completed all measurements (42% male, mean age 53.7 years 
± 14.0). Blood pressure values of the different settings: (means in mmHg ± SD, 
systolic; diastolic): pharmacy BP 129 ± 19; 82 ± 10, outpatient clinic BP 127 ± 15; 82 
± 10, home BP 119 ± 15; 73 ± 9, daytime ABP 124 ± 10; 79 ± 8. Pharmacy BP was 
significantly higher (p=0.03 systolic; p=0.02 diastolic) compared with daytime ABP 
and differences among subjects with antihypertensive medication (n=22) were even 
more significant (p<0.01). Individual differences were found between pharmacy BP 
and daytime ABP: +4.6 ± 14.8; +2.9 ± 8.3. Outpatient BP was significantly higher 
compared with daytime ABP in diastolic (p=0.04) but not in systolic values. Individual 
differences between outpatient BP and daytime ABP were +2.5 ± 13.1; +2.8 ± 9.2. 
‘Clinically important WCE’ (>=20 mmHg systolic or >=10 mmHg diastolic) was 
observed in 24% of all subjects in the pharmacy and in 20% in the outpatient clinic. 
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Conclusions 
Our findings show that white coat effect and white coat hypertension exist in 
community pharmacy practice and are similar to the effects in an outpatient clinic. 
 
Keywords 
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community pharmacy services y pharmaceutical care 
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Introduction 
Blood pressure measurement is probably the most common medical measurement 
and also offered by most community pharmacies with the aim to screen for 
undetected hypertension or to monitor treated patients. Since this contribution of 
pharmacists to health care and prevention has become normal duty, the reliability of 
the measurement is of particular importance. 
 
From several studies it is well known that standard measurement of blood pressure 
in a clinical environment may trigger an alerting reaction resulting in a rise of blood 
pressure in the patient [1, 2]. This phenomenon is called the ‘white coat effect’ (WCE) 
and is generally defined as the difference between clinic blood pressure and daytime 
ambulatory blood pressure (ABP) [3, 4]. Attention has also focused on ‘white coat 
hypertension’ (WCH), which is usually defined as an elevated clinic blood pressure 
compared to normal daytime ABP. Thus white coat hypertension (also called 
‘isolated office hypertension’) is defined as high blood pressure levels (≥140/90 
mmHg) at the clinic or medical office, but normal blood pressure levels on ABP 
monitoring with daytime mean blood pressure below 135/85 mmHg [5, 6]. The 
prevalence of WCH is approximately 20%, varying according to the criteria adopted 
for normotension and hypertension [4, 7]. It is important to mention that white coat 
hypertension and white coat effect are different entities. The first is a binary (yes/no) 
definition imposed by stratification of blood pressure and the second a quantitative 
measure of blood pressure rise resulting from clinic visit. 
 
The clinical significance of white coat hypertension and its effect is currently not well 
described. Some studies have suggested that the risk of future cardiovascular 
disease events is less in subjects with WCH (elevated clinic/office blood pressure 
and normal daytime ABP) than in those with sustained hypertension (elevated 
clinic/office blood pressure and elevated daytime ABP) [8-10]. On the other hand, 
studies suggested that subjects with WCH are also at increased risk for target organ 
damage and cardiovascular events [11, 12]. 
 
More recently, a phenomenon opposed to white coat hypertension has drawn 
attention. Masked hypertension is characterized by persistently normal blood 
pressure levels at the medical office and hypertension on ABP [13]. The prevalence 
Blood pressure measurement in community pharmacies 
43 
of masked hypertension ranges from 14% to 30%. It often occurs in older patients 
with greater body mass indices [14]. 
 
To assess the white coat phenomenon, not only ABP monitoring has been performed 
but also self-measured home blood pressure (HBP). In fact HBP showed less 
reliability than ABP in detecting WCE, but is nevertheless regarded as an eligible 
method [3, 7, 15, 16]. Self-reported blood pressure values have been shown to be 
largely reliable [17, 18], whereas other studies suggest the contrary [19], [20]. 
 
For pharmacy practice it could be expected that comparable white coat effects exist, 
possibly depending on measurement technique (with mercury sphygmomanometer 
or with automated devices). However, no findings are published on extent and 
importance of the white coat phenomenon in community pharmacies. Such 
investigations would be valuable for pharmacy practice, mainly for decisions in 
pharmaceutical triage after blood pressure measurement. The aim of the present 
study was to investigate whether the white coat effect could also be observed in a 
community pharmacy setting. For this purpose we evaluated the variation in blood 
pressure of subjects between different settings: a) blood pressure measurement in 
the pharmacy; b) in a clinical setting (measurement by a nurse); c) at home and d) 
with ambulatory blood pressure monitoring. We also studied the prevalence of white 
coat hypertension and masked hypertension in our sample. 
 
Methods 
Subjects 
Over a period of eight weeks in Spring 2003, clients were recruited to this free of 
charge study from five community pharmacies in Basel, Switzerland. The study 
population included 52 subjects who went to the pharmacies with the intention of 
having their blood pressure measured. The subjects were enrolled into the study if 
the following criteria were met: at least 18 years old and no serious sickness 
diagnosed. Out of the 52 subjects, two had to be excluded from the analysis because 
they abandoned ambulatory blood pressure monitoring. The subjects’ ages varied 
from 27 to 83 years (mean 53.7 ± 14.0 years). The present study was approved by 
the Ethics Committee of Basel and informed consent was given by all participants. 
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Blood pressure measurements 
Blood pressure was measured in the pharmacy, in the outpatient clinic, at home and 
with ABP monitoring. Before the study, the pharmacists from the five pharmacies that 
assisted in the study were carefully briefed on how perform blood pressure 
measurements properly. The pharmacist measured pharmacy blood pressure in the 
morning using a standard mercury sphygmomanometer with an appropriate cuff for 
the arm’s circumference. All sphygmomanometers used in this study had been 
calibrated at most within the last 24 months. After the study participant had rested for 
five minutes in the sitting position, the measurements were taken on the participant’s 
bare right arm, which was comfortably placed at heart level. The mean of two 
measurements was used. 
In addition to blood pressure values, the following data were obtained in the 
pharmacy: age, sex, weight, height, smoking and existing antihypertensive treatment. 
For the self-measurement of blood pressure at home (HBP), the subjects used 
Omron HEM-637IT (Omron Corp., Tokyo, Japan) digital blood pressure monitors. 
This automated oscillometric device measures wrist artery pressure and has passed 
clinical validation according to the Association for the Advancement of Medical 
Instrumentation (AAMI), but not according to the British Hypertension Society (BHS) 
and International Protocol criteria [21]. At enrolment, the pharmacist instructed the 
study participants how to use the Omron recorders and provided written guidelines 
for their operation at home. The subjects recorded their blood pressure in the 
morning (between 06:00 h and 10:00 h) and in the evening (between 18:00 h and 
22:00 h) for four consecutive days during the week. Each measurement session 
consisted of two readings after five minutes rest in the sitting position and with one 
minute in between the two recordings. Self-measured blood pressure values were 
noted by the study participant and kept in a diary. Additionally data stored in the 
memory of the devices was used to check the validity of recorded data. The average 
blood pressure of the measurement of the second to forth day was used for analysis. 
The cuff size (13.5 to 21.5 cm) of the Omron devices was suitable for all study 
participants. 
 
At the medical outpatient department of the University Hospital of Basel, a nurse 
using a standard mercury sphygmomanometer with an appropriate cuff for the arm’s 
Blood pressure measurement in community pharmacies 
45 
circumference measured blood pressure. The two nurses who assisted in the study 
were carefully briefed on how to perform blood pressure measurements properly. 
The measurements in the outpatient clinic were performed at nine o’clock. After the 
study participant had rested for five minutes in the sitting position, the measurements 
were taken on the participant’s bare right arm, which was comfortably placed at heart 
level. The mean of two measurements was used as well. 
After mercury sphygmomanometer measurement by the nurse, ABP monitoring was 
performed using oscillometric SpaceLabs 90207 monitors (Space Labs Inc., 
Redmond, Washington, USA), whose accuracies were checked monthly against a 
mercury column sphygmomanometer. The recorders were programmed to measure 
blood pressure every 20 minutes from 06:00 h and 18:00 h and every 30 minutes 
from 18:00 h to 06:00 h. 
The monitoring was always performed on a working day, and the subjects were 
instructed to maintain their usual activities throughout the day. The appropriate cuff 
for the arm’s circumference was placed on the non-dominant arm and the subjects 
were instructed to keep their arm stretched out along their body and not to move it 
during measurement. Recordings considered valid for analysis had a minimum 
duration of 24 hours and in total 54 valid readings were obtained, corresponding to at 
least 90% of all measurements. The average blood pressure of the daytime period 
was used, which was defined as the time interval between 06:00 h and 18:00 h 
 
Analysis of data 
Based on blood pressure measurements at the pharmacy and on average daytime 
ABP measurements, the subjects were divided into the following categories: a) 
sustained hypertension:  systolic blood pressure at the pharmacy ≥140 mmHg or 
diastolic blood pressure ≥90 mmHg, or both, and mean of systolic or diastolic blood 
pressure of daytime ABP, respectively ≥135 mmHg or ≥85 mmHg, or both; b) white 
coat hypertension: systolic blood pressure at the pharmacy ≥140 mmHg or diastolic 
blood pressure ≥90 mmHg, or both, and mean of systolic and diastolic blood 
pressure of daytime ABP <135 mmHg and <85 mmHg, respectively; c) 
normotension: systolic blood pressure at the pharmacy <140 mmHg and diastolic 
blood pressure <90 mmHg, and mean of systolic and diastolic blood pressure of 
daytime ABP <135 mmHg and <85 mmHg, respectively; d) white coat normotension: 
systolic blood pressure at the pharmacy <140 mmHg and diastolic blood pressure 
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<90 mmHg, and mean of systolic or diastolic blood pressure of daytime ABP, 
respectively ≥135 mmHg or ≥85 mmHg, or both. 
The WCE of each subject was defined as difference between the blood pressure 
measured in the pharmacy (systolic or diastolic) and the average daytime ABP 
(systolic or diastolic) as well as the difference between pharmacy blood pressure 
(systolic or diastolic) and the average HBP (systolic or diastolic). Subjects were also 
evaluated with regard to ‘clinically important white coat effect’ [4, 22], which was 
defined to exist if the difference between the pharmacy blood pressure measurement 
and the mean blood pressure values form the daytime ABP was ≥20 mmHg for 
systolic blood pressure and ≥10 mmgHg for diastolic blood pressure, respectively. 
Furthermore, subjects were identified as exhibiting a white coat response if they 
showed white coat hypertension (blood pressure at the pharmacy ≥140 mmHg and/or 
≥90 mmHg and daytime ABP <135 mmHg and <85 mmHg) or a clinically important 
white coat effect. 
 
Statistical analysis 
The SPSS statistical package (SPSS, Inc, Chicago, Illinois, USA) was used to store 
and analyse the data. Values are expressed as mean ± standard deviation (SD) 
including 95% confidence intervals (CI). Blood pressure values were analysed using 
repeated analysis of variance (Generalized linear model: GLM) with linear contrasts 
to detect pair-wise differences using the measured values in the pharmacy as 
reference group. In particular differences between pharmacy and the other blood 
pressure measurements were assessed by paired t-tests, values of p<0.05 being 
considered statistically significant. All p-values were calculated two-sided. 
 
Results 
Characteristics of patients 
The study group included 50 subjects of whom 21 (42.0%) were male, six (12.0%) 
were smokers and 22 (44.0%) were under antihypertensive medication. Among those 
under antihypertensive medication, 11 (50.0%) were receiving one class of 
antihypertensive drug, 7 (31.8%) were receiving two and 4 (18.1%) were receiving 
three or more different antihypertensive drugs. The subject’s mean age was 53.7 
years ± 14.0 (SD) and their average BMI was 25.2 kg/m2 ± 3.7 (SD). 
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Blood pressure measurements at different settings 
The means of blood pressure values of the different settings are given in Table 1. 
The level of blood pressure as measured in the pharmacy was significantly higher 
(p=0.032 for systolic blood pressure and p=0.018 for diastolic blood pressure, 
respectively) than that of ABP monitoring. However, there were considerable inter-
individual variations. The level of pharmacy blood pressure was particularly 
significantly elevated compared to that of HBP (p<0.001 for both systolic and diastolic 
blood pressure). Outpatient clinic blood pressure was significantly higher compared 
with daytime ABP only in diastolic values (p=0.037) but not in systolic values. 
However there was no significant difference in the levels of pharmacy blood pressure 
versus outpatient clinic blood pressure measurements. 
 
The means of blood pressure values of the subjects with antihypertensive medication 
(n=22) as well as of the subjects without antihypertensive medication (n=28) are 
given in Table 1. In the population with antihypertensive medication the level of blood 
pressure as measured in the pharmacy was higher than that of ABP monitoring with 
increased statistical significance compared with the whole population (p=0.001 for 
both systolic and diastolic blood pressure). 
 
White coat effect 
The mean of the white coat effects (individual differences between the blood 
pressure measured in pharmacy and the average daytime ABP) as well as the 
means of the differences between the blood pressure measured in the pharmacy and 
HBP of all subjects and of the populations with or without antihypertensive 
medication are given in Table 2. Analysing the white coat effect of all subjects, 
individual differences between pharmacy blood pressure and daytime ABP were +4.6 
± 14.8 mmHg for systolic blood pressure and +2.9 ± 8.3 mmHg for diastolic blood 
pressure. White coat effect in the outpatient clinic was +2.5 ± 13.1 mmHg for systolic 
blood pressure and +2.8 ± 9.2 mmHg for diastolic blood pressure and thus smaller 
than WCE measured in the pharmacy, even though not statistically significant. In the 
population with antihypertensive medication WCE was more expressed with 
individual differences between pharmacy blood pressure and daytime ABP being 
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+12.8 ± 15.3 mmHg for systolic blood pressure and +6.8 ± 8.5 mmHg for diastolic 
blood pressure. 
 
In the pharmacy clinically important white coat effect (difference between pharmacy 
blood pressure and daytime ABP ≥20 mmHg for systolic blood pressure and/or ≥10 
mmHg for diastolic blood pressure) was observed in 12 subjects (24.0%) from the 
whole study population and in 10 subjects (45.5%) of those persons with 
antihypertensive medication (n = 22). In the outpatient clinic clinically important white 
coat effect (difference between outpatient clinic blood pressure and daytime ABP ≥20 
mmHg for systolic blood pressure and/or ≥10 mmHg for diastolic blood pressure) was 
observed in 10 subjects (20.0%) of the whole study population. 
 
White coat hypertension and masked hypertension 
Analysing the whole population as well as the populations with or without 
antihypertensive medication and considering the pharmacy blood pressure values 
and the mean value of daytime ABP, the following results were observed (Table 3): 
54% of the subjects were normotensive, 18% were hypertensive, 16% showed white 
coat hypertension and 12% showed masked hypertension. In the population with 
antihypertensive medication (n=22) an increased number of persons with 
hypertension and white coat hypertension were observed: 27.3% were hypertensive, 
22.7% were white coat hypertensive and only 4.5% showed masked hypertension. In 
the population without antihypertensive medication (n=28) an increased number of 
persons with masked hypertension were found (17.9%). 
 
A white coat response (white coat hypertension and/or clinically important white coat 
effect) was shown by 16 subjects (32%) from the whole study population (n=50) and 
12 subjects (54.5%) from the population taking antihypertensive medication (n=22). 
 
Discussion 
The results of our study show that white coat effect and white coat hypertension can 
also be observed in community pharmacy practice. Statistically significant differences 
were identified between pharmacy blood pressure levels and daytime ABP levels. 
Individual differences between the pharmacy blood pressure and the average 
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daytime ABP, which is usually defined as white coat effect, were 4.6 mmHg for 
systolic blood pressure and 2.9 mmHg for diastolic blood pressure in the whole study 
population. Furthermore we identified WCH in 16.0% of all subjects and in 22.7% of 
those subjects with antihypertensive medication, which demonstrates the potential for 
misclassification of hypertensive status if only pharmacy measurements are used. 
Another remarkable finding is the higher percentage of masked hypertension in the 
untreated population (17.9%) than in the population with antihypertensive medication 
(4.5%) as this topic is of increasing interest [23],[24]. 
Using HBP instead of ABP as reference for determining white coat effect, differences 
between the pharmacy blood pressure and HBP were 9.7 mmHg for systolic blood 
pressure and 9.0 mmHg for diastolic blood pressure. The difference between HBP 
and daytime ABP found in the present work is therefore quite consistent with data 
reported in the literature [3, 15, 16]. This difference probably not only reflects the 
different circumstances of measurement but also differences in measurement 
devices and in the number of measurements. Hond et al. investigated the white coat 
effect in a physician’s practice in 247 hypertensive patients using both methods of 
ABP monitoring and HBP measurement [16]. The observed white coat effect using 
ABP, which was regarded as the reference method, was 7.2 mmHg for systolic blood 
pressure and 5.0 mmHg for diastolic blood pressure. Using HBP to determine white 
coat effect, they found 12.3 mmHg for systolic blood pressure and 8.6 mmHg for 
diastolic blood pressure. The findings of Hond et al. suggested that self-
measurement at home cannot replace ambulatory monitoring and that both 
techniques have supplementary roles in the diagnosis of hypertension [16]. Because 
home devices are easy to use and relatively cheap the recommendation of home 
blood pressure measurement by pharmacists would therefore be reasonable, 
particularly in people with elevated blood pressure. 
 
Several studies showed that the higher the blood pressure values, the more persons 
show clinically important white coat effect [4, 24]. In fact, the population with 
antihypertensive medication in the present study shows a more expressed white coat 
effect and a more frequent white coat hypertension than the untreated subjects. It 
can be supposed that if only hypertensive patients were included in our study, then 
the observed white coat effect would have been enhanced. Also the number of 
subjects exhibiting white coat hypertension would probably have been higher. 
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A limitation of the present study is the rather small number of study subjects. It would 
be very useful to perform further investigations using a greater number of patients 
with preferably comparable antihypertensive treatments. Even though not statistically 
significant, WCE found in pharmacy measurements were expressed more than in 
outpatient measures. It is possible that this could be due to an order effect (higher 
first pressures), since the pharmacy blood pressure measurements were the first 
step in the protocol. 
Both pharmacy and outpatient clinic readings were taken using mercury 
sphygmomanometers, which is still the most common method for measuring blood 
pressure in Switzerland. The pharmacist himself always took readings in the 
pharmacy. Nevertheless, it is possible that the observed WCE would be smaller if 
automated devices would have been used. 
A limitation of all studies investigating the white coat phenomenon is the definition of 
WCE. It has been criticised on the grounds that the difference between the clinic and 
ambulatory blood pressures will be influenced by many factors other than the 
stressor effect of the clinic visit. Clearly, the level of activity during the day will be a 
major factor and therefore, a patient who has a stressful day at work on the day of 
the ambulatory recording (and consequently a higher daytime blood pressure) is 
likely to show a smaller WCE than one who stays at home all day and is physically 
inactive. Another limitation of these studies is that the clinic (in our case pharmacy) 
and the ambulatory pressures are recorded on different days. This will tend to reduce 
reliability of the measure. In fact, it can be stated that because WCE is, by definition, 
a difference score, its reliability is likely to be relatively low [3]. 
 
In conclusion the white coat phenomenon also exists in community pharmacy 
practice. The results of the present study further suggest that WCE and WCH are 
even more likely to occur in the pharmacy than in an outpatient clinic, where a nurse 
measures blood pressure. This should be considered in screening for undetected 
hypertension as well as in monitoring of treated hypertensive patients. Therefore 
pharmacists as well as physicians should be aware of the existing white coat 
phenomenon in community pharmacy practice in order to give appropriate advice to 
patients. However, the white coat effect generated in community pharmacy practice 
seems to be smaller than that triggered by physicians. Thus blood pressure 
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measurements in community pharmacies seem to be at least as reliable as those of 
other health professionals. 
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Tables 
Table 1: Blood pressure values of all subjects and of subjects with or without antihypertensive medication 
 
All subjects  
 
(n=50) 
Mean (95% CI) ± SD (mmHg) 
Subjects with anti-
hypertensive medication 
(n=22) 
Mean (95% CI) ± SD (mmHg) 
Subjects without anti-
hypertensive medication 
(n=28) 
Mean (95% CI) ± SD (mmHg) 
Pharmacy BP 
 systolic (mmHg) 
 diastolic (mmHg) 
129 (124 to 134) ± 19
82 (79 to 85) ± 10
138 (129 to 147) ± 20
84 (80 to 88) ± 10
122 (117 to 127) ± 14
80 (76 to 84) ± 10
Outpatient clinic BP 
 systolic (mmHg) 
 diastolic (mmg Hg) 
127 (123 to 131) ± 15
82 (79 to 85) ± 10
134 (126 to 142) ± 18
84 (79 to 89) ± 11
121 (117 to 126) ± 11
80 (77 to 83) ± 8
Daytime ABP 
 systolic (mmHg) 
 diastolic (mmHg) 
124 (121 to 127) ± 10
79 (77 to 81) ± 8
125 (119 to 131) ± 13
77 (74 to 81) ± 8
124 (121 to 127) ± 7
80 (78 to 83) ± 7
Home blood pressure (HBP) 
 systolic (mmHg) 
 diastolic (mmHg) 
119 (115 to 124) ± 15
73 (70 to 75) ± 9
126 (119 to 134) ± 17
76 (71 to 80) ± 10
114 (110 to 118) ± 11
71 (67 to 74) ± 8
BP, blood pressure; ABP, ambulatory blood pressure 
 
  
Table 2: Means of differences between the different blood pressure (BP) measurements 
 
All subjects  
 
(n=50) 
Mean (95% CI) ± SD (mmHg) 
Subjects with anti-
hypertensive medication 
(n=22) 
Mean (95% CI) ± SD (mmHg) 
Subjects without anti-
hypertensive medication 
(n=28) 
Mean (95% CI) ± SD (mmHg) 
Pharmacy BP – Daytime ABP (=WCE) 
 systolic 
 diastolic 
4.6 (0.4 to 8.9) ± 14.8
2.9 (0.5 to 5.2) ± 8.3
12.8 (6.0 to 19.6) ± 15.3
6.8 (3.0 to 10.5) ± 8.5
-1.8 (-6.0 to 2.5) ± 11.0
-0.2 (-2.9 to 2.5) ± 6.9
Pharmacy BP – HBP 
 systolic 
 diastolic 
9.7 (6.5 to 12.8) ± 11.1
9.0 (6.6 to 11.4) ± 8.4
11.5 (6.1 to 17.0) ± 12.3
8.4 (4.5 to 12.3) ± 8.8
8.2 (4.3 to 12.1) ± 10.1
9.5 (6.3 to 12.7) ± 8.2
Outpatient clinic BP – Daytime ABP 
 systolic 
 diastolic 
2.5 (-1.2 to 6.3)  ± 13.1
2.8 (0.2 to 5.4) ± 9.2
8.8 (1.9 to 15.7) ± 15.6
6.8 (2.1 to 11.5) ± 10.6
-2.4 (-5.6 to 0.7) ± 8.1
-0.4 (-2.9 to 2.1) ± 6.4
Outpatient clinic BP – HBP 
 systolic 
 diastolic 
7.6 (4.4 to 10.8) ± 11.3
8.9 (6.4 to 11.4) ± 8.8
7.5 (1.3 to 13.8) ± 14.0
8.4 (3.3 to 13.5) ± 11.5
7.6 (4.2 to 11.0) ± 8.9
9.4 (6.9 to 11.8) ± 6.3
Pharmacy BP – Outpatient clinic BP 
 systolic 
 diastolic 
4.0 (-2.5 to 10.5) ± 14.6
0.0 (-4.7 to 4.7) ± 10.7
0.6 (-3.9 to 5.1) ± 11.7
0.2 (-3.1 to 3.4) ± 8.5
2.1 (-1.6 to 5.8) ± 13.0
0.1 (-2.6 to 2.8) ± 9.4
BP, blood pressure; ABP, ambulatory blood pressure; HBP, Home blood pressure; WCE, White coat effect 
  
 
Table 3: Diagnosis of arterial hypertension according to the criteria of blood pressure normality on ABP and at the pharmacy 
 
Pharmacy BP 
(mmHg) 
ABP 
(mmg Hg) 
Number and % of all 
subjects 
 
 
(n=50) 
Number and % of 
subjects with 
antihypertensive 
medication 
(n=22)
Number and % of 
subjects without 
antihypertensive 
medication 
(n=28)
Normotension <140 and <90 <135 and <85 27 (54%) 10 (45.5%) 17 (60.7%)
Hypertension ≥140 or ≥90 ≥135 or ≥85 9 (18%) 6 (27.3%) 3 (10.7%)
White coat hypertension ≥140 or ≥90 <135 and <85 8 (16%) 5 (22.7%) 3 (10.7%)
Masked hypertension <140 and <90 ≥135 or ≥85 6 (12%) 1 (4.5%) 5 (17.9%)
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3 Screening campaigns in community pharmacies 
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Abstract 
Background 
For early detection of persons at risk for type 2 diabetes, a combination of risk factor 
assessment and glucose measurement could be a promising approach and an 
opportunity for health promotion. A sequential screening concept was developed and 
used in a national pharmacy based screening campaign. 
 
Methods 
Community pharmacies of the German speaking part of Switzerland participating in 
the national Self Care campaign “Stop diabetes-test now” offered a free of charge 
diabetes risk assessment with consecutive capillary blood glucose measurement. 
Motivation for lifestyle change was assessed based on the Transtheoretical Model 
(TTM) of behaviour change. A 35 items data sheet served as a structured screening 
protocol and enabled quick and reliable documentation of all relevant data. 
Outcomes measures were: Age, sex, cigarette smoking, total score of the ADA 
diabetes risk-factor questionnaire, family history of diabetes, body mass index, lack 
of physical activity, blood pressure, capillary blood glucose, motivation for lifestyle 
change, counselling activities and triage decisions of the pharmacy team. 
 
Results 
During the 5 weeks of spring 2002, 530 pharmacies screened a total of 94124 
persons (33.1% male, mean age 60.9 years ± 14.1 (SD)). Risk profile: family history 
of diabetes 26.4%; BMI ≥25kg/m2 49.3%; low physical activity 27.2%; elevated blood 
pressure 45.7%; less than 2 risk factors and normoglycaemia (fasting glucose (FG) 
or non fasting (NFG) <5.3mmol/l) 21.6%; ≥2 risk factors but normoglycaemia 71.5%, 
borderline glycaemia (FG 5.3-6.1mmol/l, confirmed in a second measurement) 2.5% 
and hyperglycaemia (FG ≥6.1mmol/l or NFG ≥11.1mmol/l) 4.4%. 
Of all persons screened 6.4% were referred to a physician. More than 69000 
participants (73.6%) got targeted advice with respect to physical activity and/or 
nutrition based on their specific risk profile. 
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Conclusions 
The screening campaign attracted an important part of Swiss German speaking 
adults (2.4%). The sequential screening could successfully be implemented into 
pharmacy practice. Only 6.9% of the generally elderly persons screened were 
detected with suspicion for diabetes type 2. However, 71.5% had at least two risk 
factors. This provided an opportunity to initiate targeted counselling regarding 
therapeutic lifestyle change. 
Screening campaigns in community pharmacies 
61 
Background 
Type 2 diabetes is a serious disease with growing prevalence throughout the world. It 
often remains undetected and its complications causes a heavy burden of suffering 
[1, 2]. A number of risk factors are associated with prevalent undiagnosed diabetes 
(age, sex, family history, body mass index, insufficient physical activity). It has been 
estimated that onset of type 2 diabetes occurs at least 4-7 years before clinical 
diagnosis [3]. In individuals with type 2 diabetes, cardiovascular disease (CVD) is the 
leading cause of death. The risk for CVD starts to increase as much as 15 years 
before diabetes diagnosis [4]. Earlier detection and management of diabetes and 
related metabolic abnormalities can be beneficial and there is substantial evidence 
that type 2 diabetes can be prevented or delayed [5]. 
Different concepts and recommendations for screening have been proposed and 
evaluated [6-12]. It is important to distinguish between screening and diagnostic 
testing. The purpose of screening is to identify asymptomatic individuals who are 
likely to have diabetes, or are at increased risk for development of diabetes. 
Additional clinical examination and tests are required to establish a definitive 
diagnosis. 
The U.S. Preventive Services Task Force (USPSTF) found good evidence that 
available screening tests can accurately detect type 2 diabetes during an early, 
asymptomatic phase. But evidence from prospective studies is still insufficient to 
recommend for or against routine screening [13]. The American Diabetes Association 
(ADA) acknowledged that data were insufficient to determine the benefits of diabetes 
screening and thus concluded that the decision to test for diabetes should be based 
on clinical judgment and patient preference [14]. In 2003 the World Health 
Organisation (WHO) in collaboration with the International Diabetes Federation 
published similar recommendations in a report on different issues specific to 
screening of asymptomatic individuals [15]. 
 
For community pharmacists, uniquely positioned as the easiest accessible health 
care providers in the community, screening is an important opportunity through which 
they can help achieve public health goals [16]. However, for diabetes screening in 
pharmacies no specific guidelines, triage algorithms or validated procedures with 
specific cut-off points are known. Assessment of risk factors, blood pressure 
measurements and capillary blood glucose measurements with devices approved for 
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home use are normal duty in many pharmacies or are easy to implement. On 
regional level different initiatives have been organised in Switzerland to identify at-
risk patients for diabetes or metabolic syndrome through community pharmacy based 
diabetes screening [17]. 
 
Through therapeutic lifestyle change, especially focused on physical activity and 
healthy nutrition onset of type 2 diabetes can be prevented or delayed [11, 18]. 
Individually tailored interventions are needed to achieve behaviour change. Using the 
Transtheoretical Model (TTM) of behaviour change the traditional action-oriented 
interventions could be tailored to motivational readiness to change [19]. 
In Switzerland the TTM was introduced into pharmacy practice for counselling on 
nicotine reduction [20]. Furthermore screening for undetected diabetes proved to be 
feasible. This offers the opportunity to design a screening concept that is not only 
aimed to detect pre-diabetic persons but also to deliver individually targeted 
counselling on therapeutic lifestyle change for persons at risk. 
 
With this background the Swiss federation of pharmacists started in 2002 a national 
campaign “Stop diabetes – test now”. It was prepared in an interdisciplinary and 
multi-institutional collaboration with physicians, experts in the field of diabetes, health 
promotion or public health and representatives of patient organisations and health 
insurances. The goal of the campaign was to detect previously unidentified persons 
with or at high risk for diabetes and to deliver information and advice on lifestyle 
change. 
A study group was charged with the evaluation of the campaign.  
 
Research questions were: 
• Which population groups used the community pharmacy based free of charge 
screening? 
• What was their risk profile? 
• What were the activities of the pharmacy teams including triage decisions and 
counselling activities? 
• What was the feedback of patients and physicians after referral and who were 
accepted by the medical profession for further treatment? 
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Later the study was enlarged with a 3 step follow-up to investigate the impact of a 
community pharmacy based screening campaign on lifestyle change and health 
promotion and to open the possibility for additional intervention studies. 
 
This paper describes the screening concept and the results gathered during the 
campaign. A second paper [21] presents the 3-step follow up study with results on 
the impact and the sustainability of induced lifestyle change 3, 9 and 15 months after 
a community pharmacy based diabetes screening. 
 
Methods 
Sequential screening concept 
For community pharmacy practice a specific screening concept was developed and 
triage guidelines were established. The screening procedure was structured into 
different sequences (Figure 1): 
a) ADA risk assessment questionnaire: The questionnaire according to ADA [22] 
with 7 items was filled in by the individuals themselves before pharmacy 
screening to sensitise for diabetes risk assessment. Individuals were informed 
that a score above 10 (maximum = 27) indicated the appropriateness for a 
pharmacy diabetes screening, but no person interested in the pharmacy 
screening was excluded based on a low ADA score.  
b) Pharmacy risk assessment: Based on a questionnaire of Herman WH [23] to 
identify people at increased risk for undiagnosed diabetes, a set of risk factors 
was defined with the aim to select people for a following blood glucose 
measurement. The pharmacy risk assessment was performed by the 
pharmacy team. 
c) Blood glucose measurement: With people at risk for undiagnosed diabetes 
subsequent capillary blood glucose (CBG) was measured by a pharmacist. 
Definitions of risk factors and the cut-off points for triage are either based on ADA 
recommendations for community screening using capillary whole blood glucose [22], 
adjusted to European cut-off points for BMI (≥25 kg/m2) or adopted from the 
classification of intensity of health enhancing physical activity used in a Swiss 
physical activity survey [24, 25]. 
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Blood pressure measurement was included in the pharmacy risk assessment 
because pilot studies had shown that through a diabetes screening in community 
pharmacies unknown blood pressure was very frequently detected [17]. Cut-off 
points were based on WHO criteria with direct referral to a physician when measuring 
RR ≥160/100 mmHg or identifying as a risk factor when measuring RR ≥ 140/90 
mmHg. 
 
Screening in community pharmacies is generally performed with blood glucose 
monitoring meters using capillary whole blood (finger-stick glucose); the cut-off points 
used are adapted to this. Fasting was defined as no consumption of food or 
beverage other than water for at least 8 h before testing. To adapt to the situation in 
daily pharmacy practice besides the preferred measurement of fasting blood glucose 
also non fasting blood glucose was used. But the non fasting blood glucose results 
were only considered as normal, when normal values for fasting (<5.3 mmol/l) were 
achieved. For higher non fasting blood glucose levels an additional test in the fasting 
state was recommended. The sequential screening with the triage guidelines and 
cut-off points is summarised in a flowchart in Figure 2. 
 
The screening campaign 
Swiss pharmacies were used to participate in the so called “Self Care-campaigns”, 
which are annually organised by the Swiss federation of pharmacists. The whole 
screening and evaluation procedure for this campaign were tested 9 months before 
in a pilot campaign with a sample of 30 pharmacies. The pilot produced 300 
screenings and proved to be feasible and no relevant changes were necessary. 
The pharmacies taking part in the campaign had to subscribe and pay a fee (300 
EUR) in advance to get all promotional material (flyers, posters), blood glucose 
meters and free access to all continuing education activities. In an obligatory evening 
course, pharmacy teams were trained in blood glucose measurement and received 
oral and written information on triage and counselling guidelines. 
CBG measurements were performed in all pharmacies using the same new 
instruments (GlucometerDex®, Bayer Diagnostics). Pharmacies automatically 
received refills for their blood glucose meters, when they had delivered 25 completed 
datasheets. 
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During the campaign a hotline was installed to answer questions with respect to the 
evaluation and to the triage guidelines. 
Multi-institutional collaboration was used to create awareness in print media and 
television before and during the campaign. Persons interested could choose a 
pharmacy and participate free of charge during the 30 working days from 8th April to 
10th May 2002. Persons under treatment for diabetes and/or cardiovascular disease 
could be included, but the aim was to reach persons outside of actual medical care. 
 
Evaluation 
A 35 item data sheet was developed to serve as a structured screening protocol and 
to enable quick and reliable documentation of all relevant data. It was manufactured 
as an anonymous 3-side carbonless copy paper. The front page served as study 
record, the first copy was for the patient or his physician and the second copy for 
pharmacy documentation. Additionally, each patient was asked for an Informed 
Consent to enable follow up. This consent was linked by an individual numeric code 
to all study records and later with the questionnaires in the follow up studies. 
Persons referred to the physician received a short physician-questionnaire to be 
handed out to the physician for his feedback. 
The study was approved in Dec. 2001 by the ethic committee in Basel and later 
submitted to regional committees as demanded by Swiss Medical authorities. 
 
All datasheets were designed and automatically processed using Teleform® version 
7.0 from Cardiff Software, CA, USA. The records were collected at the study site, 
processed and stored in order to guarantee confidentiality. After scanning each 
datasheet was verified on screen and the data were transferred directly to an 
Access® database. A supervisor retested validity every 300-500 case records. This 
in-process control showed a rate of miss readings of 0.11% for numeric variables and 
of 0.18% for multiple choice fields. Distinct plausibility ranges were defined for each 
numeric variable and data were deleted when out of this range. 
 
The evaluation was based on the following outcome measures: 
General measures: year of birth, sex, smoker, total score from the self completed 
ADA questionnaire, medical treatment in the last 12 months either for a 
cardiovascular disease and/or for diabetes. 
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Measures in the pharmacy risk assessment: body mass index, lack of physical 
activity, age, family history of diabetes, history of delivering a baby weighing > 9 lbs 
and blood pressure values. 
Measures when performing blood glucose measurement: hours since last meal, 
blood glucose readings, if repeated measurement was recommended with the value 
from the eventual second visit and an interpretation if blood glucose was elevated. 
Assessment of the readiness to change for 3 domains: physical activity, daily 
consumption of 5 portions of fruit and/or vegetables and restricted consumption of 
fat. For each domain according to the Transtheoretical Model of behaviour change 
(TTM) 5 specific questions were asked by the pharmacy team resulting in 3 TTM-
scores for the readiness to change (1 = pre-contemplation, 2 = contemplation, 3 = 
preparation, 4 = action, 5 = maintenance) 
Counselling activities assessed with 3 items: recommendation of weight reduction, 
scheduling an additional counselling session in the pharmacy and other 
recommendations to specify in an open field (e.g. smoking cessation).  
Triage decisions assessed with 3 predefined options: Referral to physician, years 
until next follow up control in the pharmacy or recommendation to follow treatment 
plan if individual was already under medical treatment. 
 
Data was processed and analysed using Microsoft Access®, Excel® and SPSS® 
(SPSS, Inc, Chicago, Illinois, USA). Unpaired Student's t-tests and one-way analyses 
of variance (ANOVA) with Tukey’s correction for multiple comparison were run to 
compare different samples for dependent variables such as mean age and BMI. All 
p-values were calculated two-sided, values of p<0.05 being considered statistically 
significant. Further, Pearson's chi-square tests were performed to detect differences 
in relative frequencies of outcome variables, whereupon p-levels were adjusted for 
multiplicity of testing using Fisher’s exact test, if necessary. 
 
Results 
Out of the German speaking part of Switzerland 530 pharmacies (64.4% of n=823 
pharmacies) documented during 5 weeks of campaign a total of 96'692 screenings. 
A total of 1459 (1.5%) persons reported being treated for diabetes and were 
excluded. Finally only those individuals (n= 94124) who explicitly stated not to be in 
medical care for diabetes were included for further analysis. A further 866 (0.93 %) 
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case records with missing data on sex and/or age were excluded. Thus the eligible 
study sample included 93258 patients, of which 23279 (24.96%) gave Informed 
Consent. 
 
Characteristics of study population (Table 1) 
The mean age of participants was 60.9 ± 14.1 (SD) years (men 61.34; women 60.69) 
and 66.9 % were women. 
Total score of self completed ADA-questionnaire was noted in the screening record. 
ADA scores from 78828 (84.5%) individuals were available. Of these, 5092 (6.5%) 
persons were documented with a score of 0, 1 or 2; 29141(37.0%) persons with a 
score of 3 to 9 and 44595 (56.6%) persons with a score of 10 or higher.  
In the pharmacy risk assessment the prevalence of risk factors were age over 45 
years (85.3%), elevated body mass index (49.2%), elevated blood pressure (45.4%), 
lack of physical activity (27.0%), family history of diabetes (26.3%) and history of 
delivering a baby weighing > 9 lbs (13.1% of women). Hypertonic blood pressure (RR 
≥ 160/100 mmHg) was observed in 16.3%. Thus a total of 25155 (81.5%) men and 
47362 (75.9%) women were assessed with 2 or more risk factors according to the 
triage guidelines. 
 
Capillary blood glucose (CBG) measurements 
A CBG measurement was performed in 91’082 (97.7%) persons. Of them 42609 
(46.6%) were in the fasting state. The fasting and non fasting CBG values were 
grouped into 6 categories of glycaemia. We used the cut-off points from our triage 
flowchart (5.3 / 6.1 / 11.1 mmol/L), cut-off point 7.8 mmol/l based on the ADA 2000 
recommendations for non fasting CBG and with respect to the recent 
recommendation to lower the cut-off point for normal CBG we also used 4.8 mmol/l 
[22]; [26]; [27]. 
Table 2 shows prevalence within these blood glucose categories stratified by sex and 
fasting state. Over all categories, men showed significant higher prevalence of 
dysglycaemic blood glucose values. 
Cut-off point for normoglycaemia for fasting measurement was 5.3 mmol/l. If CBG 
value in the fasting state was ≥ 6.1 mmol (n = 3889) or in the non fasting state ≥ 11.1 
mmol/l (n=203) suspicion for diabetes was identified and these persons (n= 4029; 
4.4% of whole study population) were referred. Borderline values (fasting: 5.3 – 6.0 
Screening campaigns in community pharmacies 
68 
mmol/l; non fasting: 5.3 – 11.0 mmol/l) were observed in 11137 (12.3%) persons. In 
these cases the triage guidelines recommended a repeated measurement some 
days later in the fasting state. This was observed with a total of 8514 (76.5%) 
persons. Out of them additional 2304 persons were detected with suspicion of 
diabetes based on a second measurement showing CBG values ≥ 5.3 mmol/l. Thus a 
total of 6396 (6.9%) persons were detected in the pharmacy screening who 
warranted clinical evaluation by a physician. 
Figure 3 compares borderline CBG values (fasting and non fasting) at first 
measurement with CBG at second measurement which always was performed in the 
fasting state. The second measurement in the fasting state confirmed dysglycaemia 
in 1774 (33.2%) of 5330 individuals with low borderline values (5.3 - 7.8 mmol/L) 
from first non fasting CBG measurement. The second measurement after first 
borderline CBG in the fasting state confirmed dysglycaemia for 47.4%. 
 
Stratification of the eligible study population into risk groups is shown in Table 3. 
Thus with respect to the triage guidelines, a total of n=19677 (21.1 %) persons of the 
study population with either raised blood glucose or blood pressure warranted 
referral for clinical evaluation and final diagnosis. 
 
Counselling and triage activities 
After diabetes risk assessment the pharmacy teams could assess the readiness to 
change for all three domains in 68691 (73.7%) persons. This assessment directly 
induced counselling on lifestyle change and specific action plans could be used. The 
TTM-scores in Table 4 show that women are much more motivated to follow 
recommendations for healthy nutrition. But for physical activity, significance between 
the sexes is smaller. Additional recommendation for weight reduction was given for 
23.9% of men and 20.1% of women, other recommendations (e.g. smoking 
cessation) were given to 9.2%. In 1.1% additional counselling was scheduled. 
 
The triage decision was the last item to document and in 22.6% this was omitted. Of 
all persons screened 5983 (6.4%) were referred to a physician and 2462 (2.6%) 
persons got the recommendation to return to their treating physician because they 
already were in medical care. Total referral rate was 9.0%. A majority (55.2%) of 
them based on more than 2 risk factors with additional abnormal blood glucose, but a 
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remarkable 17.4% was referred because of high blood pressure with normal blood 
glucose values and the remaining 27.4% because of multiple risks and 
measurements near the cut-off points. Again men were much more frequently 
referred. 
 
Physician feedback 
Only persons who declared at screening not to be in medical care for diabetes were 
included. Off all persons referred only 767 (12.8%) physician questionnaires were 
returned. In 81.9% of the feedback physicians confirmed dysglycaemic blood glucose 
and reported for 74.9% scheduling of a second session. With respect to the low 
return rate we renounced to present in depth these results and the characteristics of 
non respondents. 
 
Comparison of screening approaches 
As the screening service was offered for free we collected from most individuals data 
from CBG measurement. This allowed for analysis of the pharmacy risk assessment 
and to depict differences in sensitivity and specificity in comparison with the ADA risk 
score. We constructed ROC curves including all individuals (n= 78’828) with 
complete data files concerning ADA-Score, pharmacy risk assessment and CBG 
measurement. We used abnormal CBG values according to our triage guidelines as 
reference (fasting blood glucose ≥6.1 mmol/l, non fasting blood glucose ≥11.1 mmol/l 
or borderline values if confirmed to be abnormal in a second fasting measurement). 
The resulting receiver operating curves (ROC) are shown in Figure 4. The ROC 
curves suggest that the ADA diabetes risk score of 10 is less sensitive (76 vs. 92 %) 
but more specific (45 vs. 23 %) than the cut-off point of 2 risk factors used in the 
pharmacy risk assessment. Both curves perform somewhat better (larger areas 
under the curves) for women than for men (not shown in the figure). 
 
Discussion 
The campaign attracted a remarkable number of pharmacies although they had to 
pay for participation as well as a significant part (2.4%) of the Swiss German 
speaking adult population. Experiences from similar campaigns suggest that this high 
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public interest is due to a good coverage in the mass media including TV and the 
attractiveness of the free of charge service. 
 
Demographics 
Distribution of age and sex reflect the respective distribution in pharmacy clients seen 
in other studies. But it must be clearly noted that the eligible study population is not 
representative of the Swiss population but only for individuals attracted by the 
campaign. 
The design of the campaign and all promotional activities attracted an older 
population (average age of 60.9 years vs. 48.1 years in the Swiss German adult 
population [28]). The ADA score and the prevalence of the different risk scores 
suggest that the campaign selected a higher risk study population. This assumption 
is supported by the higher prevalence of BMI ≥ 25.0 kg/m2 in the study population 
compared with the Swiss adult population (59.8 vs. 45.4% for men and 44.1 vs. 
29.3% for women) [28]. 
 
Prevalence of risk factors 
The most prevalent risks found were overweight and insufficient physical activity. For 
physical activity the dichotomous yes/no assessment was too simple. In the future 
this should be assessed exactly in number of days a week with moderate and/or high 
activity level. This would facilitate more targeted counselling and monitoring of 
induced lifestyle change. 
 
In the study sample 54% showed elevated and 16.3% hypertonic blood pressure. A 
significant part, 1.6% of all screened individuals, was referred based on a high blood 
pressure while blood glucose showed normal values. In a recent study, blood 
pressure measurement in community pharmacies showed to be at least as reliable 
as those of other health professionals and similar white coat effects were observed 
[29]. It is therefore important to introduce blood pressure measurement in the 
pharmacy screening setting. 
 
Men showed higher prevalence of overweight and elevated or high blood pressure. 
They show this in younger age while insufficient physical activity is equal and a family 
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history of diabetes is much less prevalent than in women. At the age of 31 to 45 
years, 50% of men and 37.4% of women showed > 2 risk factors for diabetes. 
 
Blood glucose measurement 
Most persons, even without risk factors, were interested to get this free of charge 
examination. They were informed that they had to come to the pharmacy preferably 
in the fasting state. Half of all screened persons followed this recommendation. 
Additionally, a very high part (87%) of those individuals with borderline results was 
willing to return for a second measurement. The results from second CBG after first 
borderline result (Figure 3) indicate that the often used cut-off point 7.8 mmol/L for 
non fasting CBG is too high. For non fasting individuals only values below 5.3 mmol/l 
should be interpreted as normal. Our findings strongly support the recommendation 
in the triage guidelines to repeat measurement in all cases of borderline values. 
The prevalence within different CBG categories for fasting and non fasting blood 
glucose in Table 2 reveals that the triage concept and the cut-off points are well 
adapted for community pharmacy based screening. Lowering of the threshold for 
normal fasting CBG from 5.3 mmol/L to 4.9 mmol/L, according to the newly 
recommended cut-off point of the ADA (5.6 mmol/L for plasma glucose respectively 
4.9 mmol/L for capillary whole blood), would for our study population increase 
prevalence of impaired fasting glucose by 79%. Among women we would observe 
even a 87% increase of prevalence. In good agreement with other studies we 
observed that men are much more likely to be at risk and show this in younger age 
[30]. Further research is required to stimulate a discussion on lowering the cut-off 
point only for women. 
Until now no valid epidemiological data for diabetes prevalence are available for 
Switzerland. The stratification of the study population into risk groups shows a 
prevalence of only 6.9% with suspicion for previously unidentified diabetes. Hereby it 
must be remembered that in our study sample we have excluded 1.5% with already 
treated diabetes. In the NHANES survey 1999-2000 [31] prevalence of diabetes and 
impaired fasting glucose was 14.9% and the Inter99 study reported a prevalence of 
impaired fasting glucose of 1.4 – 16.3% in the Danish population aged 30-60 years 
[32]. 
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A limitation to apply our results from blood glucose screening is that capillary blood 
glucose was measured with devices designed for self monitoring without special 
validation of pharmacists’ measurements. 
 
Counselling activities 
Immediately after screening (for 72.6 % of all persons) the 3 TTM-scores for the 
readiness to change lifestyle could be assessed. Overall 30.6% received 
recommendations for weight reduction or other recommendations. These counselling 
activities were prompted due to the predefined items in the study protocol and the 
simple assessment of the TTM scores. This confirms the feasibility of the 
combination of a screening with subsequent counselling on lifestyle change in 
community pharmacy practice. 
 
Triage decisions 
Here we observed the highest rate of missing data (22.6%). Some can be explained 
by the fact that individuals with borderline blood glucose results had to return for a 
second measurement before final triage decision was possible, but 12% didn’t follow 
this. And perhaps the predefined options could not cover all situations and a further 
item “other decision” was missed. Therefore we calculated the total referral rate of 
9% with respect to the total eligible sample. This referral rate is lower than expected 
and than reported from other community pharmacy screening campaigns [33]. 
 
Comparison of screening approaches 
The low return rate of physician feedback impeded this important part of validation of 
our triage concept. This remains an uncovered issue. But using CBG measurement 
as reference, the cumulative risk assessment of 6 different risk factors with 2 risks as 
a cut-off could be analysed and compared with the ADA score. ROC analysis in Fig 3 
shows that the pharmacy risk assessment setting was more sensitive, but less 
specific than the ADA score. As in the sequential approach this risk assessment is 
followed by blood glucose measurement, the low specificity is irrelevant, but good 
sensitivity is important. Dallo and Weller compared different criteria for testing for 
diabetes and showed that when any two risk factors are present, diabetes is detected 
with 98% sensitivity and 53% specificity [34]. Our results are also in agreement with 
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Rolka et al. who investigated the performance of different screening tests and 
reported >70% sensitivity of CBG > 6.8 mmol/l for the WHO diabetes criterion at 90 
% specificity, but the combination with the ADA-Score was less sensitive[9]. 
 
In our sequential screening we used fasting CBG as final criterion for referral to a 
physician. A limitation of measurement of the fasting glucose is its low sensitivity to 
detect post challenge hyperglycaemia. Pharmacists must consider this. But our 
approach is in good agreement with results from the evaluation of different screening 
strategies based on fasting glucose reported by Schmidt et al. [35]. 
 
Thus we can recommend our pharmacy risk assessment for adults older than 30 
years as pre-test to select individuals for a subsequent blood glucose measurement. 
As long as in community pharmacy practice no diagnosis is performed but the 
screening is aimed to refer persons at risk to a physician for further clinical evaluation 
the subsequent CBG measurement of fasting glucose is a rational testing. This serial 
combination of tests can improve performance of screening as is discussed in the 
report of WHO [15]. 
Early detection of persons at risk with referral to clinicians offer a variety of 
interventions during the preclinical phase, including lifestyle change, tight glycaemic 
control or targeted choice of antihypertensive or lipid lowering treatment or therapy 
with aspirin. A recent review showed that screening for diabetes with all these 
interventions during preclinical phase is mainly focused to reduce not only risk of 
diabetes development, but particularly the risk for cardiovascular disease [36]. 
Additional validation of the sequential screening concept, presented here, with 
diagnostic criteria is an important outstanding issue. 
 
Conclusions 
The evaluation of this large screening campaign show that for community pharmacy 
practice a sequential procedure can be recommended: First an assessment of all risk 
factors including blood pressure, second capillary blood glucose measurement with a 
cut-off point of 5.3 mmol/l and retest in case of borderline results and finally 
counselling the persons at risk for diabetes according to the readiness to change 
their lifestyle. 
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Despite the age of our study population only 6.9% of screened persons were 
suspected to have type 2 diabetes. However, 71.5% had at least two risk factors. 
Men were much more likely to be at risk and showed this at a younger age.  
Thus, counselling the many persons at risk regarding lifestyle change is an essential 
element in every meaningful diabetes screening. 
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Figure 1: Sequential screening concept 
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Figure 2: Flowchart and triage criteria for sequential screening in pharmacies for patients with 
risk for diabetes 
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Figure 3: Comparison of borderline CBG values at first measurement with fasting CBG values 
at second measurement 
A) Subjects at fasting state at first measurement (5.3-6.0 mmol/l; n=2555) 
B) Subjects at non fasting state at first measurement (5.3-11.0 mmol/l; n=5959) 
 
Cut-off point for normoglycaemia for fasting measurement is 5.3 mmol/l 
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Figure 4: Empirical receiver-operating characteristic (ROC) curves 
Sensitivity vs. 1-specificity is plotted over the ranges of ADA risk scores and of risk factors of pharmacy risk 
assessment for abnormal blood glucose values detected in the pharmacy. 
 
Usual cut-off point for recommendation of blood glucose measurement is a score of ≥ 10 for ADA risk 
assessment. In the present pharmacy based risk assessment cut-off point ≥ 2 risk factors was used. 
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Table 1: Baseline characteristics and results from diabetes screening 
 male / female Total male Total female Overall 
Age group [years] < 30 31-45 46-60 61-75 > 75    
n 751 / 1677 3744 / 7498 8719 / 19638 12878 / 24390 4786 / 9177 30878 62380 93258 
% of whole study population 0.8 / 1.8 4.0 / 8.0 9.3 / 21.1 13.8 / 26.2 5.1 / 9.8 33.1 66.9 100.0 
Current smoker [%] 28.3 / 16.5 22.3 / 14.6 24.3 / 8.4 19.5 / 10.1 20.5 / 4.2 17.1 12.0 13.7 
Score from ADA diabetes risk 
test 3.9  / 3.6 5.5  / 4.6 9.5  / 8.7 11.7  / 11.6 12.5  / 12.5 10.3 ± 4.6 9.8 ± 4.8 10.0 ± 4.8 
BMI [kg/m2] 24.1 / 22.8 26.0  / 24.3 26.2  / 24.8 26.3  / 25.6 25.7  / 24.9 26.1 ± 3.3 25.0 ± 4.2 25.4 ± 4.0 
Risk factor body weight [%] 34.8 / 22.5 56.6 / 34.6 60.8 / 41.1 63.2 / 50.7 55.3 / 44.6 59.8 44.1 49.24 
Insufficient physical activity [%] 33.5 / 34.9 38.6 / 34.3 32.2 / 28.2 20.4 / 23.2 24.8 / 29.5 27.0 27.4 27.05 
Family history of diabetes [%] 16.4 / 18.0 26.3 / 29.1 26.3 / 31.4 21.8 / 28.9 15.1 / 21.8 22.5 21.8 26.29 
History of delivering a baby 
weighing > 9 lbs (only females) 
[%] 
3.4 13.3 12.3 14.8 11.5  13.  
Systolic blood pressure [mm Hg] 128.2 / 116.7 130.2 / 119.7 135.4 / 128.6 143.3 / 139.7 148.0 / 148.1 139.8 ±19.1 134.5 ±20.4 136.2 ±20.1 
Diastolic blood pressure [mm Hg] 78.3 / 74.8 83.3 / 77.9 86.4 / 81.7 85.6 / 82.9 82.6 / 82.3 84.9 81.6 ±11.0 82.7 ±11.2 
Risk factor blood pressure [%] 24.7 / 8.7 34.2 / 15.5 46.7 / 31.4 59.6 / 51.9 66.7 / 66.4 53.2 42.0 45.4 
≥ 2 risk factors for diabetes [%] 31.2 / 21.5 50.2 / 37.4 85.5 / 78.1 88.2 / 82.1 88.5 / 88.3 81.5 75.9 77.7 
Fasting capillary blood glucose 
[mmol/l] 4.4 / 4.1 4.6 / 4.3 4.9 / 4.5 5.0 / 4.7 5.1 / 4.98 4.9 ±1.1 4.6 ±1.0 4.7 ±1.0 
Non fasting capillary blood 
glucose [mmol/l] 4.8 / 4.5 4.8 / 4.5 5.0 / 4.7 5.3 / 4.9 5.4 / 5.2 5.1 ±1.4 4.8 ±1.2 4.9 ±1.3 
Recommendation of second visit 
for repeated measurement [%] 7.3 / 5.7 9.9 / 6.3 12.6 / 8.3 17.0 / 12.2 20.1 / 15.3 15.1 10.6 12.1 
Interpretation as elevated blood 
glucose by pharmacists [%] 3.8 / 1.3 4.0 / 1.7 8.2 / 3.5 13.7 / 7.6 16.0 / 10.2 11.1 5.9 6.7 
Frequencies are given as % in sex and age group. Numeric variables are given as means, means ± SD for totals. 
Each baseline variable had < 0.6% missing data. 
  
Table 2: Prevalence within blood glucose categories stratified by sex and fasting state  
Blood glucose category Fasting CBG (n=42’609) Non fasting CBG (n=48473) 
 Male (%) Female (%) Overall (%) Male (%) Female (%) Overall (%) 
<4.9 mmol/l 49.8 66.3 60.7 47.6 59.7 55.8 
4.9-5.2 mmol/l 20.4 15.7 17.3 16.9 14.4 15.2 
5.3-6.0 mmol/l 20.4 12.9 15.4 19.2 15.2 16.5 
6.1-7.7 mmol/l 7.9 4.3 5.5 12.6 8.9 10.1 
7.8-11.0 mmol/l 1.3 0.6 0.8 2.9 1.5 2.0 
>=11.1 mmol/l 0.3 0.2 0.2 0.7 0.3 0.4 
 
Pearson's chi-square tests between sex groups for fasting and non fasting CBG showed highly significant (p < 0.0001) differences in relative frequencies. 
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Table 3: Stratification of the screened population into risk groups 
Persons without risk:  20168 (21.6 %)
Persons at risk (> 2 risk factors, but 
normoglycaemia): 
 
 Subgroup with blood pressure RR 
 ≥160/100mmHg: 
 
 
 
 
13281 (14.2 %) 
66694 (71.5 %)
Persons suspected to have type 2 diabetes: 
 
 Subgroup with borderline glycaemia (FG 5.3-
 6.0mmol/l or  NFG 5.3-11.0mmol/l, confirmed 
 in a second measurement at fasting state): 
 
 Subgroup with hyperglycaemia: 
  Fasting CBG ≥6.1mmol/l 
  Non fasting CBG ≥11.1mmol/l 
 
 
 
 
2304 (2.5%) 
 
 
3889 (4.2%) 
203 (0.2%) 
6396 (6.9 %)
 
Screening campaigns in community pharmacies 
85 
 
Table 4: Counselling and triage activities after diabetes screening 
N= 93258 Total male 
(%) 
Total female
(%) 
p-value Overall 
(%) 
Readiness to change 
lifestyle: 
Physical activity # 
Five a day #  
Restricted fat consumption # 
 
 
61.7 
36.5 
41.3 
 
 
60.5 
44.7 
53.3 
 
 
* 
*** 
*** 
 
 
60.9 
42.0 
49.4 
Recommendation of weight 
reduction 
 
23.9 
 
20.1 
 
*** 
 
21.4 
Scheduling an additional 
counselling session 
 
1.3 
 
1.0 
 
*** 
 
1.1 
Other recommendation 10.1 8.7 *** 9.2 
Triage decision 
• Referral to physician 
• Follow up control in the 
pharmacy 
• Follow treatment plan if 
yet in medical care 
• No decision 
 
9.3 
 
64.8 
 
2.9 
23.0 
 
5.0 
 
70.1 
 
2.5 
22.4 
 
 
 
 
 
 
*** 
 
6.4 
 
68.3 
 
2.6 
22.6 
 
# % in “action” or “maintenance” (TTM-score 4 or 5) 
 
Pearson's chi-square tests showed statistically significant differences between sex groups (* = p < 0.01; 
*** = p < 0.0001).
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3.2 Project C: 
 
Evaluation of cut-off points for the screening for metabolic 
syndrome in community pharmacies 
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Introduction 
The risk of suffering from a coronary heart disease (CHD) is increased when factors 
like obesity, hypertension, dyslipidaemia, diabetes mellitus coincide and worsens 
with additional family history of premature CHD. The coincidence of two or more risk 
factors is called the metabolic syndrome. 
Blood glucose and cholesterol measurements are offered by many community 
pharmacies. With compact analysers, community pharmacies are able to afford the 
screening for the risk factors using capillary blood. A previous study showed that if 
correctly attended, they are appropriate for an efficient screening in community 
pharmacies leading to accurate values [1]. 
However, the values gathered in a screening must be judged and reasonable 
decisions must be made for an individual situation. For community pharmacies, a 
specific setting leading to rational triage decisions is important. 
 
Objectives 
Design of a specific screening setting for community pharmacy practice with specific 
triage criteria and evaluation of the concept using data from a community pharmacy 
based screening campaign. 
 
Methods 
30 community pharmacies of the Swiss pharmacy chain TopPharm in the German 
speaking part of Switzerland offered the additional possibility of assessing the lipid 
profile during a diabetes screening campaign. 
The pharmacy teams followed a specific training program and received the 
guidelines for screening and triage as written information. Based on a multiple risk 
approach a sequential screening was designed for community pharmacy practice 
(Figure 1). 
Main outcome measures were capillary blood values for glucose, total cholesterol 
(TC), HDL-Cholesterol (HDL-C), LDL-cholesterol (LDL-C), Triglycerides (TRG), ratio 
TC/HDL-C, blood pressure values, body mass index, family history of diabetes or of 
premature cardiovascular disease, cigarette smoking, lack of physical activity and the 
triage decisions of the pharmacy teams. Results were documented by the pharmacy 
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teams with uniform datasheets, which were processed automatically with the Cardiff 
TELEform® Software. 
 
 
 
 
 
 
 
 
Figure 1: Sequential screening 
 
The levels for the risk factors and the cut-off points were adopted from the 
recommendations of the Swiss society for cardiology and the ATP III panel 
recommendations 2001 (Figure 2) [2], [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Criterions for referral to physician 
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Results 
During four weeks of campaign (September 2001) 30 pharmacies completed a total 
of 757 protocols, 528 protocols with lipid profile (62% female) (age = 59.5 years ± 
14.2 (SD)). 395 persons declared not to know their risk profile and not to be in 
medical care for cardiovascular disease or diabetes (Figure 3). 
Table 1 shows the results of the multiple risk assessment (metabolic syndrome). If 
≥2 values of the lipid profile above normal would be considered as a reason to refer 
persons to a physician, 68% of screened persons would have been referred. The 
present triage guidelines refer persons with coincidence of ≥2 values of the lipid 
profile above normal and ≥2 risk factors for CHD. Referral rate is therefore reduced to 
a total of 43%. The results of the assessment of single risks which require referral to 
a physician if present are shown in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Plot of total cholesterol (TC), LDL-cholesterol (LDL-C) and triglycerides (TRG) with 
cut-off points for single normal values (n=392 persons not in medical care) 
 
Table 1: Multiple Risk Assessment (Metabolic syndrome) 
 
 
 
 
 
 
 
Lipoprotein profile (TC, LDL-C, HDL-C, Triglycerides, Ratio TC/HDL-C)
312 (79%) with > 1 value elevated, above normal
Of them 196 (49%) with > 2 additional risk factors for CHD
267 (68%) with > 2 values elevated, above normal
Of them 171 (43%) with > 2 additional risk factors for CHD
Blood Pressure, Body Mass Index, Fasting Glucose
143 (36%) overweight (BMI > 25 kg/m2)
117 (30%) with elevated Blood Pressure (>140/90 mmHg)
92 (23%) with elevated Fasting Glucose (> 5.3 mmol/l;capillary whole blood)
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Table 2: Single Risk Assessment (Cut-off point to consider drug treatment) 
 
 
 
 
 
 
Conclusions 
Screening for persons with risk factors for CHD should be done in a multiple risk 
assessment. In a sequential approach first step is to assess person’s risk status and 
only if necessary in the next steps blood measurements. Using the desirable values 
for each risk factor as cut-off point for pharmacy practice a reasonable definition of 
coincidence is important. Single cut-off points for dyslipidaemia would be too strong 
leading to high rates for referral. When in the lipoprotein screening coincidence of ≥2 
values of the lipid profile above normal with ≥2 risk factors for CHD are considered 
referral rate is significantly reduced. 
The revised triage concept consists of screening for the coincidence of 2 values of 
lipid profile above normal with 2 other risk factors for CHD. When a single risk is high 
on the level for drug treatment (Table 2), even without coincidence with other risk 
factors, referral is required. 
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57 (14%) with 1 high lipoprotein level  
(TC>8.0 mmol/l, LDL-C > 5.0mmol/l, TC/HDL-C > 6.5 
or Triyglycerides > 5.0 mmol/l )
50 (12%) with High Blood pressure (> 160 or 100 mmHg)
26 (6.5%) with BMI > 30 kg/m2
11 (3%) with Fasting Glucose > 6.1 mmol/l (capillary whole blood)
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Abstract 
Background 
During a screening campaign for type 2 diabetes in community pharmacies, 
immediate counselling on lifestyle behaviour was provided to persons found to be at 
risk. The aim of this study was to investigate the effects of pharmacy based 
counselling on changes in lifestyle and body weight. 
 
Methods 
Three different counselling intensities were compared: Standard counselling (SC) 
with non-specific recommendations towards lifestyle change, intensive counselling 
(IC) with additional specific advice to reduce body weight, and counselling for 
persons at high risk for type 2 diabetes (HRC) with recommendation to contact a 
physician. Three months after screening a stratified sample of 3800 randomly chosen 
overweight persons were addressed with written questionnaires to assess body 
weight and lifestyle changes. Half year and one year later the assessment was 
repeated. 
 
Results 
The eligible study population included 1370 subjects, 557 in the SC group, 568 in the 
IC group and 245 in the HR group. All counselling groups showed significant weight 
loss three months after screening (0.6-1.9 kg; p<0.001). At the half-year follow-up, a 
slight weight gain was observed (seasonal interference), which was not statistically 
significant in the whole study population. A further weight reduction was observed at 
one year follow up (1.1-2.4 kg; p<0.001). The HRC group showed a higher 
percentage of weight loss than the IC and SC group three months after screening 
(-2.25% vs. -1.20% and -0.67%; p<0.001) and at one year follow-up (-2.74% vs. -
1.54% and -1.29%; p<0.01). Three months after screening, 18.0% of the subjects in 
the HRC group, 11.6% in the IC group and 7.9% in the SC group lost ≥5% of initial 
body weight (p<0.001). At one year follow-up, 24.5% in the HRC group, 17.6% in the 
IC group and 16.7% in the SC group showed this success (p<0.05). Lifestyle 
changes in physical activity and/or nutrition were reported by 81.2% in the HRC 
group, 74.1% in the IC group and 67.0% in the SC group (p<0.001). 
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Conclusions 
Our findings show that immediate counselling in community pharmacies after 
screening for type 2 diabetes can result in significant and sustainable lifestyle 
changes and weight loss in overweight individuals. 
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Background 
Type 2 diabetes mellitus is a public health concern, and projections of its future 
effects are alarming. The number of patients affected by type 2 diabetes is expected 
to increase in the future due to population growth, aging, urbanization, and increasing 
prevalence of obesity and physical inactivity [1, 2]. Type 2 diabetes is often 
asymptomatic in the early stages and can remain undiagnosed for many years. The 
risk of developing type 2 diabetes increases with age, obesity and lack of physical 
activity [3]. Early detection and treatment of type 2 diabetes can reduce the burden of 
its complications. The American Diabetes Association recommends screening for 
type 2 diabetes in persons who are 45 years or older and those with a body mass 
index (BMI) of 25 kg/m2 or greater [3]. There is substantial evidence that type 2 
diabetes can be prevented or delayed by changes in lifestyle [4, 5]. Two well-
designed randomised controlled trials have shown that intensive lifestyle 
modifications through alterations in diet and improvement in exercise regime can 
delay or prevent progression from impaired glucose tolerance to type 2 diabetes [6, 
7]. Lifestyle changes such as more exercise have shown positive effects, even 
without weight loss [8]. It is thought that the mechanisms by which lifestyle 
modifications reduce the progression to type 2 diabetes may be through alterations in 
insulin sensitivity [5]. 
Overweight, usually defined as BMI ≥25 kg/m2, and obesity, usually defined as BMI 
≥30 kg/m2, are a growing public health concern globally. Excess weight increases not 
only the risk for type 2 diabetes but also for cardiovascular disease, hypertension, 
stroke, and other chronic diseases [9]. Most approaches and products recommended 
to reduce weight are subjects to criticism due to high relapse rates and subsequent 
return to the original or even higher body weight. For most individuals, maintenance 
of weight loss is the most difficult part of any weight management program. Hence, 
programs which demonstrate long-term weight loss stability would be of great value 
[10]. 
Community pharmacists are well placed to assist in the provision of preventive care 
because pharmacies are highly accessible and often the first point of entry into the 
health care system [11, 12]. Pharmacies are regarded to be a suitable place to 
promote awareness, screen high-risk patients, and to counsel patients on 
intervention strategies to delay the onset of diabetes [3, 5]. For early detection, a 
combination of risk factor assessment and blood glucose measurement performed in 
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community pharmacies is regarded to be a promising approach and an opportunity 
for health promotion [3, 4]. Furthermore, intervention studies in community 
pharmacies were shown to have positive effects on cardiovascular risk factors, for 
example by improving outcomes in hypertension or cholesterol management [13-15]. 
A randomized controlled trial has shown that successful weight management can be 
achieved in a pharmacy setting, where patients have been consulted by the 
pharmacist every 3 weeks for a time period of 5 months [16]. 
 
With this background, the Swiss federation of pharmacists organised in spring 2002 a 
national screening campaign in Switzerland called “Stop sugar – test now”, with the 
aim to detect previously undiagnosed individuals with type 2 diabetes and provide 
counselling towards lifestyle modifications for persons at risk. The evaluation of the 
campaign is described in a previous paper [17]. The campaign was extended with a 3 
step follow-up study aiming to investigate the impact of a community pharmacy 
based screening campaign and to enable additional intervention studies. 
The pharmacy teams which participated in the screening campaign received a 
specific training program and written guidelines for screening and triage. After 
individual risk assessment, a measurement of capillary blood glucose level was 
recommended to all persons with ≥2 risk factors. The risk factors considered were: 
age >45 years, overweight (BMI ≥25kg/m2), low physical activity, family history of 
diabetes, delivery of a baby >9 lbs, and hypertension. The five week campaign took 
place in 530 pharmacies within the German speaking part of Switzerland. A total of 
93’258 persons were screened for undiagnosed type 2 diabetes. Of all the persons 
screened, 71.5% had ≥2 risk factors but showed normoglycaemia. A further 6.9% of 
the screened population showed abnormal blood glucose values and were therefore 
suspected to have type 2 diabetes, of them 4.4% with hyperglycaemia (fasting blood 
glucose ≥6.1 mmol/l or non fasting blood glucose ≥11.1 mmol/l) and 2.5% with 
borderline glycaemia (fasting blood glucose 5.3-6.0 mmol/l or non fasting blood 
glucose 5.3–11.0 mmol/l, confirmed by a second fasting measurement) [17]. After 
screening, the readiness for behaviour change in physical activity and nutrition habits 
were assessed according to the transtheoretical model (Prochaska) [18]. This 
enabled targeted counselling concerning therapeutic lifestyle change especially for 
persons at risk for type 2 diabetes. Pharmacists could freely choose whether they 
provide an additional intensive counselling concerning weight loss to the overweight 
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persons at moderate risk for type 2 diabetes (≥2 risk factors). Persons with abnormal 
blood glucose values (high risk for type 2 diabetes) were referred to a physician for 
further diagnosis and treatment. 
 
The objective of the present study was to investigate the impact of immediate 
counselling after screening for type 2 diabetes on body weight and lifestyle change 
and to compare the effects of the three different types of counselling in community 
pharmacies (standard versus intensive counselling of persons at moderate risk and 
referring persons at high risk to a physician). For this purpose we evaluated the 
changes in body weight and lifestyle in a randomly chosen sample of overweight 
persons at risk for type 2 diabetes three months after screening, as well as half year 
and one year after this first assessment. In particular we measured the differences in 
average BMI and weight as well as the percentage of weight loss between baseline 
(screening campaign) and follow-up questionnaires. Furthermore we evaluated (as 
secondary outcome measures) self-reported lifestyle changes in physical activity and 
nutrition. 
 
Methods 
Subjects 
Of 93’258 persons who have been screened for undiagnosed type 2 diabetes during 
the screening campaign (mean age 60.9 years ± 14.1 (SD), 33.1% male), 23’279 
persons have provided informed consent for further follow-up. An overview of 
subject’s recruitment is shown in Figure 1. The subjects were enrolled into the follow-
up study if the following criteria were met: at least 18 years old and BMI of ≥25.0 
kg/m2. Three months after screening, in August 2002, a stratified sample of 3800 
randomly chosen persons (who had provided informed consent and met criteria) 
were contacted with the first of three written questionnaires, of them 1400 persons at 
moderate risk for type 2 diabetes (≥2 risk factors but normoglycaemia) and with 
standard counselling in the pharmacy (SC group), 1500 persons at moderate risk for 
type 2 diabetes and with intensive counselling (IC group) and 900 at high risk for type 
2 diabetes (HRC group: ≥2 risk factors and abnormal blood glucose values defined 
as fasting blood glucose ≥6.1 mmol/l, non fasting blood glucose ≥11.1 mmol/l or 
borderline values of fasting blood glucose 5.3-6.0 mmol/l or non fasting blood 
Health promotion and lifestyle change 
98 
glucose 5.3-11.0 mmol/l, if confirmed by a second fasting measurement). In February 
2003 the study participants who returned the first questionnaire were contacted with 
the second questionnaire (half year follow-up). In a final step the last of the three 
questionnaires was sent in August 2003 to all subjects who returned the second one 
(one year follow-up). Out of 1436 subjects having returned all three questionnaires, 
14 subjects had to be excluded from analysis because of wrong linkage of their 
datasheets and another 52 subjects had to be excluded because of missing self-
reported weight data. The subjects’ ages varied from 19 to 90 years (mean 59.9 ± 
11.0 years). The present study was approved by the Ethics Committee of Basel. 
Subjects received no financial compensation for participating in this study except the 
free of charge blood glucose measurement in the pharmacy during the screening 
campaign. 
 
Counselling concerning therapeutic lifestyle change in the pharmacy 
The pharmacists who assisted in the screening campaign received a specific training 
program in the form of two obligatory evening courses, where oral and written 
information on screening and counselling guidelines were provided. Specific action 
plans, using the transtheoretical model (Prochaska) [18], were taught for counselling 
on the influence able risk factors, such as physical activity and overweight. During 
the campaign, immediately after screening, the stages of change for three domains 
according to the transtheoretical model were individually assessed. The three 
domains were health enhancing physical activity (half an hour of physical activity 
daily), reduced fat intake and consumption of 5 servings of fruits and/or vegetables 
per day (“5-a-day”). Using this information as a starting point, pharmacists were able 
to perform targeted counselling concerning weight reduction and lifestyle 
modifications. Pharmacists were free to provide either standard or intensive 
counselling to subjects at moderate risk (≥2 risk factors). The standard counselling 
included recommendations towards lifestyle modifications such as physical activity 
and nutrition. Concerning physical activity, persons were instructed to set a goal of 
half an hour physical activity daily with at least moderate intensity or three times 
twenty minutes weekly with vigorous intensity. In respect to nutrition habits persons 
received advice on reduced fat intake and “5-a-day” recommendations. The intensive 
counselling included an additional targeted counselling on weight reduction with 
further precise advices on lifestyle changes. Booklets with information on health 
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promoting lifestyle were handed out by the pharmacy teams to persons in both 
intensive and standard counselling groups. Pharmacists provided standard 
counselling to persons at high risk for type 2 diabetes (abnormal blood glucose 
values) and additionally recommended to call on a physician for further check up. 
The interventions for the three counselling groups are summarised in Table 1. 
 
Data collection 
During the screening campaign, demographics (age, sex and smoking habits) as well 
as results of individual risk assessments and measured values were recorded by the 
pharmacy teams on 35 item datasheets [17]. The individual assessment of the 
stages of change, which provided a basis for counselling, was documented on these 
datasheets. 
At three, nine and fifteen months after screening the follow-up questionnaires, to be 
completed anonymously, were sent to the study participants, each along with a reply-
paid envelope. The three questionnaires were developed by the investigators and 
included 42 pilot-tested questions including 138 items on demographics, satisfaction 
of care provided by the pharmacist, potential consultation of a physician for further 
check up, as well as the outcome measures of changes in weight and achieved 
lifestyle changes regarding physical activity and nutrition habits. Weight was 
recorded in kg without decimal places and height in cm. Lifestyle changes were 
reported in physical activity including everyday physical activities as well as sports 
activities and in nutrition habits including reduction of fat intake, increase in 
consumption of fruits and vegetables as well as unspecific reduction of food 
consumption. 
 
All datasheets and questionnaires were processed automatically with Teleform® 
version 7.0 from Cardiff Software, CA, USA. The use of automated forms processing 
(AFP) software were validated by Jorgensen et al. [19], who showed that AFP 
reduced processing time. For choice fields the error rate for AFP was very low and 
comparable to double manual data entry, while for numeric recognition the error rate 
was higher than for both single and double manual data entry. For this reason all 
numeric recognitions in the forms used were verified visually on screen. Furthermore, 
distinct ranges for each variable were defined to test plausibility and data were 
deleted when out of this range. All data files of the forms were imported into 
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Microsoft® Access databases. The datasheets from the screening campaign and the 
three questionnaires were linked to each other with a numerical code of 5 numbers, 
which identified the documents of each study participant. Thus, anonymity was 
always warranted. The correct linkage of data files was verified with individual data 
for sex and age, which were recorded on every protocol. If manual correction based 
on the original protocol was not possible, the data file of the relevant study participant 
was excluded from analysis. 
 
Data analysis 
Primary outcome measures, calculated from the three questionnaires, were the 
differences in average BMI and weight as well as percentage of weight loss between 
baseline and the assessment at 3 months after screening and further follow-up 
assessments. Further, we analysed percentage of subjects able to lose greater or 
equal than 5% of their initial body weight. All analyses were performed stratifying the 
study population in different samples of risk and counselling intensity, which resulted 
in the three different counselling groups: SC group, IC group and HRC group (Table 
1). The HRC group was also analysed for potential impact on weight control from 
physician’s consultation. For this purpose we compared percent change of body 
weight between subjects who have contacted a physician versus those who didn’t. 
Subjects were also evaluated with regard to self-reported lifestyle changes (as a 
secondary outcome). Prevalence of reported lifestyle changes were analysed in 
areas of physical activity including everyday physical activities as well as sports 
activities and in nutrition habits including reduction of fat intake, increase in 
consumption of fruits and vegetables as well as unspecific reduction of food 
consumption. Physical activity areas and nutrition areas were pooled to auxiliary 
variables of “any positive change in physical activity” and “any positive change in 
nutrition habits”. In a final step all areas were pooled to an auxiliary variable of “any 
positive lifestyle change”. Lifestyle changes were additionally analysed by comparing 
the different samples of counselling intensity. 
 
Statistical analysis was performed using SPSS 11.5 for Windows (SPSS, Inc, 
Chicago, Illinois, USA). Values are expressed as mean ± standard deviation (SD) or 
standard error (SE). Change in body mass index and weight over time was analysed 
using repeated analysis of variance (Generalized linear model: GLM) with linear 
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contrasts to detect pair wise differences and with counselling groups as covariates. 
All p-values were calculated two-sided, values of p<0.05 being considered 
statistically significant. In case of significant difference in repeated analysis of 
variance for the covariates (i.e. counselling intensities), subsequent pair wise 
comparisons were performed by Tukey’s-HSD multicomparison test. Comparison of 
the different samples and counselling groups at baseline were performed by one-way 
analyses of variance (ANOVA) with Tukey correction for multiple comparisons. In 
addition, differences in prevalence of demographic and outcome variables were 
assessed using Pearson's two-sided chi-square- or Fisher’s exact test as 
appropriate. 
 
Results 
Recruitment and characteristics of study population 
Out of the 3800 persons addressed for follow-up, 2177 returned the first 
questionnaire and 1520 returned the second one. A total of 1436 subjects (37.8%) 
answered all three questionnaires (Figure 1). Out of them, 66 subjects had to be 
excluded from analysis due to wrong linkage of datasheets or because of missing 
self-reported weight data. 
Consequently the eligible study population included 1370 subjects, of them 557 
(40.7%) in the SC group (subjects at moderate risk who received standard 
counselling), 568 (41.5%) in the IC group (subjects at moderate risk who received 
intensive counselling) and 245 (17.9%) in the HRC group (subjects at high risk who 
were referred to a physician). The mean age of the study population was 59.9 years 
± 11.0 (SD), 598 persons (43.6%) were male and 167 subjects (12.2%) declared to 
be smokers. Table 2 shows further demographic information of the study population 
and of all non-responders. Significant differences between the study population and 
non-responders were observed in age and BMI, which both were lower in the study 
population as well as height which was higher in the study population. Furthermore, 
subjects at high risk for type 2 diabetes showed a statistically significant higher drop 
out rate than those at moderate risk. 
 
Table 3 shows the comparison of the three counselling groups (SC, IC and HRC 
group) regarding their baseline characteristics. There were significant differences 
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between the HRC group and the two other groups. The HRC group’s mean age, 
weight, BMI and systolic blood pressure were greater than both the other groups’ and 
the HRC group’s average height was slightly greater than the other groups’ (p<0.04). 
Between the SC group and IC group significant differences were observed only in 
weight and BMI, both which were higher in the IC group than in the SC group 
(p<0.001). Further differences in gender were statistically significant between all 
groups and there were less smokers in the IC group than in the other two groups. 
 
Change in body weight and BMI over the four time-points of assessment 
In all three counselling groups a statistically significant weight loss over the four time-
points of assessment was observed. In Table 4 the progression of weight and BMI is 
analysed by stratifying the study population into the three counselling groups of 
subjects at moderate risk with standard counselling (SC group; n=557), subjects at 
moderate risk with intensive counselling (IC group; n=568) and subjects with high risk 
counselling (HRC group; n=245). Subjects in all counselling groups showed a 
significantly lower body weight three months after screening (p<0.001). This weight 
loss was highest in the HRC group. At half year follow-up, a slight weight gain was 
observed, which was not statistically significant in the study population as a whole. A 
further significant weight reduction (p<0.001) was observed in all counselling groups 
at one year follow-up. Therefore a seasonal interference on weight control is 
assumed, with weight loss in the warmer season and weight stability in the colder 
season. Subjects in the HRC group reached a higher percentage of weight loss than 
subjects in the IC and SC group three months after screening (-2.25% vs. -1.20% 
and -0.67%; p <0.001) as well as at half year follow-up (-1.99% vs. -0.88% and -
0.51%; p <0.01) and at one year follow-up (-2.74% vs. -1.54% and -1.29%; p <0.01). 
Furthermore subjects in the IC group reached a higher percentage of weight change 
than subjects in the SC group three months after screening (-1.20% vs. -0.67%; 
p<0.05), but not at half year and at one year follow-up. 
 
Analysing the HRC group for the impact of physician’s consultation on weight loss, a 
trend towards higher weight loss was observed three months after screening in those 
subjects who have contacted a physician (n=198; 80.8%) with a weight loss of 2.40% 
vs. 1.67% in those subjects without consultation (n=47). However, this difference was 
not statistically significant and there was no significant difference in weight loss over 
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the four time-points of assessment between subjects who called on a physician and 
those who did not. 
 
Analysing the whole study population, 154 subjects (11.2%) lost more or equal than 
5% of their initial body weight three months after screening. Considering counselling 
intensity, 7.9% of the subjects in the SC group were able to loose ≥5% of initial body 
weight, 11.6% in the IC group and 18.0% in the HRC group (p<0.001; significant 
differences between all counselling groups). At one year follow-up, 253 subjects 
(18.5%) in the whole study population lost ≥5% of their initial body weight. 
Considering counselling intensity, 16.7% of the subjects in the SC group, 17.6% in 
the IC group and 24.5% in the HRC group showed ≥5% weight loss (p<0.05; 
significant difference between HRC and IC and SC groups, but not between IC and 
SC groups). 
 
Self-reported changes in lifestyle 
Three months after screening 72.5% of the subjects in the whole study population 
(n=1370) reported to have changed their lifestyle (physical activity and/or nutrition 
habits). An influence of pharmacist’s counselling intensity was observed in self-
reported lifestyle changes (Figure 2) with 67.0% in the SC group declaring to have 
changed their lifestyle, 74.1% in the IC group and 81.2% in the HRC group 
(p<0.001). The influence of pharmacist’s counselling intensity was statistically 
significant in all areas (p<0.001) with the exception of an increase in sports activity. In 
each of the areas of lifestyle change, a similar pattern emerged. Throughout there 
were more subjects with self-reported improvements in the HRC group than in the IC 
group, with statistically significant differences in all areas measured. More persons 
were found with self-reported improvements in the IC group than in the SC group, 
with significant differences in four of the eight areas measured (any positive lifestyle 
change, increase in everyday physical activity, any positive change in nutrition, and 
reduction of fat intake). The greatest impact of counselling intensity was found on the 
reduction of fat intake. 
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Discussion 
The results of our study show that in overweight individuals at risk for type 2 diabetes 
immediate counselling after screening for type 2 diabetes can initiate significant 
lifestyle changes and weight loss. These effects were shown to be sustainable. We 
observed a significant decrease in weight and BMI three months after screening as 
well as at one year follow-up. There was also an impact of pharmacist’s counselling 
intensity on weight loss. Subjects in the HRC group reached a higher percentage of 
weight change than subjects in the IC and SC group three months after screening 
(2.25% vs. 1.20% and 0.67%; p <0.001) as well as at one year follow-up (2.74% vs. 
1.54% and 1.29%; p <0.01). In total, 11.2% of all subjects lost ≥5% of their initial 
body weight three months after screening. 
In two randomised controlled trials which investigated the effect of either sibutramine 
or orlistat on weight reduction [20, 21], the placebo groups showed an average 
weight loss of 4.6% to 6.1% after 24 or 12 months, respectively. In comparison, the 
1.3% to 2.7% average weight loss observed in our study thus appears to be modest, 
but attendance must be paid to the fact that the patients in the two randomised 
controlled trials were much more obese (average BMI of 36.1 and 36.7 kg/m2, 
respectively) than the subjects in the present study. Moreover, dietetic help with 
medical attendance was provided to the placebo groups in those two trials, whereas 
the weight loss in our study was achieved with only one intervention and in less 
obese individuals. With this background the observed weight loss represents a 
notable result which could still be associated with a significant health improvement. A 
weight loss of 5-10% can successfully reduce the consequences of co-morbid 
conditions associated with obesity such as dyslipidaemia, hypertension and diabetes 
[22, 23]. 
Furthermore 72.5% of all subjects in the follow-up study population declared to have 
changed their lifestyle in any measured area three months after screening. Subjects 
at high risk for type 2 diabetes (HRC group) as well as those who got intensive 
counselling in the pharmacy after screening for type 2 diabetes (IC group) were more 
likely to change their lifestyle than subjects in the standard counselling group (SC 
group). These differences were significant in all areas of self-reported lifestyle 
change for the HRC group vs. IC group and in four of eight areas for the IC group vs. 
SC group. Of further interest is the much smaller number of subjects declaring to 
have increased sports activities as compared to their increase in everyday physical 
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activity. It seems that especially for overweight persons there is a rather big barrier to 
increase sportive activities or even more to start with them. 
Because subjects at high risk for type 2 diabetes showed more pronounced weight 
loss as well as self-reported lifestyle changes than subjects at moderate risk with 
intensive counselling, it is probable that the blood glucose measurement in the 
pharmacy (and the measured glucose value itself) has initiated a stronger readiness 
for lifestyle change. No significant influence of a physician’s consultation was 
observed in the HRC group, even though 80.8% of subjects followed the 
pharmacist’s recommendation to call on a physician for further check up. The 
stronger effects on weight loss in the HRC group were therefore most likely not 
caused by consulting a physician but rather by the psychological effect of the 
abnormal blood glucose value detected in the pharmacy. 
It is possible that the weight reduction achieved in our study could be enhanced by 
repeating this singular pharmacy counselling after 3 months. This could reduce the 
impact of the colder season on weight control. Several studies have shown that the 
BMI of overweight as well as of normal weight individuals were higher in winter than 
in summer seasons [24, 25]. With this seasonal effect in mind, Visscher and Seidell 
suggested waist circumference to be a more sensitive indicator of variations in 
lifestyle and body composition than body mass index [25]. 
The Third Report of the National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III; ATP III) [26] recommends a multifactorial lifestyle 
approach to reducing risk for coronary heart disease (CHD). This approach is 
referred to as therapeutic lifestyle change (TLC) and includes the following 
components: reduced intake of saturated fats and cholesterol, therapeutic dietary 
options for enhancing LDL (low density lipoprotein) lowering, weight reduction and 
increased regular physical activity. According to the ATP III, at all stages of dietary 
therapy, physicians are encouraged to refer patients to registered dieticians or other 
qualified nutritionists. A high proportion of patients with the metabolic syndrome are 
overweight or obese and sedentary; for them, weight reduction therapy and physical 
activity guidance is required to obtain further CHD risk reduction beyond that 
achieved by LDL lowering through dietary alterations. Considering the design and the 
results of the present study, we would suggest that initiating TLC in community 
pharmacies could be a promising approach to reduce the risk for diabetes and 
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coronary heart disease. Especially if the screening is enlarged and dyslipidaemia is 
observed, subsequent counselling on TLC should be mandatory. 
 
The results of our study are limited by the fact that there was quite a high dropout 
rate over the three follow-up assessments. Such dropout rates have been observed 
to a slightly lesser extent also in other weight loss studies, but in those studies 
personal contact were maintained to health professionals during follow-up [16, 22]. 
The dropout rates in our study were different between the two risk samples. There 
was a higher dropout rate in the sample of subjects at high risk for type 2 diabetes 
than in the sample at moderate risk. Further, the mean age as well as the average 
BMI was greater in non-responders than in the study population. This suggests that 
subjects at lower risk for type 2 diabetes are more willing to answer three complex 
questionnaires and show concern in their lifestyle and health. It is also probable that 
the subjects who answered all three questionnaires were more inclined to change 
their lifestyle. Unfortunately the reasons why subjects dropped out and what 
happened with their weight and lifestyle after having dropped out of the study could 
not be assessed and are therefore not known. 
Interpretation of results is further limited by the design of the study itself which does 
not include a control group. It would be of special interest to include subjects who did 
not participate in screening for type 2 diabetes and received no counselling regarding 
therapeutic lifestyle change. Furthermore there was no randomisation of the 
participants into the two groups of intensive and standard counselling in the 
pharmacy. Pharmacists themselves were allowed to decide whether they provided 
intensive or standard counselling. As could be expected, the average BMI of the 
intensive counselling group was significantly higher compared to the standard 
counselling group, as pharmacists have provided intensive counselling more often to 
subjects with a higher body weight. It is further likely that time availability has 
influenced the pharmacists’ decision of providing either intensive or standard 
counselling. 
Data such as weight and height in the present study were acquired using written 
questionnaires and results therefore are based on self-reported data. There is 
substantial evidence that self-reported height and weight can result in subsequent 
misclassification of overweight status particularly in older adults, whereas other 
studies have shown self-reported data to be largely reliable [27-29]. 
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Conclusions 
The results of this study show that immediate counselling of persons screened for 
type 2 diabetes in community pharmacies can result in significant lifestyle changes. A 
measurable, significant weight loss was achieved, and further changes in important 
lifestyle areas such as physical activity and nutrition habits were reported. These 
effects were more accentuated in persons at high risk for type 2 diabetes, who 
showed abnormal blood glucose values during the screening. Counselling effects 
were likewise more pronounced in the group which received intensive counselling in 
the pharmacy than in the group with standard counselling. 
Combining screening for type 2 diabetes, including blood glucose measurement, with 
consecutive counselling activities in community pharmacies represents a promising 
opportunity to initiate therapeutic lifestyle change. Screening for type 2 diabetes in 
community pharmacies should be followed immediately by targeted counselling with 
the aim to initiate therapeutic lifestyle change in persons at risk. As we demonstrated, 
pharmacists can play an important role in helping individuals to control their weight 
and to change their lifestyle. 
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Figures 
 
Figure 1: Recruitment of the study population 
*  moderate risk: ≥2 risk factors (out of 6) but normoglycaemia 
**  high risk: ≥2 risk factors (out of 6) and abnormal blood glucose (fasting blood glucose ≥6.1 mmol/l, non 
 fasting blood glucose ≥11.1 mmol/l or borderline values of fasting blood glucose 5.3-6.0 mmol/l or non 
 fasting blood glucose 5.3-11.0 mmol/l, confirmed by a second measurement in the fasting state) 
SC: standard counselling 
IC:  intensive counselling 
HRC:  high risk counselling 
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subjects 
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to physician 
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Figure 2: Self-reported positive changes in lifestyle three months after screening 
SC: standard counselling 
IC: intensive counselling 
HRC: high risk counselling 
Statistically significant differences are indicated (*p<0.05; ** p<0.01; *** p<0.001) 
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Tables 
Table 1: Interventions for the three different counselling groups 
Counselling 
group 
Risk 
constellation Intervention 
  Assessment of 
three stages of 
change according 
to the trans-
theoretical model 
(adequate 
physical activity, 
low fat intake, 5-a-
day) 
Unspecific 
recommendations 
concerning 
physical activity 
and nutrition 
Explicit advice to 
reduce body 
weight including 
targeted 
counselling on 
weight reduction 
and additional 
precise advice 
towards lifestyle 
change 
Referral to a 
physician for 
further check up 
Standard 
counselling 
(SC group) 
Moderate risk 
(≥2 risk factors, 
but normal blood 
glucose values) 
+ +   
Intensive 
counselling 
(IC group) 
Moderate risk 
(≥2 risk factors, 
but normal blood 
glucose values) 
+ + +  
High risk 
counselling 
(HRC group) 
High risk 
(≥2 risk factors 
and abnormal 
blood glucose 
values) 
+ +  + 
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Table 2: Comparison of baseline characteristics between study population and non-responders 
 Study population 
(n = 1370) 
 
Mean ± SD 
Non-responders 
(n = 2364) 
 
Mean ± SD 
p-value 
Age [years] 59.9 ± 11.0 60.8 ± 11.3 0.03
Gender 
 male 
 female 
43.6%
56.4%
 
41.0% 
59.0% 0.12
Smoking habits 
 Current smoker 
 Not current smoker 
12.4%
87.6%
 
13.1% 
86.9% 0.58
Risk intensity for type 2 diabetes 
 moderate risk 
 high risk 
82.1%
17.9%
 
73.3% 
26.7% <0.001
Height [cm] 168.8 ±   8.5 167.6 ±   8.2 0.003
Weight [kg] 80.5 ± 11.2 80.8 ± 11.6 0.35
Body mass index [kg/m2] 28.3 ±   3.1 28.8 ±   3.3 <0.001
Systolic blood pressure [mmHg] 139.5 ± 18.2 140.1 ± 19.4 0.35
Diastolic blood pressure [mmHg] 86.2 ± 11.2 85.6 ± 11.5 0.14
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Table 3: Baseline characteristics of the three different counselling groups 
 SC group 
(n = 557) 
 
Mean ± SD
IC group 
(n = 568) 
 
Mean ± SD
HRC group 
(n = 245) 
 
Mean ± SD 
p-value 
Age [years] 59.4 ± 10.8 58.3 ± 11.6 64.9 ± 8.6 <0.001 ♣
Gender 
 male 
 female 
45.1%
54.9%
36.6%
63.4%
 
56.7% 
43.3% <0.001*
Smoking habits 
 Current smoker 
 Not current smoker 
14.4%
85.6%
9.7%
90.3%
 
14.3% 
85.7% 0.035 +
Height [cm] 168.9 ±   8.6 168.2 ±   8.4 169.8±   8.4 0.045 ♦
Weight [kg] 77.9 ± 10.4 81.7 ± 11.2 83.6 ± 11.5 <0.001 ‡
Body mass index [kg/m2] 27.3 ±   2.6 28.8 ±   3.2‡ 29.0 ±   3.3 <0.001 ‡
Systolic blood pressure [mmHg] 137.3 ± 18.1 139.0 ± 17.5 145.9 ± 18.8 <0.001 ♣
Diastolic blood pressure [mmHg] 85.5 ± 11.3 86.6 ± 10.9 86.8 ± 11.4 0.16
 
SC: standard counselling 
IC: intensive counselling 
HRC: high risk counselling 
♣ Significant differences only between HRC vs. IC group and between HRC vs. SC group 
* Significant differences between all groups 
+ Significant differences only between IC vs. SC group 
♦ Significant differences only between HRC vs. IC group 
‡ Significant differences only between HRC vs. SC group and IC vs. SC group 
 
 
  
Table 4: Change of BMI, body weight and percent change of body weight in the different counselling groups 
Variable  Screening 
campaign 
(T1) 
 3 months 
after 
screening 
(T2) 
 
 ½ year 
Follow-up 
(T3) 
   1 year 
Follow-up 
(T4) 
 
  
     p-value T1/T2   
p-value 
T2/T3 
p-value 
T1/T3   
p-value 
T3/T4 
p-value 
T2/T4 
p-value 
T1/T4 
BMI [kg/m2]              
 SC  27.3 ± 2.6  27.1 ± 2.7 ***  27.1 ± 2.7 n.s. **  26.9 ± 2.7 *** ** *** 
 IC  28.8 ± 3.2  28.5 ± 3.3 ***  28.6 ± 3.5 * ***  28.4 ± 3.4 *** * *** 
 HRC  29.0 ± 3.3  28.3 ± 3.3 ***  28.4 ± 3.3 n.s. ***  28.2 ± 3.3 *** * *** 
Weight [kg]              
 SC  77.9 ± 10.4  77.3 ± 10.6 ***  77.4 ± 10.4 n.s. **  76.8 ± 10.6 *** *** *** 
 IC  81.7 ± 11.2  80.7 ± 11.4 ***  80.9 ± 11.7 * ***  80.4 ± 11.6 *** n.s. *** 
 HRC  83.6 ± 11.5  81.7 ± 11.4 ***  81.9 ± 11.5 n.s. ***  81.2 ± 11.5 *** * *** 
Percent change of body weight            
 SC    -0.67%   -0.51%    -1.29%    
 IC    -1.20%   -0.88%    -1.54%    
 HRC    -2.25%   -1.99%    -2.74%    
 
SC: standard counselling 
IC: intensive counselling 
HRC: high risk counselling 
Values are given as mean ± SD 
The p-values refer to linear contrasts of repeated analysis of variance (* p<0.05 ** p<0.01; *** p<0.001; n.s.; not significant) 
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Abstract 
Objective 
The objective of the present study was to investigate the effect of a telephone-based 
counselling intervention on body weight and lifestyle of overweight persons at risk for 
type 2 diabetes. 
 
Methods 
Subjects were recruited among participants in a pharmacy based diabetes screening 
campaign and randomly selected for intervention and control group. Eligibility criteria 
were: age 18-75 years, BMI≥25kg/m2 and no medical care for cardiovascular disease. 
Within three months three telephone-based counselling sessions with a mean duration 
of 8 minutes were provided to the intervention group. Body weight and lifestyle were 
assessed before intervention, three months after and another half year later with written 
questionnaires. 
 
Results 
Three months after the intervention mean percent change of body weight was -0.37% 
in the intervention group (n=385) and +0.09% in the control group (n=778) (p<0.05). 
The proportion for loss of ≥3% of initial body weight was 15.1% in the intervention vs. 
10.4% in the control group (p<0.05). Half a year later differences were not significant 
anymore. The proportion of subjects who newly achieved targeted goals of either 
moderate or vigorous physical activity showed no differences. However, a greater 
proportion of subjects in the intervention group progressed at least to the next higher 
stage of change in the transtheoretical model (27.0% vs. 21.3%; p<0.05). Lifestyle 
changes in physical activity and/or nutrition were reported by 80.5% vs. 62.9% 
(p<0.001). 
 
Conclusions 
With three telephone-based counselling interventions with a mean duration of 8 
minutes a measurable weight loss and significant lifestyle changes could be achieved. 
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Introduction 
Type 2 diabetes mellitus is a public health concern, and projections of its future effect 
are alarming. The number of persons affected by type 2 diabetes is expected to 
increase in the future due to population growth, aging, urbanization, and increasing 
prevalence of obesity and physical inactivity [1], [2]. Type 2 diabetes is often 
asymptomatic in its early stages and can remain undiagnosed for many years. The risk 
increases with age, obesity and lack of physical activity [3]. 
World wide overweight (body mass index [BMI] 25–30 kg/m2) and obesity (BMI ≥30 
kg/m2) are a growing public health problem. Excess weight increases not only risk for 
type 2 diabetes but also for cardiovascular disease, hypertension, stroke, and other 
chronic diseases [4]. There is substantial evidence that type 2 diabetes can be 
prevented or at least delayed by changes in lifestyle [5], [6]. Two randomised controlled 
trials have shown that intensive lifestyle modifications through alterations in diet and 
improvement in exercise can delay or prevent progression of impaired glucose 
tolerance to type 2 diabetes [7, 8]. The 3-year follow-up of the Finnish Diabetes 
Prevention Study has even shown sustainability of reduced diabetes risk in the 
intervention group [9]. Lindstrom et al. concluded from these results that initiating 
lifestyle change by intervention programs is a feasible option to prevent type 2 
diabetes. Lifestyle changes such as physical exercising have been shown to have 
positive effects even without weight loss [10]. The mechanisms by which lifestyle 
modifications reduce the progression may be through alterations in insulin sensitivity 
[6]. 
Telephone-based counselling is an alternative to face-to-face interventions which are 
expensive due to high personnel costs. Telephone contact lacks some of the features 
that may make personal contact effective, but it is conceptually superior to mail-based 
approaches because it provides greater certainty that participants will receive regular 
reminders of their weight control objectives. However, studies on telephone-assisted 
interventions on weight control and lifestyle change are still relatively rare and show 
controversial results. Some studies have shown beneficial effects on weight control, 
physical activity and nutrition habits [11] while others did not show statistically 
significant effects on physical activity and nutrition habits [12], [13]. A randomised 
controlled trial with 64 participants showed no significant difference in weight loss 
between telephone-based intervention and control group [14]. Nevertheless, Hellerstedt 
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and Jefferey [14] concluded that this type of investigations should be continued as it is 
possible to identify a more effective design of such interventions. 
The objective of the present study was to investigate whether three telephone-based 
counselling sessions with a mean duration of 8 minutes have a beneficial influence on 
body weight and lifestyle of overweight persons at risk for type 2 diabetes. Subjects for 
this study were recruited from participants of a national diabetes screening campaign in 
Switzerland [15] and randomly assigned to either the intervention or control group. To 
assess the short term as well as the long term efficacy of the telephone-based 
counselling the differences in average weight, BMI and percentage of weight loss as 
well as in stage of change for physical activity according to the transtheoretical model 
(Prochaska) [16] were determined three and nine month after the counselling 
respectively. In addition, self-reported lifestyle changes in physical activity and nutrition 
habits were evaluated. 
 
Methods 
Recruitment of subjects 
Of 93’258 persons who have been screened during the diabetes screening campaign, 
23’279 persons provided informed consent for further follow-up studies. A total of 4700 
overweight subjects at risk for type 2 diabetes were selected for the present study. The 
participants had to meet the following criteria: 18 to 75 years old, BMI ≥25.0 kg/m2 and 
no medical care for cardiovascular disease. For baseline assessment the subjects were 
addressed with a written questionnaire three month after the screening campaign 
(August 2002). Out of 2597 persons having answered the first questionnaire, 1160 
persons were randomly assigned to the telephone-based counselling (intervention 
group) and 1437 subjects to the control group. The intervention group got three 
telephone-based counselling calls from October to December 2002. In February 2003, 
the subjects were addressed with the second questionnaire to evaluate the effect of the 
telephone-based counselling. A third questionnaire was sent in August 2003 to all 
subjects who returned the second questionnaire (half year follow-up). Subjects 
received no financial compensation for participating. The project was approved by the 
Ethics Committee of Basel. 
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Telephone-based counselling 
The counselling calls were conducted by health counsellors of the Medvantis medical 
call center in Switzerland. All counsellors were nurses or physician assistants who had 
experience with this type of counselling and were supervised weekly by physicians. 
Prior to the telephone calls, in a half-day course, the counsellors were trained in 
behavioural counselling technique. Each subject of the intervention group received 
three counselling calls with intervals of at least 3 weeks and at most 4 weeks between 
two calls. The counsellors addressed both physical activity and nutrition with the aim to 
reduce body weight. Subjects were informed about the recommendation of at least half 
an hour physical activity of moderate intensity (e.g. walking, gardening) a day or three 
times twenty minutes weekly of activities with vigorous intensity (e.g. jogging, fast 
cycling). They got advice regarding low fat intake and increased consumption of fruits 
and vegetables, in particular consumption of 5 servings of fruits and/or vegetables per 
day (“5-a-day behaviour”). Furthermore, counsellors provided tips towards physical 
activity and nutrition habits which could easily be implemented into everyday life. In 
each call the counsellors asked whether the participants reached their goals and they 
counselled about strategies to overcoming possible barriers. The counsellor focused 
the call based on a standardized script on the target behaviour the participant found 
most difficult. If the participants easily met their goals, they were encouraged to either 
increase these goals or select new ones. Mean duration of the counselling calls was 8 
minutes with a range of 5 to 20 minutes. 
 
Data collection 
The three questionnaires were to be completed anonymously and were sent to the 
study participants each along with a reply-paid envelope. They were developed by the 
investigators and were pre-tested with 20 individuals, but no adaptations were 
necessary. The basic questionnaire included 24 questions with 52 items on 
demographics and on outcome measures of body weight and achieved lifestyle 
changes in physical activity and nutrition habits. The second questionnaire contained 
26 questions with 56 items on demographics and outcome measures as well as 
towards quality of the telephone-based counselling. The third questionnaire included 15 
questions with 35 items on demographics and outcome measures. Weight was 
recorded in kg without decimal places and height in cm. Physical activity was assessed 
with the items from the Swiss HEPA (health enhancing physical activity) Survey 2001 
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[17]. Two sets of questions were used to assess activities of both moderate and 
vigorous level in a two-step-procedure (days per week; average duration). The intention 
to become more physically active within the next six months and within the next month 
as well as the duration since the introduction of the current activity behaviour were also 
assessed. To report changes in physical activity questions like new participation in 
sport courses, new workout in fitness centres, increase in sportive activities and 
increase in everyday physical activity were included. Changes in nutrition habits could 
be reported in reduction of fat intake, increase in consumption of fruits and vegetables, 
improvement in “5-a-day behaviour” and unspecific reduction of food consumption. 
All questionnaires were processed automatically using Teleform® version 7.0 from 
Cardiff Software, CA, USA. This software has been validated by Jorgensen et al. [18]. 
For choice fields the error rate was very low and comparable to double manual data 
entry, while for numeric recognition the error rate was higher than for both single and 
double manual data entry. Therefore in the present study all numeric recognitions have 
been verified visually on screen. The three questionnaires were linked to each other 
with a numerical code of 5 numbers and anonymity was always guaranteed. The link of 
data files was verified with individual data for sex and age. If manual correction based 
on the hard copy was not possible the according data file was excluded from analysis. 
 
Analysis of data 
Primary outcome measures were: differences in average BMI and weight, percent 
change of body weight and percentage of patients loosing more or equal than 3% of 
their initial body weight. Physical activity was assessed with the stages of change of the 
transtheoretical model (Prochaska) [19]. Half an hour physical activity daily (≥5 days 
per week) with at least moderate intensity and/or three times twenty minutes weekly of 
activities with vigorous intensity was used as respective target behaviours. The stages 
of change were calculated using an algorithm on the basis of the two sets of questions 
for both moderate and vigorous activity. They included: (1) pre-contemplation: inactive 
and no intention to become active; (2) contemplation: inactive with intention to become 
active within the next 6 months; (3) preparation: inactive with intention to become active 
within the next month; (4) action: meeting the moderate intensity or vigorous intensity 
recommendations since up to half a year; (5) maintenance: meeting the 
recommendations since at least half a year. 
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As secondary outcome measures prevalence rates of self-reported lifestyle changes in 
physical activity and in nutrition habits were evaluated. They were pooled to auxiliary 
variables of “any positive change in physical activity” as well as “any positive change in 
nutrition habits” and in a final step to “any positive lifestyle change”. 
 
Statistical analysis was performed using SPSS 11.5 for Windows (SPSS, Inc, Chicago, 
Illinois, USA). Values are expressed as mean ± standard deviation (SD) or standard 
error (SE). Change in BMI and body weight over time was analysed using repeated 
analysis of variance (Generalized linear model: GLM) with intervention and control 
group as covariates. Linear contrasts were applied to detect pairwise differences. All p-
values were calculated two-sided, values of p<0.05 being considered statistically 
significant. Unpaired student's t-tests were used to compare numeric variables of 
baseline characteristics and outcome measures. In addition, differences in prevalences 
of demographic and outcome variables were assessed using Pearson's two-sided chi-
square- or Fisher’s exact test as appropriate. 
 
Results 
Recruitment and characteristics of study population 
Of 1160 persons randomly chosen for telephone-based intervention 611 (52.7%) 
participated in the three counselling calls. Subjects who refused to participate in the 
intervention (non-participants) were compared with participants regarding their baseline 
characteristics and results are given in Tables 
Table 3. Statistically significant differences were found in sex with a greater prevalence 
of women in the group of participants. Further, non-participants showed a healthier risk 
constellation with a lower BMI than participants (p=0.02) and a slightly higher mean 
stage of change for physical activity (p=0.04). 
Response rates three months after the intervention were 72.2% in the intervention 
group vs. 70.9% in the control group and 94.6% vs. 94.9% at half year follow-up, 
respectively. Out of 1384 subjects having returned all questionnaires 23 subjects had to 
be excluded from analysis because of wrong linkage of their data records. Another 198 
subjects had to be excluded because of missing data in primary outcome measures. 
Thus, the eligible study population consisted of 1163 subjects, 385 of them belonging 
to the intervention group and 778 to the control group. The mean age of the study 
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population was 57.8 years ± 10.7 (SD), 484 (41.6%) were male and 134 (11.5%) 
declared to be smokers. Statistically significant differences between study population 
and non-responders were observed only in BMI (higher in non-responders) and in 
height (smaller in non-responders). The comparison of the baseline characteristics of 
intervention and control group (Tables 
Table 3) showed no statistically significant differences between intervention and control 
group except for physical activity: mean stage of change was higher in the control 
group than in the intervention group (p<0.01). 
 
Changes in body weight and BMI 
The changes in body weight and BMI are shown in Table 4. Subjects in the intervention 
group showed a statistically significant weight loss three months after counselling 
whereupon in the control group a slight, but statistically not significant weight gain was 
observed. At half year follow-up (August 2003) there was a significant weight reduction 
in both intervention and control group. Three months after the telephone-based 
counselling the intervention group has reached a higher percent change of body weight 
than the control group (-0.37% vs. +0.09%; p=0.02). At half year follow-up subjects in 
the intervention group showed also a higher percent change of body weight (-0.85% vs. 
-0.71%); however this difference was not statistically significant anymore. 
Three months after intervention, a greater part of subjects in the intervention group lost 
3 or more percent of their initial body weight (58 subjects [15.1%] in the intervention 
group vs. 81 subjects [10.4%] in the control group [p<0.05]). At half year follow-up, 84 
subjects (21.8%) in the intervention group lost ≥3% of the initial body weight vs. 156 
subjects (20.1%) in the control group (difference not significant). 
 
Changes in physical activity 
Three months after the telephone-based counselling as well as at half year follow-up 
chi-square analysis revealed no significant differences between intervention and control 
group for either moderate or vigorous physical activity in the proportion of subjects who 
newly achieved targeted goals (30 min. ≥5 times per week for vigorous activity and 20 
min ≥3 times per week for moderate physical activity). However, a significant difference 
between intervention and control group was observed regarding mean differences in 
stage of change three months after the intervention (-0.02 vs. -0.31; p=0.01). However, 
at half year follow-up this difference was not significant anymore (+0.10 vs. -0.03; n.s.). 
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Figure 3 shows the proportion of subjects who progressed at least to the next higher 
stage of change, stayed in the same stage, or regressed to a previous stage three 
months after counselling. Subjects in the intervention group were more likely to 
progress at least to the next higher stage of change (p=0.033). At half year follow-up 
26.5% of subjects in the intervention group vs. 22.5% in the control group progressed 
at least for one stage of change. However, this difference was not statistically 
significant anymore. 
Regarding development of mean stage of change, the intervention group showed no 
statistically significant differences neither after three months nor at half year follow-up. 
In contrast, subjects in the control group showed a significant decrease in mean stage 
of change three months after screening (p<0.001). At half year follow-up, the control 
group’s mean stage of change increased to its status at baseline. 
 
Self-reported changes in lifestyle 
A significant effect of the telephone-based counselling was observed in self-reported 
lifestyle changes (Figure 4). In the intervention group, 80.5% of subjects declared to 
have changed their lifestyle in any of the eight topics and in the control group 62.9%, 
respectively (p<0.001). In all domains a similar pattern emerged. In the intervention 
group there was a greater part of subjects with self-reported improvements than in the 
control group with statistically significant differences in all areas except for increase in 
sportive physical activities. Overall, a greater proportion of subjects reported 
improvements in everyday physical activity than in sportive activities. Furthermore, 
improvements were more often reported in nutrition habits than in physical activity 
domains with the exception of “5-a-day behaviour”: 44.4% in the intervention group and 
32.1% in the control group (p<0.001) reported to have generally increased their 
consumption in fruits and vegetables whereas only 9.9% vs. 7.7% (n.s.) declared to 
have improved their “5-a-day behaviour”. 
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Discussion 
The results of the present study show that 3 telephone-based counselling interventions 
with a mean duration of 8 minutes can initiate significant lifestyle changes and 
measurable weight loss in overweight persons at risk for type 2 diabetes. Subjects in 
the intervention group showed a statistically significant weight loss three months after 
telephone-based counselling whereas the control group showed a slight, statistically 
not significant weight gain. At half year follow-up in both groups a considerable weight 
loss was observed. Thus, a seasonal interference on weight control was observed in 
the control group with weight stability in the colder season and weight loss in the 
warmer season. 
Three months after counselling there was a significant difference between intervention 
and control group regarding percent change of body weight (-0.37% vs. +0.09%; 
p<0.05). In two randomised controlled trials which investigated the effect of either 
sibutramine or orlistat on weight reduction [20, 21], the placebo groups showed an 
average weight loss of 4.6% to 6.1% after 24 or 12 months, respectively. In 
comparison, the 0.9% average weight loss observed in our study appears to be 
modest, but attention must be paid to the fact that the patients in the two trials were 
much more obese (average BMI of 36.1 and 36.7 kg/m2, respectively) than the 
subjects in the present study. Moreover, dietetic help with medical attendance was 
provided to the placebo groups in those two trials, whereas the weight loss in the 
present study was achieved with only three telephone-based counsels of a mean 
duration of 8 minutes. With this background the observed weight loss represents a 
notable result which could still be associated with a certain health improvement. 
The effect on physical activity was less pronounced in the present study. No significant 
differences were detected between intervention and control group for either moderate 
or vigorous physical activity in the proportion of subjects who newly achieved targeted 
goals. Nevertheless, there was a statistically significant difference between intervention 
and control group regarding persons who progressed at least for one stage of change 
three months after the telephone-based counselling. It must be noticed that the 
identification of changes from stage 4 to stage 5 was impeded by the tight 6 months 
time frame. However the modest effect on physical activity suggests that it was easier 
to change nutrition habits than to enhance physical activity, especially as the 
intervention was carried out in the colder season. 
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Another significant effect was found in self-reported lifestyle changes. 80.5% of 
subjects in the intervention group vs. 62.9% in the control group declared to have 
changed their lifestyle in any of the eight areas (p<0.001). Moreover in 6 of the 8 
domains a statistically significant greater proportion of subjects in the intervention 
group declared to have improved their health related behaviours. Another interesting 
finding is the much smaller proportion of subjects declaring to have enhanced sportive 
activities than everyday life physical activity. It seems that especially for overweight 
individuals there is a rather big barrier to increase sportive activities or even to start 
with. 
Overall, a significant effect of the telephone-based counselling on weight control and 
physical activity was observed three months after counselling but not at half year 
follow-up. However, a seasonal interference on weight control was observed in the 
control group with weight stability in the colder season and weight loss in the warmer 
season. Several studies have shown that BMI levels of overweight as well as of normal 
weight individuals were higher in winter than in summer [22], [23]. Referring to this 
result, Visscher and Seidell [23] suggested waist circumference to be a more sensitive 
indicator of variations in lifestyle and body consumption than is body mass index. As 
the telephone-based counselling has been performed in the colder season, the 
intervention’s effect seems to be negatively influenced by this time constellation. It is 
most likely that the effect would be more pronounced if the intervention would have 
been carried out in spring instead of autumn. Further on, it might be possible that the 
effects observed in the present study could have been enhanced by repeating the 
counselling after 3 or 6 months. Continuing this type of counselling could have had 
benefited from the general positive effect of the warmer season on weight control. 
As participants were recruited out of individuals who participated in a diabetes 
screening campaign, they were already influenced by counselling provided in 
community pharmacies. A follow-up study of the campaign has shown that this 
counselling in the pharmacy has resulted in considerable weight loss and lifestyle 
changes [24].Thus, the telephone-based counselling in the present study represented 
an additional intervention to persons already sensitised on the same topics. It is likely 
that the exposure of participants to previous counselling in the pharmacy is another 
reason for the rather modest impact on primary outcome measures. 
There was a relatively high dropout rate over the three time-points of assessment. This 
is not uncommon and has been observed to similar extents in other weight loss studies 
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[25], [26]. Certainly there was a selection of willing subjects in the present study, which 
limits the generalisability of our findings. The average BMI of the non-responders was 
significantly higher than the responder’s. This suggests that subjects with less 
overweight and therefore minor health risk are more willing to answer three complex 
questionnaires and to confront themselves with their lifestyle or health situation. 
In addition, there was a further selection through telephone-based counselling by only 
52.7% of subjects randomised into the intervention group willing to participate. Women 
were more willing to participate than men. Altogether, subjects taking part in the 
intervention had a higher body mass index and a worse physical activity level and were 
therefore at higher risk for type 2 diabetes. It was probably easier to convince 
individuals with higher health risk to participate in a health promoting intervention study. 
Moreover, it is most likely that subjects who were willing to participate in the telephone-
based counselling as well as those who answered all three questionnaires are more 
disposed to change their lifestyle. Certainly this circumstance has influenced the 
results. 
In the present study data such as weight and height were collected using written 
questionnaires (self-reported data). There is substantial evidence that self-reported 
height and weight can result in subsequent misclassification of overweight status 
particularly in older adults [27], [28]. Other studies have shown self-reported data to be 
largely reliable [29], [30]. 
 
Conclusion 
The effects induced by the three telephone-based intervention sessions of a mean 
duration of 8 minutes on primary outcome measures were not drastic but clearly 
measurable and of public health relevance. They possibly would have been enhanced 
by a repeated telephone-based encouragement 3 or 6 months later. Average weight 
loss following the present intervention is less than weight loss achieved in high-contact 
programs. On the other hand such a telephone-based counselling can reach a large 
and diverse population at modest costs. Based on the findings of this study there 
appears to be an audience predestined for such programs. Best modalities and best 
time of intervention still need further exploration. However, the results of the present 
study show that a telephone-based counselling is able to induce significant lifestyle 
changes and a measurable weight loss of overweight individuals. 
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Figure 3: Proportion of subjects moving along the stages of change in physical activity three 
months after telephone-based counselling 
Intervention (n=385) and control group (n=778); statistically significant differences are indicated (*p<0.05). 
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Figure 4: Proportion of study subjects with self reported positive changes in lifestyle three months after the telephone-based intervention 
Statistically significant differences are indicated (*p<0.05; **p<0.01; ***p<0.001) 
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Tables 
Table 3: Baseline characteristics of participants vs. non-participants and of intervention vs. control group 
 Participants 
(n = 611) 
 
 
Mean ± SD
Non-participants 
(n = 549) 
 
 
Mean ± SD
 Intervention 
group 
(n = 385) 
 
Mean ± SD
Control group 
(n = 778) 
 
 
Mean ± SD
 
Age [years] 57.3 ± 10.7 57.7 ± 11.2 57.4 ± 10.3 58.0 ± 10.9
Gender 
 male 
 female 
39.3%
60.7%
 
49.0% 
51.0% **
41.6%
58.4%
 
41.6% 
58.4%
Smoking habits 
 Current smoker 
 Not current smoker 
12.7%
87.3%
 
13.8% 
86.2%
11.7%
88.3%
 
11.5% 
88.5%
Height [cm] 168.7 ± 8.4 169.5 ± 8.7 * 169.1 ± 8.2 168.8 ± 8.6
Weight [kg] 81.4 ± 11.0 81.1 ± 11.0 81.3 ± 10.9 80.8 ± 11.3
BMI [kg/m2] 28.6 ± 3.0 28.2 ± 2.8 * 28.4 ± 2.8 28.3 ± 3.0
Mean stage of change for 
physical activity 
3.0 ± 1.7 3.2 ± 1.7 * 2.9 ± 1.7 3.2 ± 1.7 **
Stages of change for physical 
activity 
 Stage 1 
 Stage 2 
 Stage 3 
 Stage 4 
 Stage 5 
27.2%
24.9%
9.3%
3.5%
35.2%
 
 
27.4% 
16.5% 
11.1% 
4.1% 
41.0% **
28.3%
25.7%
9.6%
2.9%
33.5%
 
 
26.9% 
17.5% 
9.0% 
4.6% 
42.0% **
Statistically significant differences are indicated (*p<0.05; **p<0.01), others p≥0.05 
  
Table 4: BMI, body weight and percent change of body weight 
Variable  Before 
intervention 
(T1) 
 After 
intervention 
(T2) 
  Half year 
follow-up 
(T3) 
  
     p-value 
1 
T1/T2   
p-value 1 
T2/T3 
p-value 1 
T1/T3 
BMI [kg/m2]          
 Intervention  28.37 ± 0.14  28.26 ± 0.14 *  28.12 ± 0.15 ** *** 
 Control  28.30 ± 0.11  28.32 ± 0.11 n.s.  28.09 ± 0.11 *** *** 
Weight [kg]          
 Intervention  81.30 ± 0.55  80.98 ± 0.56 *  80.56 ± 0.56 ** *** 
 Control  80.79 ± 0.41  80.85 ± 0.41 n.s.  80.19 ± 0.41 *** *** 
   
p-value 2 
Intervention 
vs. Control 
  
p-value 2 
Intervention 
vs. Control 
 
Change in body weight [kg]        
 Intervention    -0.32 *  -0.74 n.s.  
 Control    +0.06   -0.60   
Percent change of body weight        
 Intervention    -0.37% *  -0.85% n.s.  
 Control    +0.09%   -0.71%   
Values are given as mean ± SE 
1 The p-values refer to linear contrasts of repeated analysis of variance (GLM) (* p<0.05 ** p<0.01; *** p<0.001; n.s.; not significant) 
2 The p-values refer to unpaired t-test within groups (* p<0.05; n.s.; not significant)  
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5 General discussion and conclusions 
In this thesis screening concepts for cardiovascular risk factors (particularly for type 2 
diabetes and dyslipidaemia) and related health promoting activities were evaluated. 
 
With the aim to validate blood pressure measurement in community pharmacies, 
project A revealed that white coat effect and white coat hypertension exist in 
community pharmacy practice and are at least similar to the effects in an outpatient 
clinic, where a nurse measures blood pressure. The results of this study were limited 
by the rather small number of 50 included subjects. As several studies have shown 
more expressed white coat effect in subjects with stronger hypertension, it can be 
supposed that if only hypertensive patients were included in this study, then the 
observed white coat effect would have been enhanced. No studies on extent and 
importance of the white coat phenomenon in pharmacies could be retrieved to 
compare our findings. However, the white coat effect generated in community 
pharmacy practice seems to be smaller than that triggered by physicians as reported 
in the literature. This indicates that blood pressure measurements in community 
pharmacies are at least as reliable as those of other health professionals.  
 
In project B, a national diabetes screening campaign in community pharmacies 
called “Stopp Zucker – Jetzt testen!” provided the possibility to evaluate a sequential 
screening concept for type 2 diabetes to be used in community pharmacy practice. 
Triage guidelines and appropriate cut-off points for blood glucose measurement in 
capillary blood were elaborated. A total of 94124 persons were screened for 
previously undiagnosed type 2 diabetes. The screening campaign therefore attracted 
a large number of Swiss German speaking adults (2.4% of the total population) and 
the screening concept has successfully been implemented into pharmacy practice. 
Despite the advanced age of the screened population, only 6.9% were suspected to 
have type 2 diabetes using the developed triage guidelines. Hereby it must be noted 
that 1.5% of the screened persons with already treated diabetes were excluded from 
analysis. Epidemiologic studies revealed prevalence rates of diabetes and impaired 
fasting glucose of 1.4 – 16.3%. This wide range illustrates the difficulties of assessing 
diabetes prevalence rates in the population. Risk factor assessment of the screened 
persons suggested that the campaign has selected a higher risk population which 
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further impedes the assessment of prevalence rates. Individuals suspected to have 
type 2 diabetes were referred to a physician for further check-up. Due to the low 
physicians’ response rate it was not possible to assess the outcome of these 
consultations after referral by the pharmacists. Another 71.5% of the screened 
persons had at least two risk factors. This provided the opportunity to deliver targeted 
counselling towards lifestyle change to a large population group. As community 
pharmacies are highly accessible health promoting counselling in community 
pharmacies could easily be implemented into daily practice. This would represent a 
significant contribution to preventive and health promoting care in community health. 
The evaluation of this large screening campaign showed that for community 
pharmacy practice the elaborated sequential screening procedure can be 
recommended: First an assessment of all risk factors should be performed including 
blood pressure with cut off point ≥2 risk factors to select individuals for blood glucose 
measurement. This pre-screening showed higher sensitivity but lower specificity than 
the ADA questionnaire. As the risk assessment is followed by blood glucose 
measurement, the low specificity is irrelevant, but high sensitivity is important. For the 
subsequent capillary blood glucose measurement cut-off point, 5.3 mmol/l was used. 
Lowering of this threshold for normal fasting capillary blood glucose from 5.3 mmol/l 
to 4.9 mmol/l, according to the new recommendation by the ADA (5.6 mmol/l for 
plasma glucose respectively 4.9 mmol/l for capillary whole blood), would increase the 
prevalence of impaired fasting glucose by 79% in this study population. Thus for 
community pharmacy practice a cut-off point of 5.3 mmol/l is a rational threshold, but 
in case of borderline results retest is required. 
 
In project C, a pharmacy-based screening concept for metabolic syndrome including 
a multiple risk assessment for coronary heart disease was evaluated during a 
campaign in 30 community pharmacies. The triage guidelines and cut-off points for 
dyslipidaemia were elaborated based on the ATP III guidelines. The results of this 
pilot study suggested that screening for the coincidence of ≥2 values of lipid profile 
above normal with ≥2 other risk factors for coronary heart disease is a reasonable 
approach. Exclusive screening for ≥1 or even ≥2 abnormal lipid values without 
coincidence with other cardiovascular risk factors would produce large rates for 
referral to physicians. On the other hand, if a single value is elevated at a level at 
which drug therapy is considered, even without coincidence with other risk factors, 
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referral to a physician is required. The results of this pilot study are based on a rather 
small number of individuals. Therefore further comprehensive investigations including 
validation of the triage guidelines by evaluating outcomes resulting from physicians’ 
consultations after referral by the pharmacists would be of particular interest. 
 
Project D showed that immediate counselling after screening for cardiovascular risk 
in community pharmacies can result in significant and sustainable lifestyle changes 
and weight loss in overweight individuals. Subjects with abnormal blood glucose 
values measured in the diabetes screening (see project B) showed stronger effects 
than those with normal values. It is therefore most likely that the measured blood 
glucose value itself has initiated a stronger readiness for lifestyle change. Moreover, 
an abnormal value probably provided a basis to the pharmacist in counselling 
towards health promoting lifestyle. The drop out rate over the three assessments 
possibly lead to a selection of subjects being more inclined to change their lifestyle. 
In addition, the uncontrolled design of the study did not allow for stringent 
conclusions. Nevertheless, the results of this study suggest that community 
pharmacies are a promising setting to initiate lifestyle change. Pharmacists could 
therefore play an important role in helping individuals to control their weight and to 
change their lifestyle. The opportunity to initiate therapeutic lifestyle change and to 
provide targeted counselling to persons at risk after screening for type 2 diabetes 
should not be missed. 
 
A randomised controlled trial (project E) showed that a three times 15 minutes 
telephone-based counselling is able to result in significant lifestyle changes and 
measurable weight loss. It has to be considered, however, that subjects for this 
randomised controlled trial were recruited out of individuals who participated in the 
national diabetes screening campaign (see project B). Therefore they were already 
influenced by counselling provided in community pharmacies. This may have lead to 
a higher level of awareness also in the control group and may have reduced possible 
differences. The quite high drop out rate over the three time-points of assessment is 
not uncommon when compared to literature but certainly has lead to a selection of 
more willing subjects. Due to the controlled design this affects the results of this 
study not in the same manner as those in project D. However, there was also a 
selection through the telephone-based counselling as not all individuals were willing 
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to participate. It is most likely that subjects who were willing to participate in the 
telephone-based counselling were more inclined to change their lifestyle. The effects 
of this telephone-based counselling were not drastic and smaller than those achieved 
in high-contact programs as reported in literature. Nevertheless, they are of particular 
relevance as this sort of counselling can be delivered easily and can reach a large 
and diverse population at modest costs. Best modalities and, because of seasonal 
interference, the best point in time of a telephone-based counselling need further 
exploration. 
 
In conclusion this thesis shows that: 
 
• Screening for cardiovascular risk in community pharmacies benefits from a 
sequential procedure: First an assessment of all risk factors including blood 
pressure, second capillary blood glucose measurements with retest in case 
of borderline results and with measurement of lipid profile if possible and 
finally counselling of persons at risk to initiate lifestyle change. 
 
• The elaborated and evaluated triage guidelines with the cut-off points for 
diabetes and for lipid screening (project B and C) appear to be appropriate 
and can be recommended for community pharmacy practice. 
 
• A total of 6.9% of the population screened in the national diabetes screening 
campaign were suspected to have type 2 diabetes showing abnormal blood 
glucose values. This rate is representative for the population screened but 
due to selection effects not for the general Swiss population. 
 
• Blood pressure measurements in community pharmacies are as reliable as 
those of other health professionals. They are subject to a white coat effect as 
reported also for measurements by physicians and nurses. The validation of 
community pharmacists’ measurements of blood glucose and lipid profile in 
capillary blood as well as the outcome after referral to a physician remain 
outstanding issues. 
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• Health promoting activities provided in community pharmacies or by nurses 
through telephone-based counselling can have positive effects on lifestyle 
behaviour and therewith on public health. 
 
• After screening for cardiovascular risk pharmacists should offer targeted 
counselling to persons at risk according to the readiness to change their 
lifestyle. They can also consider expanding this lifestyle counselling with 
repeated interventions using telephone-based counselling and continuous 
monitoring. This could add to effectiveness and sustainability. 
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7.4 Data sheet of the diabetes screening campaign 
Erfassungsblatt Apotheke
Initialen:
Geschlecht: männlich weiblich
Raucher: ja nein
Punktetotal aus Diabetesrisiko-
Fragebogen:
Jahrgang:
Wenn mindestens 2 Risikofaktoren vorhanden sind --> Blutzuckermessung
BERATUNGSPROTOKOLLBLUTGLUCOSE - SCREENING
Patient nüchtern?
letzte Nahrung vor > 8h
ja nein
Messwert Glucose:
kapilläres Vollblut mmol/l
Falls Messwert grenzwertig:
mmol/l
Beurteilung Apotheke:
ja nein
ENTSCHEID nach Screening Apotheke (nur 1 Antwort)
Bewegung
Fettarme Ernährung
Früchte & Gemüse
Geburt eines Babys mit Geburtsgewicht über 4000 g (nur bei Frauen): ja nein
Übergewicht:  BMI > 25 kg/m2
Körpergewicht:
ja nein
Grösse: mkg BMI: kg/m2
Blutdruck erhöht:
Messwert: syst. mmHg
ja nein
diast. mmHg
Bewegungsmangel:
- Patient macht zur Zeit nie oder weniger als 30 Min. täglich körperliche Aktivitäten von mittlerer Intensität
- oder Patient macht an weniger als 3 Tagen pro Woche während mind. 20 Min. körperliche Aktivitäten von
   hoher Intensität
ja nein
In ärztl. Behandlung wegen
Herz-Kreislauferkrankung:
ja nein
In ärztl. Behandlung wegen Diabetes: ja nein
Datum der Messung: 0 0 0 0
Tag  Monat Jahr
Empfehlung Gewichtsreduktion
Weiterer Beratungstermin vereinbart
andere Empfehlungen:
Familiäres Diabetes-Risiko:
Erstgrad-Verwandte (Eltern, Geschwister) mit Diabetes Typ 2
ja nein
Alter über 45 Jahre: ja nein
2002
,
IC-Nummer
Etikette hier aufkleben
Bitte lassen Sie den 'Informed Consent'
vom Patienten unterzeichnen!
Wiederholungsmessung
nüchtern:
Blutglucose erhöht?
)
nüchtern > 6.1 mmol/l
oder nicht nüchtern  > 11.1 mmol/l
oder Wiederholungsmessung > 5.3 mmol/l
Letzte Mahlzeit vor: h Abklärung Motivationsstufe (1 - 5):
,
,
Vorläufiger Entscheid:
Weiterleitung an Arzt (zur Diagnosestellung)
Nachkontrolle in           Jahr(en)
Fortsetzung der ärztlichen Behandlung
Visum:   ..................
(Angaben des Patienten)  (BMI = Körpergewicht [kg] / Grösse [m] / Grösse [m])
INSTITUT FÜR KLINISCHE PHARMAZIE 
Departement Pharmazie der Universität Basel
Pharmaceutical Care Research Group
Klingelbergstr. 50/4056 Basel
syst. > 140  und/oder diast.  > 90 mmHg
Wiederholungsmessung empfohlen
,
17844
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7.5 Flow chart and triage criteria of the diabetes screening 
campaign 
 
SEQUENTIELLES SCREENING VON PATIENTEN MIT DIABETESRISIKO
Ablaufschema und Triagekriterien für die Apothekenpraxis
BZ-Messung
Nachkontrolle:
in ca. 5 Jahren
(ab 45 J. in
ca. 3 Jahren)
oder
entsprechend
Risikoprofil
Kommentare
Mindestens
2
Risikofaktoren vorhanden
nein
ja
Definition "nüchtern":
Letzte Nahrung vor ≥ 8h
Messung nicht
nüchtern
Messung
nüchtern
WEITERLEITUNG AN DEN ARZT!
Wiederholungsmessung
nüchtern
5.3 - 11.0
mmol/l
≥ 6.1
mmol/l
Nachkontrolle in
ca. 1 - 2 Jahren
Nachkontrolle in
ca. 1 - 2 Jahren
Wert im
Normbereich
Blutzuckermessung
sollte wenn möglich nüchtern
erfolgen.
Blutdruck
(Erhöhter Blutdruck ist zwar kein Risikofaktor für
Diabetes per se, aber bei einem manifesten
Diabetes besteht bei erhöhtem Blutdruck ein
erhöhtes Risiko für Herz-Kreislauferkrankungen.)
≥ 11.1
mmol/l
< 5.3
mmol/l
< 5.3
mmol/l
Wert im
Normbereich
5.3 - 6.0
mmol/l
R
IS
IK
O
-S
C
R
EE
N
IN
G
B
LU
TZ
U
C
K
ER
-S
C
R
EE
N
IN
G
Weiterleitung an den Arzt
bedeutet, dass der Verdacht auf
Diabetes durch die Apotheke von
einem Arzt überprüft werden soll.
Nach erfolgter Diagnose
entscheidet er über entsprechende
Massnahmen (z.B. Einleitung der
Therapie).
Hier geht es um körperliche Aktivitäten, bei
denen man mindestens ein bisschen ausser
Atem kommt (z.B. zügiges Gehen, Wandern,
Tanzen, leichte Gartenarbeiten); hier können
alle Aktivitäten über den Tag
zusammengezählt werden, die mind.
10 Min. dauern.
Alle Angaben beziehen sich auf
die Messung in kapillärem
Vollblut .
Im Plasma sind die Werte um
ca. 10 - 15%  höher als im Vollblut.
Messwerte im Grenzbereich
sollen durch eine Wiederholungs-
messung nüchtern  bestätigt
werden.
 Self Care "Unerkannter Diabetes" 2002 / K. Hersberger, UNI BS
≥ 5.3
mmol/l
Hier geht es um intensive körperliche
Aktivitäten, bei denen man ziemlich ins
Schwitzen kommt (z.B. Joggen, Aerobic,
Tennis, schnelles Radfahren,
Spielsportarten, Schwimmen, Lasten tragen,
schwere Gartenarbeiten).
 **
  *
Bewegungsmangel
hyperton
syst. ≥ 160 und/oder diast. ≥ 100 mmHg
ist als einzelner Risikofaktor bereits Grund für
Weiterleitung an Arzt.
Alter über 45 Jahre
Bewegungsmangel:
Patient macht zur Zeit nie oder weniger als 30 Min.
täglich körperliche Aktivitäten von mittlerer Intensität*
oder an weniger als 3 Tagen pro Woche während
mindestens 20 Min. Aktivitäten von hoher Intensität**.
Familiäres Risiko:
Elternteil und/oder Geschwister hat Diabetes Typ 2
Übergewicht:
BMI > 25 kg/m2
Geburt eines Babys über 4000 g (nur bei Frauen)
Blutdruck erhöht:
Syst. ≥ 140 mmHg und/oder
 Diast.  ≥ 90  mmHg
 UNI 
BASEL 
© 
erhöht grenzwertig
140 - 159 mmHg und/oder 90 - 99 mmHg
sollte in Wiederholungsmessung bestätigt
werden.
BMI = Body Mass Index
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7.6 Informed Consent for the follow-up 
Ich bin mit der Teilnahme an der Nachbefragung einverstanden:
Teilnahme an der Nachbefragung: Self Care "Unerkannter Diabetes"
Der Nutzen von Früherfassungskampagnen und die beste Art ihrer Durchführung sind noch nicht
ausreichend dokumentiert. Am wichtigsten ist dabei die Erfahrung der Teilnehmerinnen und
Teilnehmer. Deshalb ist im Anschluss an die Früherkennungskampagne "Unerkannter Diabetes"
eine schriftliche Nachbefragung geplant, welche von einer Arbeitsgruppe an der Universität Basel
unter der Leitung von Dr. Kurt Hersberger durchgeführt wird. Ca. 10% der in dieser Kampagne
erfassten Personen werden nach dem Zufallsprinzip für diese Nachbefragung ausgewählt. Diese
Personen werden den ersten Fragebogen in ca. 4 Monaten erhalten. Weitere Befragungen sind
geplant.
Wir ersuchen Sie um Ihr ausdrückliches Einverständnis für die Nachbefragung, damit wir auch
Ihre Erfahrung einbeziehen können. Für Sie entsteht zwar aus der Nachbefragung kein direkter
persönlicher Nutzen, aber Sie helfen mit, die Qualität künftiger Kampagnen zu verbesseren. Die
Teilnahme an dieser Nachbefragung ist freiwillig. Sie können sich jederzeit und ohne Angabe von
Gründen zurückziehen; dies hat für Sie keinerlei Nachteile.
Nur die Studienleitung wird Zugang zu den persönlichen Angaben haben. Diese dienen
ausschliesslich der Kontaktnahme und werden nach Abschluss der Nachbefragung wieder
gelöscht. Ausserhalb der Nachbefragung erfolgt die Auswertung der erhobenen Daten strikt
anonym.
Sehr geehrte Dame / Sehr geehrter Herr
Unterschrift:
Geburtsdatum:
IC-Nummer Für Erfassungsblatt Apotheke Für Patientenkarte Für Arztbericht
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Pharmaceutical Care Research Group
Klingelbergstr. 50/4056 Basel
Name / Vorname:
Adresse:
PLZ / Ort:
Datum:
Informed Consent                  (Schriftliche Einverständniserklärung des Patienten)
47690
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7.7 Patient’s report sheet of the diabetes screening campaign 
Ihre Erfahrungen sind wichtig
Patientenbericht nach Arztbesuch
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Pharmaceutical Care Research Group
Klingelbergstr. 50/4056 Basel
Kontrolle der Augen
Welche Ratschläge hat Ihnen der Arzt
betreffend Diabetesrisiko erteilt?
Vermehrte körperliche Aktivität oder Sport
Umstellung der Ernährung
Besuch einer Diabetesberatung
Empfehlung Gewichtsreduktion
Beginn einer medikamentösen Therapie
Keine Therapie und keine Massnahmen
Welche Untersuchungen oder Messungen
wurden in der  Arztpraxis durchgeführt
oder  sind für später geplant?
ja nein
Haben Sie einen weiteren
Arzttermin vereinbart?
(gleicher oder anderer Arzt)
ja nein
Kontrolle der Füsse ja nein
Blutzucker
ja nein
Empfehlung zu mehr
Bewegung
Zu welchen Themen wurden Sie in der
Apotheke beraten?
ja nein
Empfehlung  zur
Gewichtsreduktion
ja nein
Empfehlung zur
Umstellung der Ernährung
ja nein
Risikoabklärung und
Beratung waren gut und
kompetent ausgeführt
ja nein
ja nein
Sie begrüssen diese
Zusammenarbeit zwischen
Apothekern und Ärzten
zur Risikofrühabklärung
ja nein
Die Überweisung an den Arzt
durch die Apotheke war aus
Ihrer Sicht berechtigt
Wie beurteilen Sie die Risikoabklärung in
der Apotheke?
Arztbesuch am:
 Tag  Monat
Ihr letzter Arztbesuch
erfolgte im Jahre: in der gleichen Praxis in einer anderen Praxis
Jahr
2002
Fragen zu Ihrem Apothekenbesuch: Fragen zu Ihrem Arztbesuch:
erforderlich betreffend Diabetesrisiko
Cholesterin/Blutfette ja nein
Sehr geehrte Dame, sehr geehrter Herr
Sie haben Ihr persönliches Risiko für eine Zuckerkrankheit in der Apotheke überprüfen
lassen. Die ermittelten Werte sollten von einem Arzt abgeklärt werden. Ihr Apothekenteam hat
Ihnen deshalb einen Arztbesuch empfohlen und Ihnen Unterlagen für den Arzt mitgegeben.
Die Aktion zur Früherkennung der Zuckerkrankheit wird in einer wissenschaftlichen Studie
untersucht. Wir bitten Sie deshalb freundlich, uns diese vorfrankierte Postkarte nach
Ihrem Arztbesuch ausgefüllt zurückzusenden. Das Formular wird elektronisch
verarbeitet; verzichten Sie deshalb auf zusätzliche Angaben wie Name und Adresse. Dank
eines Codes können Ihre anonymisierten Angaben mit den in der Apotheke und vom Arzt
ermittelten Daten verglichen werden.
Wir danken Ihnen für Ihre Mithilfe.
Dr. Kurt Hersberger Prof. Dr. Rudolf Bruppacher Andrea Botomino
Kontrolle Herz (EKG) ja nein
IC-Nummer-Etikette in der
Apotheke immer hier anbringen
47676
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7.8 Physician’s report sheet of the diabetes screening campaign 
Datum der Konsultation:
 Tag Monat
Blutglucosekontrolle:
Messwert Glucose:
*) Messung in Apotheke
erfolgte in kapillärem Vollblut,
im Plasma sind Werte um ca.
10 - 15% höherWurde dieser Befund in Ihrer Praxis erstmals erfasst?
Weitere Planung:
keine Therapie erforderlich
Ernährungsberatung
Tabakentwöhnung
Ueberweisung an Augenarzt
Ueberweisung an Diabetologe
Therapie mit "Aspirin"
Medikamentöse Therapie bei:
in welchem Jahr war die letzte Konsultation?
wenn nein:   betrifft/betraf die Behandlung
Patient nüchtern? letzte Nahrung vor > 8 Std.
, mmol/l
War der Patient/die Patientin erstmals bei Ihnen in der Praxis? ja nein
Messung im Plasma? *)
ja nein
Hypertonie
Diabetes
Dyslipidämie
andere
Arztbericht nach Weiterleitung durch Apotheke
Jahr
Herz-Kreislauferkrankung Diabetes Andere
Weitere Untersuchungen,  welche durchgeführt
wurden oder geplant sind:
Fusskontrolle
Augenhintergrundkontrolle
Kontrolle Morgenurin (Mikroalbuminurie)
EKG
Andere Untersuchungen:
2002
Messung: durchgeführt geplant nicht nötig
Visum: ...........................Wurde ein weiterer Arzttermin vereinbart ? ja nein
IC-Nummer-Etikette in der
Apotheke immer hier anbringen
Sehr geehrte Frau Doktor, sehr geehrter Herr Doktor
Im Rahmen der Self Care Kampagne "Unerkannter Diabetes" wird eine Screening-Aktion zur
Früherfassung von Risikopatienten für Diabetes Typ 2 durchgeführt. In einer Apotheke wurde
ein Risikoprofil ermittelt, welches eine ärztliche Abklärung rechtfertigt.
Die Kampagne wird begleitet von einer Studie, in welcher sämtliche Aktivitäten der
Apothekenteams evaluiert werden. Den Triageentscheid der Apotheke im vorliegenden Fall
können Sie durch Ihre Untersuchung validieren.
Sofern der Patient Ihnen das Einverständnis gibt, ersuchen wir Sie, uns als
Studienzentrale nach der Erstkonsultation nachstehende Angaben zu übermitteln.
Verzichten Sie dabei auf Angaben zu Ihrer Praxis und zum überwiesenen Patienten. Das
untenstehende Formular wird elektronisch verarbeitet. Dank eines Codes können Ihre
anonymisierten Angaben mit den in der Apotheke ermittelten Daten verglichen werden.
Wir danken Ihnen für Ihre Mitarbeit.
Dr. Kurt Hersberger  Prof. Dr. Rudolf Bruppacher Andrea Botomino
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Pharmaceutical Care Research Group
Klingelbergstr. 50/4056 Basel        e-mail: diabetes-pharma@unibas.ch
ja nein
ja nein
Messwert liegt noch nicht vor
45221
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7.9 Data sheet of the pharmacy based screening for metabolic 
syndrome 
 UNI 
BASEL 
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Pharmaceutical Care Research Group
Klingelbergstr. 50/4056 Basel
Auf dem Kopieblatt für
Patient und für Ablage in
der Apotheke hier je eine
Adressetikette anbringen
Das Deckblatt bleibt anonym!Erfassungsblatt Metabolisches Syndrom
Initialen:
Datum der Messung:Geschlecht: männlich weiblich
Rauchen:
 Tag Monat
in ärztl. Behandlung wegen
Herz-Kreislauferkrankung ja nein
Jahrgang:
Beratung zur Verhaltensänderung bezüglich:
Blutglucosemessung
Messwert Glucose:
Vollblut kapillär
Geburt eines Babys mit Geburtsgewicht über 4100 g (nur bei Frauen): ja nein
Übergewicht:  BMI > 25 kg/m2
 Körpergewicht:
ja nein
Grösse:  m kg BMI: kg/m2
Blutdruck erhöht: > 140  und/oder > 90 mmHg
Messwert: syst.  mmHg
ja nein
diast.  mmHg
Bewegungsmangel: ja nein
Familiäres Risiko:
Patient hat Erstgrad-Verwandte (Eltern, Geschwister) mit Typ-2 Diabetes
oder Erstgrad-Verwandte mit Hirnschlag, Herzinfarkt oder Angina pectoris vor dem 55.
Lebensjahr (Männer) oder vor dem 65. Lebensjahr (Frauen)
ja nein
ja nein
Erfassung Lipidprofil (im Vollblut kapillär)
Gesamtcholesterin TC
Grenzwert > 5.0 mmol/l
HDL-Cholesterin
Grenzwert: < 1.0 mmol/l
LDL-Cholesterin
Grenzwert: > 3.0 mmol/l
Triglyzeride
Grenzwert: > 2.0 mmol/l
mmol/l
mmol/l
mmol/l
mmol/l
TC / HDL-Cholesterin
Grenzwert: > 5.0
Risiko Dyslipidämie
> 1 Grenzwert überschritten? ja nein
Wurde mind. 1 erhöhter Wert
heute erstmals erfasst?
ja nein
Jahr
Copyright © 2001
in ärztl. Behandlung wegen
Diabetes
ja nein
Messmöglichkeit bekannt
durch: TopMail Presse Lokal-TV Apotheke selbst
Anlass für die Messung unbekannte Werte Überprüfung bekannter Werte
.
.
.
.
.
.
.
Notizen (z.B. Medikamenten-Anamnese)
ENTSCHEID
Weiterleitung an Arzt
Nachkontrolle in 1 - 2 Jahren
Nachkontrolle in ca. 3 Jahren (ab 45 J.)
Nachkontrolle in ca. 5 Jahren (vor 45 J.)
Empfehlung Gewichtsreduktion
andere Empfehlungen:
fettarme Ernährung
Früchte & Gemüse
Bewegung
Entrauchen
Alter über 45 Jahre: ja nein
2 0
1 9
Wiederholungsmessung
nüchtern, Vollblut kapillär mmol/l
Patient nüchtern?
letzte Nahrung vor > 8 Std.
ja nein Blutglucose erhöht?> 5.3 mmol/l
ja nein
Wurde ein normaler/erhöhter
Wert heute erstmals erfasst?
ja neinmmol/l.
 cm
0
Patient macht zur Zeit nie oder weniger als 30 Min. täglich körperliche Aktivitäten von mittlerer Intensität oder
Patient macht an weniger als 3 Tagen pro Woche während mind.  20 Min. körperliche Aktivitäten von hoher Intensität
25641
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7.10 Flow chart and triage criteria of the pharmacy based screening 
for metabolic syndrome 
SEQUENTIELLES SCREENING METABOLISCHES SYNDROM
Triagekriterien für die Apothekenpraxis
BZ-Messung
Nachkontrolle:
in ca. 5 Jahren
(ab 45 J. in
ca. 3 Jahren)
oder
entsprechend
Risikoprofil
Kommentare
Mindestens
2
Risikofaktoren vorhandennein
ja
Definition "nüchtern":
Letzte Nahrung vor ≥ 8h
Messung nicht
nüchtern
Messung
nüchtern
WEITERLEITUNG AN DEN ARZT!
Wiederholungsmessung
nüchtern
5.3 - 11.0
mmol/l
≥ 6.1
mmol/l
Nachkontrolle in
ca. 1 - 2 Jahren
Nachkontrolle in
ca. 1 - 2 Jahren
Wert im
Normbereich
Blutzuckermessung
sollte wenn möglich nüchtern
erfolgen.
Blutdruck
(Erhöhter Blutdruck ist zwar kein Risikofaktor für
Diabetes per se, aber bei einem manifesten
Diabetes besteht bei erhöhtem Blutdruck ein
erhöhtes Risiko für Herz-Kreislauferkrankungen.)
≥ 11.1
mmol/l
< 5.3
mmol/l
< 5.3
mmol/l
Wert im
Normbereich
5.3 - 6.0
mmol/l
R
IS
IK
O
-S
C
R
EE
N
IN
G
B
LU
TZ
U
C
K
ER
-S
C
R
EE
N
IN
G
Weiterleitung an den Arzt
bedeutet, dass der Verdacht auf
Diabetes durch die Apotheke von
einem Arzt überprüft werden soll.
Nach erfolgter Diagnose
entscheidet er über entsprechende
Massnahmen (z.B. Einleitung der
Therapie).
Hier geht es um körperliche Aktivitäten, bei
denen man mindestens ein bisschen ausser
Atem kommt (z.B. zügiges Gehen, Wandern,
Tanzen, leichte Gartenarbeiten); hier können
alle Aktivitäten über den Tag
zusammengezählt werden, die mind.
10 Min. dauern.
Alle Angaben beziehen sich auf
die Messung in kapillärem Vollblut
.
Im Plasma sind die Werte um
ca. 10 - 15%  höher als im Vollblut.
Messwerte im Grenzbereich
sollen durch eine Wiederholungs-
messung nüchtern  bestätigt
werden.
 Institut für Klinische Pharmazie, Uni Basel
≥ 5.3
mmol/l
Hier geht es um intensive körperliche
Aktivitäten, bei denen man ziemlich ins
Schwitzen kommt (z.B. Joggen, Aerobic,
Tennis, schnelles Radfahren,
Spielsportarten, Schwimmen, Lasten tragen,
schwere Gartenarbeiten).
 **
  *
Bewegungsmangel
hyperton
syst. ≥ 160 und/oder diast. ≥ 100 mmHg
ist als einzelner Risikofaktor bereits Grund für
Weiterleitung an Arzt.
Alter über 45 Jahre
Bewegungsmangel:
Patient macht zur Zeit nie oder weniger als 30 Min. täglich  (5-7
Tage pro Woche) körperliche Aktivitäten von mittlerer Intensität*
oder an weniger als 3 Tagen pro Woche während mindestens
20 Min. Aktivitäten von hoher Intensität**.
Familiäres Risiko:
Elternteil und/oder Geschwister hat Diabetes Typ 2
Übergewicht:
BMI > 25 kg/m2
Geburt eines Babys über 4000 g (nur bei Frauen)
Blutdruck erhöht:
Syst. ≥ 140 mmHg und/oder
 Diast.  ≥ 90  mmHg
 UNI 
BASEL 
© 
erhöht grenzwertig
140 - 159 mmHg und/oder 90 - 99 mmHg
sollte in Wiederholungsmessung bestätigt
werden.
BMI = Body Mass Index
- TC > 5.0 mmol/l und/oder
- HDL-C < 1.0 mmol/l und/oder
- LDL-C > 3.0 mmol/l und/oder
- Triglyzeride > 2.0 mmol/l und/oder
- TC/HDL-C > 5.0
- BMI
- Bewegungsmangel
- Alter
- Familiäres Risiko
- Blutdruck
- Blutglucose
- Rauchen
Arzt+> 2 Werte ausserhalb Norm > 2 Risikofaktoren
Triage bei Erfassung Lipidprofil
= Grenzwerte für Indikation zur Lipidtherapie,
AGLA 1999
(Arbeitsgruppe Lipide und Atherosklerose)
- TC > 8.0 mmol/l
- LDL-C > 5.0 mmol/l
- Triglyzeride > 5.0 mmol/l
- TC/HDL-C > 6.5
> 1 Einzelrisiko überschritten
  
7.11 Flow chart follow-up diabetes screening campaign and telephone-based intervention 
102'717    Teilnehmer Self Care Kampagne
612
Kooperierend
(alle 3 Anrufe)
550
Nicht
kooperierend
Kontrollgruppe: 1437
(Y: 460, Z1: 97, Z2: 55) (Y: 413, Z1: 90, Z2: 47)
(Y: 995, Z1: 168, Z2: 274)
X: 1051
Self Care
(Stufe 0)
Nachbefragung 1
(Stufe 1)
Intervention
(Stufe 2)
4604
Response 1 (0.57)
X: 633
3259
Response 2 (0.71)
3063
Response 3 (0.94)
441
Kooperierend
(alle 3 Anrufe)
357
Nicht
kooperierend
1019
Kontrolle
417
Kooperierend
(alle 3 Anrufe)
329
Nicht
kooperierend
967
Kontrolle
(Y: 307, Z1: 70, Z2: 40)
und 4724 Adressierte für Interventionsprojekt
(alle Personen adressiert, die die Einschlusskriterien erfüllten)
Davon 3423 Adressierte für Follow up Self Care
ohne Ein-/Ausschlusskriterien (zufällig ausgewählt)
X: 1051
Flow Chart der Populationen DSPP-Study
96692 deutsch 6025
französisch
22000mit Informed Consent
2500
mit Inf. Cons.
Insgesamt 8147 Adressierte 1. Nachbefragung
Y: 4535 Z: 2561 (Z1:1716, Z2:845)
Y: 1234 Z: 1138 (Z1:982, Z2:156) Y: 3301 Z2: 689Z1: 734
2005 Response 1
Y: 827 Z: 545 (Z1:438, Z2:107) Y: 1868
2599 Response 1
Z1: 355 Z2: 376
X: 493
1442 Response 2
Y: 593 Z: 356 (Z1:284, Z2:72
X: 457
1350 Response 3
Y: 559 Z: 334 (Z1: 264, Z2: 70)
X: 457 Y: 1796 Z: 810 (Z1: 489, Z2: 321)
Einschlusskriterien:
-Alter > 18 Jahre
-Alter < 75 Jahre
-BMI > 25
-nicht in ärztl. Behandlung
-BZ-Messwert vorhanden
-Score Risiko-FB vorhanden
Z1: wegen BZ an Arzt
Z2: wegen BD an Arzt
15.3.2004
X, Y, Z nach 3. Nachbefragung
Interventionsgruppe: 1162
(Y: 873, Z1: 187, Z2: 102)
Tel. anrufe
1817 Response 2
1713 Response 3
zufällig ausgewählt
(Y: 710, Z1: 111, Z2: 198) (Y: 275, Z1: 56, Z2: 26)(Y: 327, Z1: 70, Z2: 44)
(Y: 252, Z1: 52, Z2: 25)(Y: 678, Z1: 103, Z2: 186)
Nachbefragung 2
Nachbefragung 3
94124 nicht in ärztlicher Behandlung wegen Diabetes
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7.12 First questionnaire of follow-up 
Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Nachbefragung im Anschluss an die Aktion "Stopp Zucker - jetzt testen"
Herzlichen Dank, dass Sie sich die Zeit nehmen, diesen Fragebogen auszufüllen!
Vorab einige Hinweise zum Ausfüllen dieses Fragebogens:
- "Diabetes Typ 2" ist der Fachausdruck für Zuckerkrankheit. Man spricht auch von "Alterszucker" oder
  "Altersdiabetes", obwohl heute immer öfter auch junge Personen betroffen sind.
- Bitte verwenden Sie zum Ausfüllen einen dunklen Kugelschreiber oder Filzstift
- Bitte setzen Sie die Kreuze so exakt wie möglich in die Kästchen:
1  Risikoabklärung und Beratung in der Apotheke
1.1 Wie wurden Sie auf die Aktion "Stopp Zucker - jetzt testen" aufmerksam?
(Mehrere Antworten sind möglich)
1.2 Was war der Grund für Sie, vom Angebot "Stopp Zucker - jetzt testen" Gebrauch zu machen?
(Mehrere Antworten sind möglich)
1.3 Haben Sie in der Apotheke schriftliche Unterlagen erhalten?
(Mehrere Antworten sind möglich)
ja...
nein, ich habe keine dieser Unterlagen erhalten
weiss nicht
 
 
 
Seite 1
IC-Nummer
Richtig Falsch
Apotheke (Schaufenster)
Apotheke (Postkarte/Zirkular)
Apotheke (Information durch das Personal)
Apothekenmagazin zB. "astrea", "optima"
Krankenkasse (Mitgliedermagazin)
Artikel in der Tageszeitung
Artikel in der Zeitschrift "Schweizer Familie"
TV-Sendung PULS (SF DRS)
TV-Spot "Stopp Zucker - jetzt testen"
Hinweis von Verwandten / Bekannten
auf andere Art:
ich wollte wissen, wie hoch mein Diabetesrisiko ist
ich wollte wissen, wie hoch mein Blutzuckerwert ist
ich hatte im Diabetesrisikofragebogen eine hohe Punktzahl
ich kenne meine Blutzuckerwerte, wollte sie aber in der Apotheke überprüfen lassen
ich habe die Dienstleistung genutzt, weil sie gratis war
andere Gründe
Risikofragebogen mit 7 Fragen Leitfaden "Werden Sie aktiv" Broschüre action-d
"Tun Sie etwas für
Ihre Gesundheit"
52686
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
1.4 Zu welchen Themen wurden Sie in der Apotheke beraten?
1.5 Wurde Ihnen in der Apotheke empfohlen, einen Arzt aufzusuchen, um Ihr Diabetesrisiko
überprüfen zu lassen?
ja
nein
weiss nicht
1.6 Haben Sie seit Mai 2002 nach der Aktion "Stopp Zucker - jetzt testen" einen Arzt aufgesucht?
ja, um mein Diabetesrisiko beim Arzt überprüfen zu lassen...
aufgrund der schriftlichen Unterlagen (Risikofragebogen, Leitfaden, Broschüre action d)
aufgrund der Empfehlung in der Apotheke
anderes
ja, aber nicht wegen meinem Diabetesrisiko
nein
1.7 Falls Ihnen in der Apotheke empfohlen wurde, einen Arzt aufzusuchen, Sie aber bis jetzt keinen
Arzt aufgesucht haben, was war der Grund dafür?
Ich habe bis jetzt keinen Arzt aufgesucht...
Ein Arztbesuch ist in den nächsten 6 Monaten geplant
weil ich das Risiko für Diabetes Typ 2 nicht als bedrohlich einschätze
weil ich mich damit nicht auseinandersetzen möchte
weil ich keine Zeit hatte
weil ich nicht weiss, an wen ich mich wenden soll (habe keinen Hausarzt)
anderer Grund:
1.8 Wie beurteilen Sie die Aktion "Stopp Zucker - jetzt testen" in der Apotheke?
schlecht
Risikofragebogen mit 7 Fragen
Broschüre action-d "Tun Sie etwas für Ihre Gesundheit"
Leitfaden "Werden Sie aktiv"
Blutzuckermessung in der Apotheke
Beratung in der Apotheke
Aktion "Stopp Zucker - jetzt testen" insgesamt
akzeptabel gut sehr gut
Seite 2
weiss nicht
vermehrt Früchte und Gemüse in der Ernährung
weniger Fett in der Ernährung
mehr Bewegung
Gewichtsreduktion / Gewicht halten
ich wurde in der Apotheke zu keinem der Themen beraten
weiss nicht
(Mehrere Antworten sind möglich)
52686
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 3
2  Beratung und Untersuchungen beim Arzt/bei der Ärztin
(Nur beantworten, falls Sie die Frage 1.6 mit "ja, um mein Diabetesrisiko beim Arzt überprüfen zu lassen"
beantwortet haben)
2.1 Wurden folgende Untersuchungen in der Arztpraxis durchgeführt?
(Mehrere Antworten sind möglich)
ja...
nein, keine dieser Untersuchungen wurden durchgeführt
weiss nicht
2.2 Welche Ratschläge hat Ihnen der Arzt betreffend Diabetesrisiko erteilt?
(Mehrere Antworten sind möglich)
2.3 Wurde bei Ihnen jemals durch einen Arzt ein Diabetes Typ 2 festgestellt?
ja
nein
weiss nicht
Wenn ja, wann? Monat Jahr
3  Diabetes Typ 2 - Risikofaktoren
3.1 Was, denken Sie, kann eine Person tun, um ihr Risiko für Diabetes Typ 2 zu senken?
(Mehrere Antworten sind möglich)
Messung des Blutzuckers
Messung Cholesterin/Blutfette
Messung des Blutdruckes
Kontrolle der Füsse
Kontrolle der Augen
vermehrt Früchte und Gemüse in der Ernährung
weniger Fett in der Ernährung
mehr Bewegung
Gewichtsreduktion / Gewicht halten
Beginn einer medikamentösen Therapie
der Arzt hat mir keine Ratschläge betreffend meines Diabetesrisikos erteilt
weiss nicht
nichts: das Risiko, an Diabetes Typ 2 zu erkranken, ist nicht beeinflussbar
regelmässige Einnahme von Aspirin
gesunde Ernährung
genügend Schlaf
genügend Bewegung
Übergewicht vermeiden
52686
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 4
4  Körpergewicht
4.1 Wieviel beträgt Ihr Körpergewicht zur Zeit?
Gewicht: kg
4.2 Denken Sie, dass Sie übergewichtig sind?
ja
nein
weiss nicht
4.3 Welches Ziel verfolgen Sie bezüglich Ihres Körpergewichts?
ich möchte zunehmen
ich möchte mein Gewicht halten
ich möchte abnehmen
ich verfolge keine Ziele bezüglich meines Körpergewichts
4.4 Welches Ziel haben Sie bezüglich Ihres Körpergewichts?
Gewicht: kg
5  Ernährung
5.1 Auf was sollte eine Person bei der Ernährung achten, damit ihre Gesundheit positiv
beeinflusst wird?
(Mehrere Antworten sind möglich)
5.2 Wieviele Portionen Früchte oder Gemüse assen Sie in den letzen beiden Monaten
durchschnittlich pro Tag?
0 1 2 3 4 5 mehr als 5
6  Bewegung
6.1 Wie oft und wie lange, denken Sie, sollte sich eine Person im Minimum bewegen, um
gesund zu bleiben? (Nur eine Antwort ist möglich)
täglich zehn Minuten
täglich eine halbe Stunde
täglich dreimal eine halbe Stunde
zweimal pro Woche eine halbe Stunde
weniger Süssigkeiten konsumieren
nur eine Mahlzeit pro Tag einnehmen
weniger Fett konsumieren
Bier als Durstlöscher konsumieren
mehr Fleisch konsumieren
viel Früchte und/oder Gemüse konsumieren
52686
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 5
6.2 Hier geht es um körperliche Aktivität, bei der Sie mindestens einen leicht beschleunigten Atem
bekommen (zum Beispiel zügiges Gehen, Wandern, Tanzen, leichtere Gartenarbeiten):
Bitte beachten Sie: Bei Frage 6.2 und Frage 6.3 fragen wir nach zwei verschiedenen Arten von Bewegung!
a) An wie vielen Tagen pro Woche waren Sie in den letzten beiden Monaten durchschnittlich in dieser Art
körperlich aktiv?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
c) Seit wann sind Sie schon auf diese Weise aktiv?
weniger als 1 Monat
weniger als 6 Monate
6 - 12 Monate
länger als 1 Jahr
länger als 5 Jahre
d) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
6.3 Hier geht es um sportliche oder körperliche Aktivitäten, bei denen Sie ziemlich ins Schwitzen
kommen (z. B. Joggen, Aerobics, Tennis, schnelles Radfahren, Spielsportarten, Schwimmen,
Lasten tragen, Graben, Schaufeln):
a) An wie vielen Tagen pro Woche haben Sie in den letzten beiden Monaten Aktivitäten dieser Art gemacht?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
c) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
)
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 6
7  Änderungen des Lebensstils
7.1 Haben Sie seit Mai 2002 aufgrund der Aktion "Stopp Zucker - jetzt testen" ihren Lebensstil
geändert?
(Mehrere Antworten sind möglich)
ja...
nein...
7.2 Hatten Sie mit der Änderung Ihrer Gewohnheiten Erfolg?
(Nur beantworten, falls Sie Frage 7.1 mit "ja" beantwortet haben)
(Mehrere Antworten sind möglich)
ja...
nein...
7.3 Haben Sie aufgrund der Aktion "Stopp Zucker - jetzt testen" Ihre Ernährungsgewohnheiten
geändert?
ja...
nein, aber ich habe vor, meine Essgewohnheiten zu ändern
nein, und ich habe auch nicht vor, meine Essgewohnheiten zu ändern
ich nehme neu an einem Bewegungskurs teil
ich trainiere neu in einem Fitnesscenter
ich achte beim Kauf und bei der Wahl von Lebensmitteln auf ihren Fettgehalt
ich mache mehr Sport
ich habe mich für eine Ernährungsberatung angemeldet
ich bewege mich mehr im Alltag (z.B. zu Fuss gehen, Velo benutzen)
ich habe meine Ernährung umgestellt
aber ich habe mir einen Termin gesetzt, wann ich meinen Lebensstil ändern werde
ich will meinen Lebensstil beibehalten
ich bin zu wenig motiviert, meinen Lebensstil zu ändern
ich habe meinen Lebensstil aus anderen Gründen nicht geändert
ich konnte mein Gewicht halten oder in die gewünschte Richtung beeinflussen
ich fühle mich wohler in meiner Haut
ich nehme bis jetzt keine Fortschritte wahr
ich habe es wieder aufgegeben, meine Gewohnheiten ändern zu wollen
ich achte auf den Fettgehalt in meiner Nahrung
ich esse generell mehr Früchte und Gemüse
ich esse häufiger 5 Portionen Früchte oder Gemüse pro Tag
ich esse generell weniger
(Mehrere Antworten sind möglich)
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 7
7.4 Was ist oder wäre für Sie hilfreich, um Ihren Lebensstil zu ändern?
Zusammen mit Gleichgesinnten etwas für meine Gesundheit unternehmen
Fitnessangebote in der Nähe (z.B. Fitnesscenter, Vita Parcours)
Kennzeichnung gesunder Lebensmittel im Lebensmittelgeschäft
Kennzeichnung gesunder Menus im Restaurant
Ernährungsberatung
Beratung zu gesundheitsförderlicher Bewegung
Unterstützung durch die Krankenkasse (Information/Gutscheine)
Unterstützung durch den Hausarzt
Unterstützung durch die Apotheke
Unterstützung durch Personen, die im gleichen Haushalt wohnen
Unterstützung durch andere Personen, die mir nahe stehen
Anderes:
(- -  gar nicht hilfreich, -  mässig hilfreich, + ziemlich hilfreich, ++ sehr hilfreich) _ _ _ + ++
8  Fragen zu Ihrer Person
8.1 Persönliche Angaben
Jahrgang:
Körpergrösse:
Geschlecht:
cm
männlich
weiblich
8.2 Wohnen Sie mit anderen Personen im gleichen Haushalt?
ja...
nein
mit Partner/-in
mit Kind(ern)
mit anderen Verwandten
mit nicht verwandten Personen
mit den Eltern
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Pharmaceutical Care Research Group
Klingelbergstr. 50 / 4056 Basel
INSTITUT FÜR KLINISCHE PHARMAZIE
Departement Pharmazie der Universität Basel
Seite 8
8.3 Was haben Sie für eine Nationalität?
Schweiz
Andere, nämlich:
Falls "Andere": Wie lange leben Sie schon in der Schweiz? Jahre
8.4 Welches ist die höchste Ausbildung, die Sie abgeschlossen haben?
keine Ausbildung
Obligatorische Schule
Berufslehre, Berufsschule
Maturitätsschule, Lehrerseminar; andere allgemein bildende Schule
Höhere Berufsausbildung (Meisterdiplom, Eidg. Fachausweis, höhere Fachschule, HTL, HWV)
Universität, Hochschule
8.5 Wie hoch ist das gesamte monatliche Bruttoeinkommen Ihres Haushaltes?
< Fr. 3000.-
Fr. 3000.- bis 6000.-
Fr. 6000.- bis 9000.-
> Fr. 9000.-
8.6 Rauchen Sie?
8.7 Zahlt Ihre Krankenkasse einen Beitrag zur Förderung gesunden Verhaltens (z.B. Fitnessstudio)?
ja
nein
weiss nicht
8.8 Bei welcher Krankenkasse sind Sie versichert?
Helsana
Visana
CSS
ÖKK
Concordia
Andere
9  Kommentare, Bemerkungen
ja
nein, ich habe aufgehört zu rauchen...
nein, ich habe noch nie geraucht
...in den letzten 12 Monaten
...vor mehr als 12 Monaten
Herzlichen Dank für Ihre wertvolle Mitarbeit!
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2. Nachbefragung im Anschluss an die Aktion "Stopp Zucker - Jetzt testen"
Herzlichen Dank, dass Sie an unserer ersten schriftlichen Nachbefragung im August 2002 teilgenommen
haben. Ihre Mitarbeit ist für uns sehr wertvoll!
Vorab einige Hinweise zum Ausfüllen dieses Fragebogens:
- "Diabetes Typ 2" ist der Fachausdruck für Zuckerkrankheit. Man spricht auch von "Alterszucker" oder
  "Altersdiabetes", obwohl heute immer öfter auch junge Personen betroffen sind.
- Bitte verwenden Sie zum Ausfüllen einen dunklen Kugelschreiber oder Filzstift
- Bitte setzen Sie die Kreuze so exakt wie möglich in die Kästchen:
1  Fragen zu Ihrer Person
Seite 1
IC-Nummer
Richtig Falsch
Jahrgang: männlich weiblich
2  Beratung und Untersuchungen beim Arzt/bei der Ärztin
2.1 Haben Sie seit unserer ersten schriftlichen Befragung im August 2002 einen Arzt aufgesucht?
ja, um mein Diabetesrisiko beim Arzt abklären zu lassen
ja, aber nicht wegen meines Diabetesrisikos
aufgrund der Aktion "Stopp Zucker - Jetzt testen"
aufgrund der telefonischen Beratung, die ich im Herbst 2002 erhalten habe
anderes
nein (Ö weiter mit Frage 3.1!)
In welchem Monat fand dieser Arztbesuch statt? August 2002
September 2002
Oktober 2002
November 2002
Dezember 2002
Januar 2003
Februar 2003
2.2 Welche der folgenden Untersuchungen wurden in der Arztpraxis durchgeführt?
(Mehrere Antworten sind möglich)
Messung Cholesterin/Blutfette
Messung des Blutzuckers
Messung des Blutdruckes
keine dieser Untersuchungen wurden durchgeführt
weiss nicht
(Ö weiter mit Frage 3.1!)Ich war vor August 2002 beim Arzt
Geschlecht:
Rauchen Sie zur Zeit? ja
nein
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2.3 Welche Ratschläge hat Ihnen der Arzt erteilt?
(Mehrere Antworten sind möglich)
Ratschläge zur Umstellung der Ernährung
Ratschläge zu mehr Bewegung
Ratschläge zur Gewichtskontrolle/Gewichtsreduktion
Beginn einer medikamentösen Therapie
der Arzt hat mir keine Ratschläge betreffend meines Diabetesrisikos erteilt
weiss nicht
2.4 Wurde bei Ihnen seit unserer ersten schriftlichen Befragung im August 2002 durch einen Arzt
ein Diabetes Typ 2 festgestellt?
ja
nein
weiss nicht
Wenn ja, wann? Monat Jahr 2 0 0
3  Körpergewicht und Ernährung
3.1 Wieviel beträgt Ihr Körpergewicht zur Zeit?
Gewicht: kg
3.2 Welches Ziel haben Sie bezüglich Ihres Körpergewichts?
ich möchte zunehmen
ich möchte mein Gewicht halten
ich möchte abnehmen
ich verfolge keine Ziele bezüglich meines Körpergewichts
3.3 Welches Körpergewicht möchten Sie erreichen?
Gewicht: kg
3.4 Wieviele Portionen Früchte oder Gemüse assen Sie in den letzen beiden Monaten
durchschnittlich pro Tag?
0 1 2 3 4 5 mehr als 5
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4.1 Hier geht es um körperliche Aktivität, bei der Sie mindestens einen leicht beschleunigten Atem
bekommen (zum Beispiel zügiges Gehen, Wandern, Tanzen, leichtere Gartenarbeiten):
Bitte beachten Sie: Bei Frage 4.1 und Frage 4.2 fragen wir nach zwei verschiedenen Arten von Bewegung!
a) An wie vielen Tagen pro Woche waren Sie in den letzten beiden Monaten durchschnittlich in dieser Art
körperlich aktiv?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
c) Seit wann sind Sie schon auf diese Weise aktiv?
weniger als 1 Monat
weniger als 6 Monate
6 - 12 Monate
länger als 1 Jahr
länger als 5 Jahre
d) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
4.2 Hier geht es um sportliche oder körperliche Aktivitäten, bei denen Sie ziemlich ins Schwitzen
kommen (z. B. Joggen, Aerobics, Tennis, schnelles Radfahren, Spielsportarten, Schwimmen,
Lasten tragen, Graben, Schaufeln):
a) An wie vielen Tagen pro Woche haben Sie in den letzten beiden Monaten Aktivitäten dieser Art gemacht?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
c) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
)
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
4  Bewegung
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5  Änderungen des Lebensstils
5.1 Haben Sie seit unserer ersten schriftlichen Befragung im August 2002 Ihren Lebensstil geändert?
(Mehrere Antworten sind möglich)
ja...
nein...
5.2 Hatten Sie mit der Änderung Ihrer Gewohnheiten Erfolg?
(Mehrere Antworten sind möglich)
ja...
nein...
ich nehme neu an einem Bewegungskurs teil
ich trainiere neu in einem Fitnesscenter
ich mache mehr Sport
ich habe mich für eine Ernährungsberatung angemeldet
ich bewege mich mehr im Alltag (z.B. zu Fuss gehen, Velo benutzen)
ich habe meine Ernährung umgestellt:
aber ich habe vor, meinen Lebensstil ändern:
ich will meinen Lebensstil beibehalten
ich bin zu wenig motiviert, meinen Lebensstil zu ändern
ich habe meinen Lebensstil aus anderen Gründen nicht geändert
ich konnte mein Gewicht halten oder in die gewünschte Richtung beeinflussen
ich fühle mich in besserer körperlicher Verfassung
ich nehme bis jetzt keine Fortschritte wahr
ich habe es wieder aufgegeben, meine Gewohnheiten zu ändern
ich achte beim Kauf und bei der Wahl von Lebensmitteln auf ihren Fettgehalt
ich habe meinen Fettkonsum reduziert
ich esse generell mehr Früchte und Gemüse
ich esse häufiger 5 Portionen Früchte oder Gemüse pro Tag
ich esse generell weniger
im nächsten Monat
in den nächsten 2-6 Monaten
(Nur beantworten, falls Sie Frage 5.1 mit "ja" beantwortet haben)
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5.4 Würden Sie persönlich die Gelegenheit nutzen, kostenlos durch eine Fachperson per Telefon
bei einer Verhaltensänderung unterstützt zu werden?
ja, auf jeden Fall ja, eventuell eher nicht nein, sicher nicht weiss nicht
6  Fragen zur erfolgten telefonischen Beratung
Folgende Fragen bitte nur beantworten, falls Sie zwischen September 2002 und Januar 2003 die
telefonische Beratung durch eine Gesundheitsberaterin von action d erhalten haben!)
6.1 Wie beurteilen Sie die Qualität der telefonischen Beratung, die Sie durch die
Gesundheitsberaterin von action d erhalten haben?
sehr gut
Fachwissen der Gesundheitsberaterin
Freundlichkeit der Gesundheitsberaterin
Hilfsbereitschaft der Gesundheitsberaterin
Einfühlungsvermögen der Gesundheitsberaterin
Tipps/Empfehlungen der Gesundheitsberaterin
gut akzeptabel schlecht weiss nicht
6.2 Wie beurteilen Sie die durchschnittliche Dauer der Telefongespräche, die Sie von der
Gesundheitsberaterin erhalten haben?
Die Dauer war meiner Meinung nach:
zu kurz
gerade richtig
zu lang
weiss nicht
6.3 Wie beurteilen Sie die Anzahl der Telefongespräche, die Sie von der Gesundheitsberaterin
erhalten haben?
Die Anzahl der Anrufe (in der Regel 3 Anrufe) war meiner Meinung nach:
zu wenig
gerade richtig
zu viel
weiss nicht
5.3 Wie finden Sie die Idee, bei einer Änderung des Lebensstils (Bewegung und Ernährung)
durch eine Fachperson per Telefon unterstützt zu werden?
sehr gut gut wenig sinnvoll gar nicht sinnvoll weiss nicht
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6.4 Wie beurteilen Sie den zeitlichen Abstand zwischen den Telefongesprächen, die Sie von der
Gesundheitsbeaterin erhalten haben?
Der zeitliche Abstand zwischen den Anrufen (in der Regel 3 Wochen) war meiner Meinung nach:
zu kurz
gerade richtig
zu lang
weiss nicht
6.5 Konnte die telefonische Unterstützung durch die Gesundheitsberaterin Sie zu einer Änderung
Ihres Lebensstils anregen?
ja, sehr ja wenig nein, gar nicht weiss nicht
6.6 Haben Sie dank der telefonischen Unterstützung durch die Gesundheitsberaterin Ihren Lebensstil
tatsächlich verändert?
ja, sehr ja teilweise nein, gar nicht weiss nicht
6.7 Würden Sie bei einer solchen Telefonberatung wieder mitmachen?
ja
eventuell
nein
weiss nicht
7  Weitere Kommentare und Bemerkungen
Herzlichen Dank für das Ausfüllen dieses Fragebogens!
6.8 Was waren für Sie positive Aspekte der telefonischen Unterstützung?
6.9 Was waren für Sie negative Aspekte der telefonischen Unterstützung?
a)
b)
c)
a)
b)
c)
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3. Nachbefragung im Anschluss an die Aktion "Stopp Zucker - Jetzt testen"
Herzlichen Dank, dass Sie an unseren ersten beiden Nachbefragungen im August 2002 bzw. im Februar
2003 teilgenommen haben. Ihre Mitarbeit ist für uns sehr wertvoll!
Vorab einige Hinweise zum Ausfüllen dieses Fragebogens:
- "Diabetes Typ 2" ist der Fachausdruck für Zuckerkrankheit. Man spricht auch von "Alterszucker" oder
  "Altersdiabetes", obwohl heute immer öfter auch junge Personen betroffen sind.
- Bitte verwenden Sie zum Ausfüllen einen dunklen Kugelschreiber oder Filzstift
- Bitte setzen Sie die Kreuze so exakt wie möglich in die Kästchen:
1  Fragen zu Ihrer Person
Seite 1
IC-Nummer
Richtig Falsch
Jahrgang: männlich weiblichGeschlecht:
Rauchen Sie zur Zeit? ja
nein
2  Beratungen in einer Apotheke
 Haben Sie seit der Aktion "Stopp Zucker - Jetzt testen" im Mai 2002 eine der folgenden 
Dienstleistungen in einer Apotheke beansprucht?
ja, ich habe folgende Dienstleistung(en) beansprucht:
nein, ich habe keine der oben aufgeführten Dienstleistungen beansprucht
weiss nicht
Beratung zur Umstellung der Ernährung
Beratung zu mehr Bewegung
Beratung zur Gewichtskontrolle/Gewichtsreduktion
Beratung zu Rauchstopp
Messung des Blutzuckers
Messung Cholesterin/Blutfette
Messung des Blutdruckes
(Mehrere Antworten sind möglich)
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3  Beratung und Untersuchungen beim Arzt/bei der Ärztin
3.1 Haben Sie seit unserer zweiten schriftlichen Befragung im Februar 2003 einen Arzt aufgesucht?
ja, um mein Diabetesrisiko beim Arzt abklären zu lassen
ja, aber nicht wegen meines Diabetesrisikos
aufgrund der Aktion "Stopp Zucker - Jetzt testen"
aufgrund der telefonischen Beratung, die ich im Herbst 2002 erhalten habe
anderes
nein (Ö weiter mit Frage 3.4!)
In welchem Monat fand dieser Arztbesuch statt? Februar 2003
März 2003
April 2003
Mai 2003
Juni 2003
Juli 2003
August 2003
(Ö weiter mit Frage 3.4!)Ich war vor Februar 2003 beim Arzt
3.2 Welche der folgenden Untersuchungen wurden in der Arztpraxis durchgeführt?
(Mehrere Antworten sind möglich)
Messung Cholesterin/Blutfette
Messung des Blutzuckers
Messung des Blutdruckes
keine dieser Untersuchungen wurden durchgeführt
weiss nicht
3.3 Welche Ratschläge hat Ihnen der Arzt erteilt?
(Mehrere Antworten sind möglich)
Ratschläge zur Umstellung der Ernährung
Ratschläge zu mehr Bewegung
Ratschläge zur Gewichtskontrolle/Gewichtsreduktion
Beginn einer medikamentösen Therapie
der Arzt hat mir keine Ratschläge betreffend meines Diabetesrisikos erteilt
weiss nicht
3.4 Wurde bei Ihnen jemals ein Diabetes Typ 2 festgestellt?
ja
nein
weiss nicht
Wenn ja, wann? Monat Jahr
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4  Diabetes Typ 2 - Risikofaktoren
Was, denken Sie, kann eine Person tun, um ihr Risiko für Diabetes Typ 2 zu senken?
(Mehrere Antworten sind möglich)
nichts: das Risiko, an Diabetes Typ 2 zu erkranken, ist nicht beeinflussbar
regelmässige Einnahme von Aspirin
gesunde Ernährung
genügend Schlaf
genügend Bewegung
Übergewicht vermeiden
5  Körpergewicht und Ernährung
5.1 Wieviel beträgt Ihr Körpergewicht zur Zeit?
Gewicht: kg
5.2 Welches Ziel haben Sie bezüglich Ihres Körpergewichts?
ich möchte zunehmen
ich möchte mein Gewicht halten
ich möchte abnehmen
ich verfolge keine Ziele bezüglich meines Körpergewichts
5.3 Welches Körpergewicht möchten Sie erreichen?
Gewicht: kg
5.5 Wieviele Portionen Früchte oder Gemüse assen Sie in den letzen beiden Monaten
durchschnittlich pro Tag?
0 1 2 3 4 5 mehr als 5
5.4 Auf was sollte eine Person bei der Ernährung achten, damit ihre Gesundheit positiv
beeinflusst wird?
(Mehrere Antworten sind möglich)
weniger Süssigkeiten konsumieren
nur eine Mahlzeit pro Tag einnehmen
weniger Fett konsumieren
Bier als Durstlöscher konsumieren
mehr Fleisch konsumieren
viel Früchte und/oder Gemüse konsumieren
Seite 3
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6.2 Hier geht es um körperliche Aktivität, bei der Sie mindestens einen leicht beschleunigten Atem
bekommen (zum Beispiel zügiges Gehen, Wandern, Tanzen, leichtere Gartenarbeiten):
Bitte beachten Sie: Bei Frage 6.2 und Frage 6.3 fragen wir nach zwei verschiedenen Arten von Bewegung!
a) An wie vielen Tagen pro Woche waren Sie in den letzten beiden Monaten durchschnittlich in dieser Art
körperlich aktiv?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
c) Seit wann sind Sie schon auf diese Weise aktiv?
weniger als 1 Monat
weniger als 6 Monate
6 - 12 Monate
länger als 1 Jahr
länger als 5 Jahre
d) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
)
6  Bewegung
6.1 Wie oft und wie lange, denken Sie, sollte sich eine Person im Minimum bewegen, um 
gesund zu bleiben? (Nur eine Antwort ist möglich)
täglich zehn Minuten
täglich eine halbe Stunde
täglich dreimal eine halbe Stunde
zweimal pro Woche eine halbe Stunde
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7  Änderungen des Lebensstils
7.1 Haben Sie seit Februar 2003 Ihren Lebensstil geändert?
(Mehrere Antworten sind möglich)
ja...
nein...
ich nehme neu an einem Bewegungskurs teil
ich trainiere neu in einem Fitnesscenter
ich mache mehr Sport
ich habe mich für eine Ernährungsberatung angemeldet
ich bewege mich mehr im Alltag (z.B. zu Fuss gehen, Velo benutzen)
ich achte beim Kauf und bei der Wahl von Lebensmitteln auf ihren Fettgehalt
aber ich habe vor, meinen Lebensstil zu ändern:
ich will meinen Lebensstil beibehalten
ich bin zu wenig motiviert, meinen Lebensstil zu ändern
ich habe aus anderen Gründen meinen Lebensstil nicht geändert
im nächsten Monat
in den nächsten 2-6 Monaten
ich habe meinen Fettkonsum reduziert
ich esse mehr Früchte und Gemüse
ich esse generell weniger
6.3 Hier geht es um sportliche oder körperliche Aktivitäten, bei denen Sie ziemlich ins Schwitzen
kommen (z. B. Joggen, Aerobics, Tennis, schnelles Radfahren, Spielsportarten, Schwimmen,
Lasten tragen, Graben, Schaufeln):
a) An wie vielen Tagen pro Woche haben Sie in den letzten beiden Monaten Aktivitäten dieser Art gemacht?
0 1 2 3 4 5 6 7
b) Wie lange waren Sie durchschnittlich an jedem dieser Tage in dieser Art aktiv?
c) Haben Sie vor, diese körperliche Aktivität zu steigern?
ja...
nein
im nächsten Monat
in den nächsten 2-6 Monaten
weniger als 10 Minuten pro Tag
10 Minuten pro Tag
20 Minuten pro Tag
eine halbe Stunde pro Tag
mehr als eine halbe Stunde pro Tag
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7.3 Was ist oder wäre für Sie hilfreich, um Ihren Lebensstil zu ändern?
Zusammen mit Gleichgesinnten etwas für meine Gesundheit unternehmen
Unterstützung durch eine telefonische Beratung
Unterstützung durch Personen, die mir nahe stehen
Bewegungsangebote am Arbeitsplatz
Gesundes Ernährungsangebot am Arbeitsplatz
Mehr Freizeit
Anderes:
(/ /  gar nicht hilfreich, /  mässig hilfreich, ☺ ziemlich hilfreich, ☺☺ sehr hilfreich)
/ / / ☺ ☺ ☺
7.4 Sind Sie daran interessiert, von action d in Zukunft aktuelle schriftliche Informationen über
Diabetes Typ 2 zu erhalten?
ja
nein
7.2 Hatten Sie mit der Änderung Ihrer Gewohnheiten Erfolg?
(Nur beantworten, falls Sie Frage 7.1 mit "ja" beantwortet haben)
(Mehrere Antworten sind möglich)
ja...
nein...
ich konnte mein Gewicht halten oder in die gewünschte Richtung beeinflussen
ich fühle mich in besser körperlichen Verfassung
ich nehme bis jetzt keine Fortschritte wahr
ich habe es wieder aufgegeben, meine Gewohnheiten ändern zu wollen
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8  Neue Medikamente
Wurden Ihnen seit der Aktion "Stopp Zucker - Jetzt testen" im Mai 2002 Medikamente verordnet, 
die Sie zur Zeit regelmässig einnehmen müssen?
ja
nein
weiss nicht
Wenn ja, welche? (Bitte notieren Sie hier alle regelmässig einzunehmenden Medikamente, die Ihnen
seit Mai 2002 neu verordnet wurden.)
9  Weitere Kommentare und Bemerkungen
Herzlichen Dank für das Ausfüllen dieses Fragebogens!
1)
2)
3)
4)
5)
6)
Seite 7
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